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Abstract 
 
 Cancer affects about 1 in 1000 pregnancies, which is estimated to account for 
approximately 5000 pregnancies in Europe each year. Despite affluent availability of 
clinical practice guidelines for cancer management in the course of pregnancy, there is 
very little ethical guidance consolidated for everyday use. Therefore, the aim of this work 
is to construct a framework, which would serve healthcare professionals as a reference tool 
when addressing ethical issues in cancer care during pregnancy. 
 The framework is constructed around relational approach to respect for patient’s 
autonomy and ethics of care. It combines classical biomedical ethics principles and 
relational approaches to patient care. It emphasizes the importance of recognising the 
patient as another human being with her views on life, relationships and wishes, as well as 
forming a relationship between the patient and healthcare team, which is known as 
relational ethics.  
 However, respect for individual autonomy is not discarded entirely. First and 
foremost, evidence-based information disclosure is essential to personalised patient care. 
The latter invites to integrate technical aspects of personalised medicine with relational 
approach to patient care. Furthermore, protection of the vulnerable also serves as a 
safeguard ensuring that patient is not compelled to choices that are not her own. 
 Overall, this framework is expected to serve as a tool supporting ethical decision-
making in cancer care during pregnancy. It can also be utilised by a variety of patient 
counselling services. 
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For those facing difficult decisions
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Olga (35) lives in a remote area of the country with her husband Giulio (39) and 
their 5-year-old daughter Eliza. Their attempts to have a second child were marked with 
few miscarriages. Currently Olga is 20 weeks pregnant and her last scan revealed that 
they are expecting a boy. Delight and excitement, however, is overshadowed by a recent 
diagnosis of Olga’s locally advanced, HER 2 positive breast cancer. She was offered three 
therapeutic options in order to treat her disease: 1) standard treatment which is not 
compatible with pregnancy; 2) surgery followed by adapted chemotherapy which is 
compatible with foetal development but has lower response rate to treatment; 3) just 
surgery, postponing all other treatments until after the delivery of the baby.  
Giulio is categorically against any choices which could compromise Olga’s 
chances of complete recovery and survival. He would rather have one child with a mother 
than raise two children as a widower.  Giulio’s parents and extended family share the 
same view and encourage Olga to fight her disease and stay alive for Eliza.  
Meanwhile, Olga’s treating physician Dr. Silvia feels that Olga is being compelled 
by her husband’s family into having her current pregnancy terminated.  Dr. Silvia believes 
that based on currently available evidence, Olga could continue her pregnancy to term 
while also receiving treatment for her breast cancer. Hence Olga seems to be inclined to 
submit to her husband’s view because if she dies, Giulio will have to bring up the children 
on his own. Dr. Silvia feels that the developing baby also has a right to live and finds it 
difficult to accept Olga’s reasoning. Dr. Silvia is tempted to refer Olga to another hospital 
with a hope that additional hurdles in accessing pregnancy termination will make Olga to 
reconsider her choice. 
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 Due to an interdisciplinary nature of this work the extensive use of abbreviations is 
avoided and they are explained as they occur. Footnotes are used to explain the terms and 
concepts which are specific to one particular discipline. This is done to assist the readers 
who might not be familiar with discipline specific concepts. 
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Introduction 
 
Cancer is usually considered a disease of older adults. It is not very common that it 
affects children, adolescents or women and men in reproductive age. Lifetime risk of 
developing cancer for people below 65 years of age is around 50%, which means that over 
half of the people will be affected by cancer at some point of their lives (Ahmad, 
Ormiston-Smith, and Sasieni 2015). Developing cancer under the age of 40 is still a rare 
event in the general population of women (Cardoso et al. 2012)(Andersson et al. 2015) as 
more than half of all cancer cases are diagnosed in individuals who are 70 years old or 
older1. However, the Center for Disease Control in the US reports that cancer is the second 
most common cause of death in women between the ages of 25-34, while in women aged 
35-65 cancer is the leading cause of death2. Moreover, increasingly concerns are raised that 
cancer incidence is becoming more prevalent in all age groups around the world 
(Fitzmaurice et al. 2015)(Global Burden of Disease Study 2013 Collaborators 2015)(Ward 
et al. 2014).  
The biggest coordinated attempt to advance research, train clinicians and provide 
care and support to cancer patients regarding fertility issues is the Oncofertility 
                                                 
1 Cancer incidence by age, Cancer Research UK, http://www.cancerresearchuk.org/health-
professional/cancer-statistics/incidence/age [accessed 2016-04-04]. 
2 Leading causes of death by age group, all females-United States 2013, The Center for Disease Control 
(CDC) http://www.cdc.gov/women/lcod/2013/womenall_2013.pdf [accessed 2016-04-04]. 
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Consortium3 in Chicago, USA. This is where multi-disciplinary attempts to launch a new 
field of oncofertility were started.  
 Oncofertility is perceived as “an interdisciplinary field that bridges biomedical and 
social sciences and examines issues regarding an individual’s fertility concerns, options, 
and choices in light of cancer diagnosis, treatment, and survivorship” (Snyder 2007). It 
uses expertise from different fields of research to offer state of the art services for cancer 
patients, their families, healthcare professionals and other support service providers. 
Oncofertility does not necessarily claim the status of a new independent discipline; it is 
rather a field where multidisciplinary expertise is merged together to train clinicians 
(Coutifaris 2012) and provide counselling support to patients (Jungheim, Carson, and 
Brown 2010).  
 Being a young field, it mainly focuses on fertility preservation4 and, in addition to 
practical clinical approaches, also offers some theoretical considerations on the ethical, 
social, legal as well as medical implications that fertility preservation practices might have 
in the future. Cancer care during pregnancy is not in the mainstream oncofertility debate 
but has its place under this wide umbrella (Wang 2012), as well as work already done in 
the  areas surrounding fertility preservation can offer in-depth insights to ethical problems 
arising when caring for pregnant patients diagnosed with cancer. 
 For example, the last few years witnessed a release of numerous clinical practice 
guidelines concerning cancer management in reproductive age patients. All of them 
                                                 
3 The Oncofertility Consortium® is a national, interdisciplinary initiative designed to explore the 
reproductive future of cancer survivors https://oncofertility.northwestern.edu/ 
4 Fertility preservation options available for reproductive age women are embryo cryopreservation, oocyte 
cryopreservation (established) and ovarian tissue cryopreservation (experimental); for reproductive age men 
sperm and also embryo cryopreservation is available (established); only experimental ovarian and testicular 
tissue cryopreservation methods are available for pre-pubertal children.  
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unanimously suggest that fertility issues should be discussed with all cancer patients of 
reproductive age. Summary of these guidelines5 is provided in Appendix A.  
 Therefore, distinction has to be noted between fertility preservation for cancer 
patients and cancer care during pregnancy, which usually does not include fertility 
preserving interventions.  I will start with some key findings concerning fertility 
preservation but my main focus through entire thesis will be on care of pregnant cancer 
patients.  
 Returning to the mainstream oncofertility findings, it is known that despite 
available recommendations, nearly half of reproductive age cancer patients are not given 
enough information about cancer treatment effect on their future fertility (Linkeviciute et 
al. 2014). Other studies report that cancer patients have a strong desire to be informed 
about fertility preservation options available to them even if they do not chose to proceed 
with fertility preservation for themselves (Penrose et al. 2012)(Geue et al. 2014). 
Moreover, fertility concerns are not limited to young and childless patients who are in a 
relationship (Yee et al. 2012). While patient’s age, relationship status, sexual orientation, 
religion and/or a number of existing children should not be an indication to withhold 
fertility consultation, it appears to influence physicians’ decision to address patient’s 
fertility concerns (Linkeviciute et al. 2014). Unfortunately, numerous studies exploring 
physicians’ attitudes towards fertility consultations with cancer patients report that some 
physicians are misled by their personal biases and do not always inform their patients 
about cancer treatment effect on their future fertility (Linkeviciute et al. 2014). 
Discussion, however, remains open, if reservations towards fertility preservation 
are determined by the lack of medical knowledge, conservative attitude towards pregnancy 
                                                 
5 This summary is not a systematic review and originally was presented in Cancer Treatments Review journal 
(Linkeviciute et al. 2014) and was expanded based on a systematic review, which appeared in Asian Pacific 
Journal of Cancer Prevention (Haddadi et al. 2015).  
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after cancer or genuine survival fears by physicians and patients alike (Lambertini et al. 
2013)(Linkeviciute et al. 2014). It has to be acknowledged that fertility preservation 
techniques (e.g. oocyte freezing) remain highly ineffective in some cases (von Wolff, 
Germeyer, and Nawroth 2015) and, in addition to therapeutic solutions they offer to cancer 
patients, some unintended implications also emerge6 (Linkeviciute et al. 2015). For 
example, oocyte cryopreservation for non-medical reasons might result in more women 
delaying pregnancy for later age, which by itself increases the risks to the mother and her 
foetus. Pregnancy in the advanced maternal age is also known to carry increased medical 
risks to the mother and the foetus due to already existing chronic conditions such as 
hypertension (Dietl et al. 2015), more frequent occurrences of pregnancy induced diabetes, 
preeclampsia (von Wolff, Germeyer, and Nawroth 2015) and placentation defects (Jackson 
et al. 2015).  
This is especially relevant for women who are due to take hormonal therapy (e.g. 
tamoxifen) following their cancer treatment. Such therapies have to be taken for 5 or even 
10 years following their cancer treatment and are contraindicated during pregnancy 
(Lambertini, Peccatori, and Azim 2015). Therefore, cancer survivors either have to wait 
until they finish their therapy and by that time they might already be of advanced maternal 
age, or interrupt their therapy, risking higher chances of cancer reoccurrence (Davies et al. 
2013). One study suggests that a third of reproductive age women, who are on hormonal 
therapy, are willing to compromise their chances of survival by discontinuing the therapy 
in order to have a baby (Llarena et al. 2015) and another study reveals that similar numbers 
would be willing to take part in clinical trials investigating the effects of tamoxifen therapy 
interruption due to attempts to conceive (Pagani et al. 2015).  
                                                 
6 Declaring oocyte cryopreservation as an established procedure for fertility preservation in cancer patients 
(Loren et al. 2013) resulted in fast commercialization of oocyte cryopreservation for non-medical purposes 
(Linkeviciute et al. 2015) which raises numerous ethical, social and legal problems (Petropanagos et al. 
2015).  
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Despite established fertility preservation methods for cancer patients and numerous 
recommendations to make fertility preservation consultation an integral part of cancer 
management, some reservations are still held based on bad or uncertain prognosis and 
varying effectiveness of fertility preservation procedures (Linkeviciute et al. 2014). Since 
some fertility preservation methods are expensive7 and may not be covered by public 
healthcare funds or an individual patient’s insurance, it is reasonable to resort to it if 
successful pregnancy and healthy live birth can be expected to occur. For example, not all 
cancer survivors are going to be cured or regain good enough health to carry the pregnancy 
and look after the resulting children8. Common critiques of pregnancy attempts by cancer 
survivors refer to the shorter parental lifespan (Pennings and Mertes 2012), greater health 
problems these patients face, unrelated to cancer (Córdoba et al. 2013) and their frequent 
admissions to the hospital (Richardson et al. 2015) as well as potentially having less 
energy for looking after the children (Schover 2005). Despite the above criticisms, the 
debate surrounding parenthood after cancer quite often focuses on parental rights and 
interests to have a “completed family” (Wenzel 2005)(Niemasik et al. 2012) even if other 
forms of parenting are recognised as viable options for people affected by cancer 
(Rodriguez et al. 2013).  
Despite the above concerns and reservations, cancer occurrence in the course of 
pregnancy is a relatively rear event. Professional societies, as the European Society of 
Medical Oncology (ESMO), offer an estimation that 1 out of 1000 pregnancies is 
complicated by cancer (Pentheroudakis et al. 2010)(Peccatori et al. 2013) which is 
diagnosed either during the course of pregnancy (Cardonick, Usmani, and Ghaffar 2009) or 
                                                 
7 Oocyte cryopreservation might cost up to USD 18 000 at https://www.fertilityauthority.com/egg-
freezing/cost [accessed 2015-11-17] and slightly less in Europe: GBP 4000-5000 in the UK (Hawkes 2014), 
CHF 3000-5300 in Switzerland (Wunder 2013), EUR 3000 in Germany (Geue et al. 2014).  
8 Those who want genetically related children might use surrogacy but that is an ethically, socially and 
legally problematic practice in itself which is not elaborated on in this work.  
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up to two years post-partum (Murphy et al. 2012)(Andersson et al. 2015). These numbers, 
however, may vary depending on the type of malignancy and the age of a pregnant woman. 
Research group from Catholic University of Leuven (K.U.Leuven) estimates that in 
Europe there might be up to 5000 women diagnosed with cancer during pregnancy every 
year9. 
The most common malignancies occurring in the course of pregnancy are breast, 
thyroid, cervical, ovarian cancers and melanoma (Moran et al. 2007)(Pentheroudakis et al. 
2010) but currently available data is limited mainly to the regions in Western/Central 
Europe and North America (Loibl et al. 2012)(Córdoba et al. 2013). Some recent reports 
suggest that other types of cancers might be more prevalent in pregnant women in specific 
regions such as more cases of melanoma in Scandinavia (Andersson et al. 2015) and more 
frequent occurrences of gastrointestinal cancer in Asia (Shim et al. 2016). 
Moreover, it is plausible that these figures are going to rise as a consequence of 
social trend to delay motherhood for an older age (Oduncu et al. 2003)(Pereg, Koren, and 
Lishner 2008)(Rizack et al. 2009)10. The older maternal age is associated with an increased 
number of benign (Stagnaro-Green et al. 2011) and malignant tumours  (Schedin 2006) as 
well as with various maternal and foetal health risks not necessarily related to cancer (von 
Wolff, Germeyer, and Nawroth 2015). Older women’s attempts to take the last chance for 
motherhood are well document in mass media describing women in their late thirties or 
early forties desperately seeking assisted reproduction services with a hope for motherhood 
                                                 
9 Cancer in Pregnancy (CIP) study https://www.uzleuven.be/en/cancer-in-pregnancy/research-project, 
http://www.uzleuven.be/sites/default/files/Kanker_tijdens_zwangerschap/Poster%20CIP%20versie%20EN%
20leken.pdf [accessed 2016-04-04]. 
10Reports show that maternal age at the birth of the first child is reaching or even exceeding 30 years of age 
in some developed countries (Laopaiboon et al. 2014)(Sauer 2015), including the increased number of 
women having their children in a very advanced maternal age, which is currently considered to be 45 years 
and above (Carolan 2013). 
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(Burrell 2014)(Kennedy 2015) with the consequence that some countries are making the 
attempts to introduce age limits for accessing IVF and related services at public expense 
(Berg Brigham, Cadier, and Chevreul 2013)11 as well as due to moral concerns regarding 
some recent news headlines reporting women in their sixties and seventies having children 
with the help of assisted reproduction technologies12.  
A trend to pursue motherhood later in life is influenced by various factors as 
women delay childbearing for different reasons13 (Statista 2014). Current technologies 
make motherhood possible in the late forties or even after menopause, using either self-
stored oocytes that have been frozen early in life, or donated oocytes. The former 
procedure is known as social egg freezing (Linkeviciute et al. 2015). The procedure is still 
under scrutiny by ethicists, policy makers and healthcare providers. None of the 
professional bodies such as American Society for Medical Oncology (ASCO), American 
Society for Reproductive Medicine (ASRM), European Society for Medical Oncology 
(ESMO), European Society for Human Reproduction and Embryology (ESHRE) 
                                                 
11Hence some countries as for example Sweden exercise rather liberal policies offering the state funded IVF 
including single women (Savage 2016). Moreover, continuous attempts to create artificial gametes might 
change how artificial reproduction in viewed and its services organised (Cyranoski 2016).  
12 Such stories are Annegret Raunigk, who at 65 gave birth to quadruplets: 
http://www.dailymail.co.uk/news/article-3200884/This-not-egotism-selfishness-like-children-65-year-old-
gave-birth-QUADS-gets-ready-babies-home.html [accessed 2016-05-19]; Indian couple in their seventies 
celebrate the birth of their first child: http://www.theguardian.com/world/2016/may/12/indian-doctors-ivf-
woman-70s-gives-birth-fertility-treatment-daljinder-kaur [accessed 2016-05-19]. 
13 Even though a lot of attention is given to gender disparities in the employment market and possible 
exploitation of female employees by ‘forcing’ them to delay childbearing, empirical research data suggest 
that even bigger problem for educated career women is finding a committed partner to have family with. In 
popular media it is referred to as ‘finding Mr. Ready’, which invites further debates on how people view 
reproductive choices and what meanings they ascribe to their relationships with romantic partners. 
18 
 
endorsed14 it for the use by healthy patients while in 2013 it has been approved as non-
experimental procedure for fertility preservation in female cancer patients by ASCO15 
(Loren et al. 2013)(Linkeviciute et al. 2015). Meanwhile, success stories are reported 
concerning fertility preservation in cancer patients and the later use of reproductive 
materials for conception, such as cryopreserved embryos (Luke et al. 2016), oocytes 
(Perrin et al. 2016), and ovarian tissue, which remains an experimental fertility 
preservation technique (Demeestere et al. 2015). One recent review suggests that oocyte 
cryopreservation is an “established procedure” but it mainly focuses on the procedure itself 
and its acceptability among the patients rather than pregnancy and long-term outcomes for 
the children conceived from frozen oocytes (Argyle, Harper, and Davies 2016). 
Facing a potentially lethal disease and expecting a baby at the same time can be 
challenging not only for the patient but also for her relatives, friends and healthcare team. 
Therefore, the knowledge about cancer effect on the course of pregnancy and pregnancy 
effect of the progression of cancer is of crucial importance for successful treatment of the 
                                                 
14 The Human Fertilisation and Embryology Authority (HFEA) in the UK, however, expresses rather flexible 
position stating that reproductive age women, who are concerned about their fertility decline due to age and 
are not in the position currently to have a baby might want to discuss oocyte cryopreservation options with 
their clinic. “Freezing and storing eggs” at http://www.hfea.gov.uk/46.html [Accessed 2016-03-16, last 
updated 2015-06-15] 
15 Even though such fertility preservation procedure is not recommended to the healthy women as a family 
planning method and some countries even restricted it (e.g. China (“BBC News” 2015)), the interest has been 
recorded (Tan et al. 2014)(Stoop, Nekkebroeck, and Devroey 2011)  and positive attitudes towards the 
procedure documented (Nekkebroeck, Stoop, and Devroey 2010)(Stoop et al. 2015). A possibility to preserve 
fertility leads to two types of future implications. Firstly, it allows cancer survivors to achieve pregnancy 
after fertility impairing treatment. Secondly, it allows healthy women to delay childbearing until the age 
when cancer becomes more common. Both scenarios raise complex ethical concerns which are intertwined 
with medical aspects surrounding pregnancy after cancer and/or at increased maternal age, social attitudes 
and expectations towards women, personal wishes and family influences on the patient’s decisions.  
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mother and favourable outcome for the foetus (Morice, Uzan, and Uzan 2012). Evidence-
based knowledge is also essential for running patient counselling services. However, such 
knowledge is still being consolidated, mostly in a patchwork manner since controlled 
clinical trials are not always possible due to the rarity and diversity of the condition. 
Moreover, even evidence-based knowledge can be presented to the patients in a biased 
manner due to personal views held by healthcare team. 
Furthermore, pregnancy occurring at advanced maternal age is associated with an 
increased medical risk for the mother and for the foetus (Jackson et al. 2015) but it is not 
always clear which risks arise due to increased maternal age and which occur as a result of 
using assisted reproduction technologies (Linkeviciute et al. 2015). It is known, however, 
that risk of cancer increases with age and women carrying pregnancies in advanced age 
face higher risk of cancer diagnosis due to their age. Hence, pregnancy in itself, if 
occurring in advanced age has not been identified as a risk factor for maternal cancer. 
Meanwhile, currently available data suggests that pregnancy and maternal cancer 
treatment could be compatible (Amant, Vandenbroucke, et al. 2015)(Cardonick et al. 2015) 
but there are also calls for caution when interpreting and using this data (Greene and 
Longo 2015)(Reichman, Eldar-Gava, and Paltiel 2016). Moreover, most studies focus on 
outcomes for the children born after gestational exposure to cancer treatments (Peccatori, 
Corrado, and Fumagalli 2015) while maternal outcomes are surrounded by much more 
uncertainty and potential bias16 (Royal College of Obstetricians and Gynaecologists 
2011)(Andersson et al. 2015). 
In general, it is accepted that cancer and its treatment can be compatible with 
pregnancy. However, opinions concerning maternal prognosis and children’s health after 
cancer treatment during pregnancy are still divided. Currently available evidence can only 
offer some provisional guidance and decisions, concerning cancer management during 
pregnancy, and treatment decisions have to be taken under numerous uncertainties. 
                                                 
16 For example, healthy mother effect. 
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Moreover, careful considerations of much broader aspects than just clinical knowledge 
have to be considered in cancer during pregnancy care. This includes but is not limited to 
patient’s values, preferences and impact that the decision will have on different parties17.  
Ethical dimensions of each case could extend far over and above the requirements of sound 
medical knowledge, evidence-based data and good clinical practice, neither solution could 
be reduced to solely consequentialist or exceptionally duty based thinking.  
In this work I will show that ethical concerns are deemed to be important by 
clinical practice guidelines and give in depth overview of existing theoretical and practical 
approaches, which could offer potential solutions to ethical conflicts arising in cancer care 
during pregnancy. Hence, at the same time, it has to be recognised that only limited ethical 
guidance is available to healthcare professionals who have to manage ethical problems 
while caring for pregnant cancer patients and finding the solutions which best fit individual 
situations.  
Therefore, I developed a framework for ethical care of pregnant cancer patients. 
Firstly, I strive to assist the healthcare professionals by providing a conceptual guidance 
for addressing ethical issues in cancer care during pregnancy. My framework could 
serve as a reference tool when searching for ethically sound solutions in problematic 
cases. Secondly, I would like to show how theoretical concepts found in biomedical 
ethics18 can be incorporated in the structures of everyday clinical practice and help to 
deliver a higher quality care for pregnant cancer patients.  
                                                 
17 Here I mean those who might be directly affected by pregnant cancer patient’s treatment decisions. 
Primarily these parties are pregnant woman’s partner, the fetus and in some case other dependants of a 
pregnant woman.  
18 I consistently use the term “biomedical ethics” in reference to the principles of biomedical ethics 
(Beauchamp and Childress 2013) and also to avoid any potential confusion concerning the diversity of the 
terms such as medical ethics, clinical ethics, healthcare ethics, etc. My take is that they all fit under the 
umbrella of biomedical ethics, or bioethics, which I perceive as a multidisciplinary field where knowledge 
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The material for my work is gathered by employing the classical sources and tools 
used in biomedical ethics. I use the principles of biomedical ethics and feminist 
contributions to bioethics to lay a foundational background for addressing ethical conflicts 
in cancer care during pregnancy. I refer to the ethics of care19 and relational ethics as 
feminist contributions crucial to my work. Both have been developed in the context of 
nursing care urging for compassion, recognition and empathy when attending to the 
physical needs of the patient. That closely coincides with patient-centred personalised care 
and personal philosophy of pregnant cancer patient. Therefore, incorporating contributions 
from feminist scholarship to principlism based thinking helps me to show the importance 
of relational approaches to patient care. 
The conceptual part of the framework I build on relational approach to respect for 
patient’s autonomy (relational autonomy) and also use three additional concepts to support 
my relational proposal. The supporting concepts, which I use, are the following: evidence-
based information disclosure, personalised patient care and protection of the vulnerable. 
After exploring and scrutinising currently available evidence, practices and solutions for 
cancer care during pregnancy, I construct a framework for ethical care and discuss 
remaining limitations.   
                                                                                                                                                    
and expertise from different fields is merged together in order to reach sustainable solutions in ethically 
challenging situations in a field of biomedical sciences and medicine. 
 
19 Ethics of care (or care ethics) forms a cluster of normative ethical theories which emphasise the importance 
of relationships, interaction and response criticising the application of universal standards and principles. It 
began with attention given to care provided by women in their own homes by pleading for redistribution of 
chores (van Heijst 2011). Carol Gilligan can be considered as one of the founders of care ethics as her book 
‘In a Different Voice’ (1982) marks a landmark in understanding that male and female view morality in 
different terms. Other important contributions to care ethics are made by Joan Tronto, Sara Ruddick, Chris 
Gastmans, Michael Slote, to name just a few, whose work I found inspiring.  
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In order to be relevant to the actual clinical world, I took the effort and made every 
attempt to stay informed by available empirical evidence in clinical, biomedical and social 
sciences research. This includes an entire chapter devoted to an overview of clinical 
complexity of cancer management during pregnancy (Chapter 1), ethical concerns arising 
in cancer care during pregnancy, including a deep analysis of choices available to a 
pregnant woman, who is diagnosed with cancer (Chapter 2), physicians’ and patients’ 
perspectives towards cancer treatment and other critical conditions in the course of 
pregnancy as well as challenges of facing cancer and fulfilling parental commitments 
(Chapter 3), a systematic review of clinical practice guidelines concerning cancer treatment 
in the course of pregnancy  (Chapter 4) and ethics support services available to healthcare 
professionals and patients in order to address pressing ethical problems (Chapter 5). 
 In terms of terminology, I tend to use “pregnancy termination” rather than 
“abortion” as my focus is on a very narrow set of circumstances where pregnancy 
termination could be considered as one of available options. I also use “interests” rather 
than “rights” when referring to maternal and foetal welfare claims (Chapter 2) as this work 
is not meant to be a legal study. Interests are also used with an intention to stay neutral 
concerning wider debates on pregnancy termination. In addition, evaluating foetal welfare-
related interests, especially those relating to welfare of a future child often requires making 
judgements about parental capacities to take care of the child. The later is often limited to 
the scrutiny of such capacities of the mother but not others who might also be playing a 
role in care of the future child. 
Therefore, in this work I focus more on maternal cancer and its implications on the 
developing foetus, such as prenatal harm and future health related welfare, but only touch a 
few key points from pregnancy termination debate as this is a very broad and inconclusive 
field in itself (Chapter 2). Furthermore, I do not harbour the ambition to make a substantial 
contribution to the debate concerning pregnancy termination in general. Hence, I do 
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explore the concept of foetal patienthood and spend some time discussing the role that 
foetal viability plays in decision-making concerning maternal cancer treatment. 
It is important to note that empirical data concerning medical aspects as well as 
physicians and patients’ attitudes and experiences are limited and should be interpreted 
with caution.  Therefore, clinical practice guidelines first and foremost are aimed at 
guiding clinical management of cancer during pregnancy and not ethical decision-
making. This signifies the importance of my work as I aim to fill this gap by laying a 
solid foundation for future development of a guideline focusing on ethical aspects of 
cancer care during pregnancy, which is thoroughly informed by evidence offered by 
clinical and social science research. 
For some parts of this work I used systematic review methods which are known as 
empirical turn in Bioethics and have been extensively developed by some Belgian scholars 
(Borry, Schotsmans, and Dierickx 2005). Depending on research questions there can be 
different types of systematic reviews. Initially they have been modelled mirroring the 
reviews of medical literature, suggesting that reviews identifying and evaluating arguments 
in normative ethics literature can serve as a formal tool for clinicians (McCullough, 
Coverdale, and Chervenak 2004).  
Being systematic and recording search strategy is widely agreed to be an important 
feature of bioethics research (McCullough, Coverdale, and Chervenak 2004)(Strech, 
Synofzik, and Marckmann 2008)(Strech and Sofaer 2012)(McDougall 2015), especially 
following the critique that methods used by bioethicists are very diverse among and within 
themselves (Walker and Morrissey 2014). Diverse approaches to bioethics research reflect 
the multidisciplinarity of the field but at the same time can create confusion when 
discoveries are compared among themselves or have to be applied practically. As a result 
evidence-based ethics mirroring evidence-based medicine has not been welcomed 
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enthusiastically (Goldenberg 2005) but it seems to provide empirical content for informed 
deliberation towards normative implications (e.g. guideline drafting, policy formation).  
Therefore, precisely for the later reason I took an advantage of systematic review 
approach to ensure that relevant previous works are taken into consideration, empirical 
bioethics findings noted and different normative stand points presented and evaluated. I 
believe that systematic approach to existing literature helps avoiding biases and allows 
informed discussion. It also hopefully serves as a safeguard preventing cherry-picked 
examples and ideas used to support the author’s views and safeguards objectivity. 
Systematic approach is employed in numerous parts of this work when exploring 
existing guidelines, writing medical overview of particularities surrounding cancer 
treatment during pregnancy, gathering empirical data on attitudes, experiences and 
practices towards these unfortunate cases. Depending on the question I used different types 
of systematic reviews. In some cases I used systematic reviews of empirical bioethics 
(Strech, Synofzik, and Marckmann 2008), systematic reviews of normative bioethics 
literature providing arguments (McCullough, Coverdale, and Chervenak 2004) and/or 
reasons (Strech and Sofaer 2012) and critical interpretative literature reviews (McDougall 
2015) for my background research and later refined the contents for this work through 
critical narrowing down.  Sometimes I blend these approaches together as my primary goal 
was not always limited to information gathering but also interpretation and critical 
evaluation of existing data and ideas. Systematic review tools mainly served me as a 
springboard for further intellectual endeavour. 
Concerning the practical applicability of my conceptual work, I show how my 
conceptual proposal fits in a wide variety of patient counselling services aimed at 
supporting decision-making processes. Approaches to patient counselling and decisional 
support are very diverse and practice itself is still being developed. Two mainstream 
approaches can be distinguished in this heterogeneous field. The first one is predominant in 
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the USA and Canada. It exercises an effort to resolve the conflicts and aims to offer an 
ethically justified solution to the problem it addresses (Tarzian 2013). The second 
approach found in the Western Europe and partly in the Nordic countries focuses on 
facilitating an ethical reflection, offering advice and support but not a resolution for  
troubling clinical cases (Gaucher, Lantos, and Payot 2013)(Stolper, Molewijk, and 
Widdershoven 2015)(Silén et al. 2015). One more model, specifically developed for 
Obstetrics and Gynaecology domain is known as preventive ethics (McCullough and 
Chervenak 1994). Preventive ethics model advocates for informed consent as the main 
clinical strategy for preventing ethical conflicts. It seeks to prevent dehumanization of the 
patient and dehumanization of clinician by treating female patient and pregnant patient as a 
unique individual with her own needs for information and desired level of participation in 
medical decision-making process. It is pictured as an ongoing dialogue between the patient 
and physician, sometimes involving negotiation and respectful persuasion (McCullough 
and Chervenak 1994).  
The main argument I develop through the entire work is that in order to 
deliver ethically minded care to the patients, who are diagnosed with cancer in the 
course of their pregnancies, a biomedical ethics principle known as respect for 
patient’s autonomy needs to be refined by recognising its socially embedded nature. 
The position I hold is that decisions concerning cancer treatment are not made in 
isolation and might have significant implications on the parties other than pregnant 
cancer patient herself. Therefore, a framework for ethical care is constructed around 
relational approach to respect for patient’s autonomy and ethics of care. This does not 
mean that pregnant woman’s autonomy regarding her medical care should be diminished 
or abolished. On the contrary, to empower a pregnant cancer patient to make decisions that 
are in-line with her values, expectations and correspond to her particular circumstances, 
her relationships have to be recognised and she should not be forced to ignore or abandon 
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them. Therefore, accommodating the respect for patient’s relational autonomy I view 
through the prism of ethics of care which emphasises the importance of compassion, 
recognition and empathy from healthcare professionals. I build this on the basis offered by 
clinical practice guidelines (Chapter 4) informed by extensive background research 
concerning ethical issues arising in cancer care during pregnancy (Chapter 2 and 
Chapter 3). Hence, I also recognise the dangers of relational approach to pregnant 
woman’s individuality, autonomy and personal philosophy (Chapter 6). 
Therefore, I do not view maternal-fetal relationship as a fight between the two, nor 
subscribe to one single model of motherhood such as self-sacrifice or self-defence 
(McDonagh 2002). I construct my framework under the premise that most patients who are 
diagnosed with cancer during pregnancy have welcoming20 attitudes towards their 
pregnancies and cancer diagnosis is compromising their protective and nurturing maternal 
role. Furthermore, I accept that foetuses have certain health and welfare related interests 
which could (and possibly should) be granted some level of protection. However, I 
recognise that such protection can be a two-edged sword and discuss this in more detail by 
examining the implications the establishment of foetal patienthood might have on maternal 
interests (Chapter 2).  
Moreover, I also recognise that under some circumstances maternal-foetal conflict 
does exist and some compromises have to be made. Therefore, I analyse different positions 
and arguments concerning maternal and foetal interests with a significant focus on 
                                                 
20 I chose to use ‘welcomed pregnancy’ rather than planned, wanted or voluntary to respect the previous 
choices patients made disregarding the circumstances of conception. Using the above term I mean that a 
woman accepted her pregnancy and is willing to experience some discomforts associated with carrying her 
pregnancy to term. Hence I recognise that there might be numerous social and political determinants of 
woman’s choice to be in a situation where she might fall pregnant, attempt to get pregnant and remain 
pregnant (Torres and De Vries 2009).  
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justifications offered to the permissibility of prenatal harm (McMahan 2006) to the future 
child when the pregnant woman has to be treated for a disease that might endanger her own 
life (Chapter 2). 
Such treatment decisions closely relates to a personalised care, where patient’s 
values, preferences and particular ways of seeing life play an important role in medical 
decision-making. I use a broad definition of personalised care, taking into account patient’s 
psychological needs, religious beliefs, cultural inclinations and ethical views (Cornetta and 
Brown 2013). It strongly corresponds to patient’s personal philosophy, which in this work 
is perceived as “…a coherent and justified set of beliefs, assumptions, principles, and 
values each individual posses. …[it] characterises individual in the way […] she sees, 
understands, and approaches the world, life, and death” (Linkeviciute et al. 2015). 
Therefore, the framework which I put together offers conceptual background built on 
respect for patient’s relational autonomy in the context of ethics of care and relational 
ethics. Since my main aim is to assist healthcare professionals to address ethical issues 
arising in cancer care during pregnancy, I also show how it could be used by ethics support 
services such as ethics consultation and counselling, if and when they are deemed to be 
needed.  
A framework I propose for ethical care (Chapter 6) focuses on the situations 
where a pregnant woman is diagnosed with cancer. It does not reject the principlist 
approach which is widely used in Western Judo-Christian biomedical ethics (especially in 
the North America) but rather delivers a balanced specification of respect for patient’s 
autonomy principle recognising its relational segments when a pregnant woman is 
facing cancer diagnosis and treatment decisions such as whether to continue with 
pregnancy, delay treatment until after the delivery of the baby or have treatment while 
pregnant. This is further elaborated through the lens of ethics of care and relational ethics. 
I also show how theoretical concepts can enrich patient counselling services and contribute 
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to a higher standard of patient care by being more patient focussed, compassionate, 
recognising and empathetic.  
To date most more or less established ethics support services are mainly healthcare 
professional focused (Gaucher, Lantos, and Payot 2013)(Linkeviciute and Sanchini 2016) 
while ethics support for patients come in many different forms often blended with other 
forms of patient support (Feary 2003)(Chiavari et al. 2015)(Lawson et al. 2015)(Boniolo 
and Sanchini 2016). In this work I support the idea that patients should be recognised as 
active participants and, in some cases, independent ethics support service users. 
In summary, the framework for ethical care of pregnant cancer patients can be used 
as a reference tool when addressing ethical conflicts, it can also serve as a base for further 
research on clinical practices, patient experiences and attitudes as well as experiences of 
other stakeholders. Together with theoretical concepts which I present in this work it can 
be used for drafting a clinical practice guideline focusing predominantly on ethics as 
currently the importance of ethics is recognised but only scarcely addressed in clinical 
practice guidelines for cancer management during pregnancy. 
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Chapter 1. Cancer during pregnancy: clinical background 
1.1. A complex condition  
Cancers diagnosed during pregnancy are not different from those affecting non-
pregnant women. However, in some cases (e.g. thyroid cancer, melanoma) pregnancy 
might be related to a worsened outcome (Vannucchi et al. 2010)(Khosrotehrani et al. 2011) 
while in other malignancies (e.g. breast cancer) pregnancy can suppress or promote the 
progression of neoplastic development (Schedin 2006). To date, there is no consolidated 
clinical opinion if pregnancy can induce the occurrence or re-occurrence of cancer and 
how, if at all, it correlates with maternal age21other than the statistical data indicating that 
older people are more likely to be affected by cancer. Some studies speculate that women 
with preclinical malignant disease are less likely to conceive due to physiological changes 
induced by malignancy (Andersson et al. 2015) and might have to rely on assisted 
reproduction services in order to achieve pregnancy. Interventions used in artificial 
reproduction (Storegen et al. 2012) and the use of hormonal contraception (Cibula et al. 
2010) have been also associated with an increased cancer risk but data is still lacking for 
drawing concrete conclusions. Moreover, the modern reproductive patterns, such as a 
younger age at menarche, older age at the birth of the first child and fewer pregnancies 
leading to increased number of menstrual cycles, are reported to contribute to the increased 
risk of oestrogen positive breast cancer (Aktipis et al. 2015)22.  
                                                 
21 The term ‘pregnancy-associated cancer’ is sometimes used but it usually refers to cancers occurring in the 
course of pregnancy or in the post-partum period indicating the correlation in time but not necessarily a 
causation (Ibrahim et al. 2000)(Martires et al. 2015). 
22 In this work I have not explored the effect which pregnancy termination after cancer diagnosis could have 
on tumour development.  
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Expert estimations suggest that approximately 1 in 1000 pregnancies is complicated 
by cancer (Pereg, Koren, and Lishner 2008)(G. Koren et al. 2013). However, not all 
registries contain the information on how many pregnancies were terminated because of 
cancer diagnosis, recording just those pregnant cancer patients who decided to continue 
their pregnancies (Andersson et al. 2015). Such recording practices are subject to 
numerous biases and require caution when interpreting the numbers. 
 1.1.1. Clinical challenges in cancer care during pregnancy 
 
Despite high hopes and reassuring observational data that cancer and pregnancy 
can be compatible with each other, some challenges still remain. One of them is timely 
diagnosis of maternal malignancy because cancer symptoms can be easily mistaken for 
normal physiological changes related to pregnancy. For example, enlarged breasts, 
constipation, aching joints, general tiredness or nausea are usual symptoms that most 
pregnant women experience at some point of gestation. However, there are numerous case 
reports confirming that the same symptoms can also be an indication of malignant disease 
(Jaspers, Gillessen, and Quakernack 1999)(Moran et al. 2007)(Pentheroudakis et al. 
2010)(Stensheim et al. 2015). Fortunately, constant development of diagnostic tools and 
regular antenatal care can help to detect even asymptomatic cancers in pregnant women. 
For example, ultrasound scans might detect pelvic tumours (e.g. ovarian), vaginal 
examination might reveal potential malignant cervical changes, routine blood tests could 
lead to detecting thyroid abnormalities and screening for foetal trisomy is also reported to 
detect tumour DNA in maternal plasma samples (Amant, Verheecke, et al. 2015). All these 
tests are of great importance for maintaining a healthy pregnancy and detecting cancer 
before it progresses to an advanced stage. Such findings, however, are usually regarded as 
incidental findings and should be communicated to the patient with extreme caution 
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avoiding unnecessarily stressing the patient23. Moreover, it is also important to consider the 
possibility of overdiagnosis which can lead to stress, anxiety, unnecessary testing and 
treatment24 (Ferretti, Linkeviciute, and Boniolo 2016).  
The second challenge arises when optimal doses of therapeutic agents need to be 
determined for a pregnant cancer patient. There is only scarce body of knowledge available 
about effectiveness of different treatment regiments when patient is pregnant. Common 
recommendation is that pregnant cancer patients should be treated as closely as possible to 
non-pregnant patients (Amant et al. 2010) but it is still unclear, what impact pregnancy 
specific physiological changes (e.g. hormonal balance, gut microbiota, immunotolerance 
towards the foetus) have on pharmacokinetics of chemotherapeutic agents. Therefore, 
adjusting the optimal doses of chemotherapy for pregnant patients still requires further 
research (van Hasselt et al. 2014). Targeted therapies are similarly under investigation with 
additional concerns surrounding placental crossing (Jovelet et al. 2015) and effect on the 
developing foetus (Lambertini, Peccatori, and Azim 2015). Decrease in maternal drug 
exposure due to pregnancy has been reported, but establishing dose adaptations requires 
further studies of pregnancy effects on pharmacokinetics of therapeutic agents used to treat 
cancer (van Hasselt et al. 2014).  
                                                 
23This is important not only as a human factor but also as potential teratogenic exposure. Stress is shown to 
have a teratogenic effect on fetal development (Hansen, Lou, and Olsen 2000)(Mulder et al. 2002). 
24This is especially relevant to the older women who are routinely offered enrolment in cancer screening 
programmes and might be missing their appointments during the course of pregnancy. Hence, it is important 
to distinguish preventive (used for colorectal and cervical cancer screening) and early detection methods 
(used for breast, prostate and lung cancer screening). Preventive methods help to reduce the mortality from 
cancer while early detection sometimes only results in more cancer cases diagnosed in an early stage but 
overall mortality from screened disease remains the same (Croswell, Ransohoff, and Kramer 
2010)(Wegwarth and Gigerenzer 2013). 
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Furthermore, alterations in maternal microbiota25 during pregnancy are observed 
(O. Koren et al. 2012)(Rautava et al. 2012)(Mueller et al. 2015), which presupposes that 
response to cancer therapies can also be affected.  It is thought that gut changes related to 
pregnancy can affect maternal response to cancer treatment as gut microbiota is shown to 
influence the response to chemotherapy and immunotherapy (Viaud et al. 2013)(Vetizou et 
al. 2015).  
The third challenge complicating cancer management during pregnancy is the 
occurrence of advanced maternal cancer. This imposes two problems: 1) managing the 
metastatic spread of cancer and 2) prolonging mother’s life to allow foetal maturity, which 
might include heavy sedation and in some cases keeping the pregnant cancer patient on life 
support. 
Metastases to the placenta are rarely reported and mainly occur in advanced cancers 
such as bronchial carcinoma (Kochman et al. 2001), gastric cancer (Miller et al. 
2012)(Chen et al. 2014), pancreatic cancer (Al-Adnani, Kiho, and Scheimberg 2007), 
colorectal cancer with metastases to liver (Robson et al. 2015), melanoma, metastatic lung 
cancer, and haematological malignancies (Al-Adnani, Kiho, and Scheimberg 2007). Even 
though melanoma is not the most common malignancy26 occurring during pregnancy, it 
accounts for about a third of all the cases involving placental or foetal metastases 
(Valenzano Menada et al. 2010). It is a standard good clinical practice to send the placenta 
for histological examination after the delivery, if mother was affected by cancer during the 
gestation (Loibl et al. 2006)(Pentheroudakis, Pavlidis, and Castiglione 2008)(Amant et al. 
2009). Foetal metastases from maternal malignancies are known to be fatal in most cases 
(Alexander et al. 2003). However, there are some cases reporting spontaneous regression 
                                                 
25 Microbiota is the community of microorganisms living in symbiosis with our body. 
26 It appears that melanoma is the most common cancer diagnosed during pregnancy in the Nordic regions, 
e.g. Sweden (Andersson et al. 2015). 
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of foetal metastases and infants reaching a complete remission (Valenzano Menada et al. 
2010) but any infant born to the mother with placental metastases has a higher risk of 
developing tumours and should be considered at high-risk (Alexander et al. 2003).  
 1.1.2. Maternal-foetal microchimerism and cancer 
 
Pregnancy could be a potential model for further understanding how a single 
malignant cell could proliferate and metastasize. For example, in normal human pregnancy 
the development of placenta invades the uterus, and a semiallogeneic27 foetus escapes the 
rejection from maternal immune system which is an example of immunologic tolerance 
(Holtan et al. 2009). Furthermore, presence of foetal cells in maternal blood and tissues, 
also known as foetal cell microchimerism, can be linked to the induction of immunological 
tolerance towards the foetus and also the development of autoimmune diseases (Fugazzola, 
Cirello, and Beck-Peccoz 2010). Interestingly, some reports suggest that foetal cells, which 
enter maternal circulation during pregnancy and engraft in a variety of maternal tissues, 
can induce the formation of blood and lymphatic vessels (Nguyen Huu et al. 2009) which 
play a role in maternal tumour formation. Further research suggests that in some cancers 
(e.g. melanoma) pregnancy induced lymphangiogenesis contributes to the subsequent 
metastases (Khosrotehrani et al. 2011). Disagreement still exists, however, if currently 
available evidence allows to conclude that pregnancy has an effect on the progression of 
melanoma (Martires et al. 2015) or the prognosis for any other types of cancer (Crivellari 
and Militello 2013)(Peccatori et al. 2013). In a light of differing hypothesis on foetal 
microchimerism and its role, some researchers take a different approach trying to 
understand the therapeutic uses of maternal-foetal microchimerism. As a result, 
suggestions are made that it is not necessarily associated with a rise in the incidence of 
malignant disease (Koopmans et al. 2008) but on the contrary could potentially be used to 
                                                 
27Semiallogeneic means that two organisms share some but not all of their genes. 
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treat maternal tumours by using infusions of microchimeric foetal cells (Fugazzola, 
Cirello, and Beck-Peccoz 2010).  
Furthermore, microchimerism is also shown to be a two-way process and is not 
limited to the presence of foetal cells in the maternal organism as maternal cells can also be 
transferred to the fetal tissues and remain present in neonatal organs (Srivatsa et al. 2003). 
It is speculated that such phenomenon might be quite common (Srivatsa et al. 2003). 
However, it can also have a detrimental effect on the foetus. There are two reports 
describing a malignant cells transfer from cancer affected mother to the foetus. They 
include infantile acute monocytic leukaemia, which was caused by transmission of 
maternal leukemic cells, and transplacental transmission of aggressive natural killer cell 
lymphoma (Fugazzola, Cirello, and Beck-Peccoz 2010). Fortunately, such cases of 
maternal cancer transfer to the foetus are extremely rare, but despite reassuring data, the 
interaction of pregnancy, maternal cancer and its treatment can be difficult to predict, 
control and manage due to multiple factors which still have to be explored, investigated 
and understood. 
1.2. Approaches to treatment  
 
The typical modes of cancer treatment include surgery, chemotherapy, radiotherapy 
and targeted therapies (summarised in Table 1.2.)  The latter three can be used as curative 
or neoadjuvant therapies, which are usually given following or preceding the surgical 
removal of the malignant tumour. 
Surgery is generally considered safe during the course of pregnancy. Some 
recommend to postpone surgery until after the 12th gestational week due to higher risk of 
spontaneous abortion in the first trimester, especially if surgery site is close to the pregnant 
uterus (Mlynarsky and Lishner 2011). Other modes of treatment initially were deferred 
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until after the delivery (Molho et al. 2008)(Lishner and Osadchy 2011) but growing 
amount of evidence suggests that standard treatment can be given to pregnant patients 
without adverse consequences to the foetus. Moreover, staging initially thought to be 
potentially harmful to the foetus, now is considered to have an added value when detecting 
distant metastases in pregnant cancer patients (Montagna et al. 2014). 
Chemotherapy works by stopping the rapid division of malignant cells but, while 
this is an intention in the case for cancer, it also affects normal functioning of bone 
marrow, gastrointestinal tract and growth of hair follicles leading to complications such as 
anaemia, various infections and hair loss. Therefore, for a long time it has been thought 
that administering chemotherapy during pregnancy would have a detrimental effect on the 
developing foetus as rapidly dividing cells characterise foetal development. The 
breakthrough occurred after the observation that placenta plays a key role in protecting the 
foetus from toxic effects of chemotherapeutic agents (Dekrem, Van Calsteren, and Amant 
2013). Small reports of long longitudinal studies suggest that in haematological 
malignancies chemotherapy can also be given in the first trimester without adverse effects 
to the foetus and with significant survival benefit to the mother, even if data are still scarce 
(Avilés, Neri, and Nambo 2012). Hence, concerns remain about the effect of 
chemotherapeutic agents which are accumulated in the placenta (Abellar et al. 
2009)(Jovelet et al. 2015). There are not many reports on maternal adverse effects specific 
to pregnancy in the course or as a result of chemotherapy. As such preeclampsia was 
reported once (Massey Skatulla et al. 2012) with reservation that this was just an accidental 
occurrence. Moreover, as already mentioned, pregnancy, especially in the older women, 
can have some maternal health related complications not necessarily directly related to 
cancer (Loibl et al. 2012)(Carolan 2013)(Jackson et al. 2015)(Dietl et al. 2015). 
Ionizing radiation is used in radiotherapy which aims to control the division of 
malignant cells. Generally pregnant women are advised to delay radiotherapy until after 
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the delivery but some argue that such recommendation is not supported by scientific 
evidence and can be given safely with proper shielding of pregnant uterus.  The gestational 
radiation exposure of 0,1-0,2 Gy28 and above is used as a threshold leading to mental 
retardation and organ malformation. It is not usually reached during the course of treatment 
during pregnancy (Kal and Struikmans 2005), particularly when the target is far from the 
uterus. A review of more than 100 cases suggests that radiotherapy could be associated 
with adverse outcomes to the foetus but it also cautions that not all adverse effects 
occurring after radiation exposure are necessarily caused by it (Luis et al. 2009). Some 
reports of using heavy doses of radiotherapy to control brain tumour metastasis during 
pregnancy suggest good outcome for the foetus (Tachibana et al. 2015). There appears to 
be very little data reporting long-term outcomes after gestational exposure to radiotherapy. 
Despite the small numbers, findings seem to be consistent and it is suggested that upper 
body radiation before the third trimester with a shielding of pregnancy is not harmful for a 
foetus (Amant, Han, et al. 2015)(Amant, Vandenbroucke, et al. 2015).  
Targeted therapies are a general term for a wide range of therapies used in cancer 
treatment such as hormonal therapy, immunotherapy, antibody therapy, etc.  The common 
feature they all share is that they work by aiming at a particular receptor to block one 
particular pathway which is responsible for malignancy inducing molecular activities. 
Widely held expectation is that targeted therapies might be more effective in treating 
certain cancers (e.g. HER2-positive breast cancer) and produce less side-effects because of 
specific action as compared to systemic effect of chemotherapy. Still a good number of 
                                                 
28 There are four different but interrelated units for measuring radiation: radioactivity, exposure, absorbed 
dose and dose equivalent/effective dose. Radiotherapies for cancer refer to radiation absorbed dose (rad) by 
the patient’s body which is the amount of energy that radioactive source deposing in the materials (patient’s 
body tissues) through which they pass. One gray (Gy) is the international system of units (SI) equivalent of 
100 rads, which is equal to an absorbed dose of 1 Joule/kilogram. An absorbed dose of 0,01 Gy means that 1 
gram of material absorbed 100 ergs of energy (United States Nuclear Regulatory Commission 2014). 
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targeted agents are contraindicated in pregnancy due to the lack of clinical data about their 
effect on the foetus (Lambertini, Peccatori, and Azim 2015). Agents used as targeted 
therapies are diverse, and while some can be compared to chemotherapy because of small 
molecules (e.g. tyrosine kinase inhibitors - TKI); others require active transport across 
placenta to reach the foetus (e.g. monoclonal antibodies). TKIs raise particular concerns 
due to worrying preclinical and clinical data showing a potential to interfere with vital 
physiological functions of foetal development (Apperley 2009) but some case reports 
suggest normal foetal development and neonatal outcome under gestational exposure to 
imatinib, which is a TKI used to treat some forms of haematological malignancies and 
gastrointestinal tumours (Goel et al. 2013). Nevertheless, some leading experts suggest that 
using targeted agents during pregnancy might be possible and not all of them should be 
avoided completely during pregnancy (Lambertini, Peccatori, and Azim 2015)(Lishner et 
al. 2016). Hence, the use of targeted therapies during pregnancy cannot be presented to the 
patients as an established practice and each case has to be assessed individually. The 
adverse effects, when targeted agents are used include foetal renal insufficiency, which 
was reported following trastuzumab (monoclonal antibody) treatment (Gottschalk et al. 
2011) and numerous other agents show embryo-toxicity, teratogenicity and might induce 
spontaneous abortions (Lambertini, Peccatori, and Azim 2015).  
Hormonal therapies are used to manipulate the endocrine system. Steroid 
hormones (e.g. antiestrogens, aromatase inhibitors) can regulate gene expression in some 
cancer cells. Therefore, it has a potential to stop tumour growth and make it shrink. 
Generally it is contraindicated in pregnancy. Tamoxifen is the standard hormonal agent 
used in treating pre-menopausal women with endocrine-responsive breast cancer (e.g. 
HER2-positive, endocrine (oestrogen and progesterone) receptor positive, triple (HER2 
and endocrine receptors) positive  breast cancer) but due to reported congenital 
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abnormalities is advised not to be used during pregnancy (Azim, Peccatori, and Pavlidis 
2010b). 
Application of immunotherapies to cancer treatment is a relatively new approach. It 
refers to a number of treatment approaches which either activate the immune system in 
order to fight the malignancy or provide it with some of the components needed to boost 
the immune response. Not all immunotherapeutic agents share the same mechanism of 
action and not all of them are considered targeted therapies. Sometimes a term of 
biological therapies is used instead to better describe them. This, for example applies, to 
vaccines and bacteria, which are used to stimulate bodily reaction against cancer cells. 
Initially, the most focus was put on vaccines as studies showed that they can initiate or 
amplify a host organism response against evolving tumours (Siguo Hao, Moyana, and 
Xiang 2007). Various vaccine components activate resting dendritic cells29, which migrate 
to a local lymph node where they display fragments of proteins in the form of small 
peptides, also known as antigens, to T naive lymphocytes. After this presentation, T 
lymphocytes become cytotoxic T lymphocytes (CTLs), which are specific and able to kill 
the target. More recent approaches are centred around blocking the immune checkpoint 
molecules with monoclonal antibodies (Drake, Lipson, and Brahmer 2013) which are 
artificially made immune system proteins designed to target very specific part of cancer 
cell. One such mechanism involves cell-surface expression of molecules that limit T cell 
proliferation and their killing capacity (Pardoll 2012). Molecules which show the ability to 
block the activity of T cells are referred to as immune check points (Drake, Lipson, and 
Brahmer 2013). Many of them are initiated by ligand-receptor interactions and can be 
                                                 
29 The main function of dendritic cells is to act as a messenger between innate and adaptive immune system. 
They do this by processing antigen material and transporting it to the surface of T cells (Reis e Sousa 2004; 
Malissen, Tamoutounour, and Henri 2014). 
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blocked by antibodies or modulated by recombinant forms of ligands or receptors (Pardoll 
2012).  
One more option is delaying treatment until after the delivery of a baby. This is 
possible because not all cancer cases, especially in early stages (e.g. breast cancer), require 
immediate intervention, but in other cases it can lead to worse prognosis (e.g. acute 
leukaemia) (Shapira-Rotenberg and Lishner 2011). Therapeutic abortion or preterm 
delivery before initiation of maternal cancer treatment has not shown to improve prognosis 
(Peccatori et al. 2013). 
General approach to managing cancer during pregnancy is to apply the same treatment 
as to non-pregnant patients as closely as possible (Helewa et al. 2002)(Cardoso et al. 
2012)(Peccatori et al. 2013)(Galofré, Riesco-Eizaguirre, and Álvarez-Escolá 2014)(Ali et 
al. 2015) and to allow foetus to mature as closely as possible to term (Amant et al. 
2010)(Loibl, Han, and Amant 2012)(Peccatori et al. 2013)(Amant et al. 2014). It is also 
generally accepted that pregnancy does not seem to compromise maternal survival as 
compared to non-pregnant cancer patients (Pentheroudakis, Pavlidis, and Castiglione 
2008)(Amant et al. 2014)(Eyre et al. 2015). The latter, however, is still debated and subject 
of further studies. 
 
Table 1.2. Summary of cancer therapies 
Therapeutic 
intervention 
Expected benefits General challenges Pregnancy specific 
challenges 
Surgery Removes the tumour 
from its locality in 
the body 
Some cancer cells or small 
metastases might be left 
behind.  
Might increase the 
risk of miscarriage 
in 1st trimester, 
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Therefore, following 
chemotherapy or 
radiotherapy treatment 
might be required. 
especially if close to 
the pregnant uterus. 
Chemotherapy Acts systemically by 
destroying all tumour 
cells irrespectively 
from their location in 
the body 
It has an adverse effect on 
other rapidly dividing cells 
in the body (e.g. bone 
marrow) which results in 
infections, anaemia, hair 
loss, subsequent infertility. 
Placenta plays a key 
role in protecting the 
foetus. 
 
Gestational exposure 
might result in lower 
birth weight, 
preterm delivery and 
IUGR. 
Radiotherapy Can be targeted 
locally following the 
surgery or before it 
Might result in sore skin, 
anaemia and tiredness, 
nausea, loss of appetite, 
subsequent infertility, and 
secondary cancer caused 
by radiation exposure. 
Could cause 
miscarriage in early 
stages of pregnancy, 
fetal organ 
malformation and 
mental retardation. 
 
Contraindicated in 
third trimester as 
limiting fetal 
growth. 
Targeted Targets the tumour Can cause rash (EGFR Could cause 
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therapies cells directly through 
their mechanism of 
action 
inhibitors), high blood 
pressure, bleeding and 
slow wound healing 
(angiogenesis inhibitors), 
heart damage (HER2 
inhibitors), autoimmune 
reactions (immune 
checkpoint inhibitors). 
miscarriage, major 
malformations, data 
is still lacking for 
most agents. 
 
1.3. Maternal and foetal outcomes  
 
Data on maternal survival and prognosis remain controversial. Despite reassuring 
data for some cancers (e.g. breast cancer), experts recognise that it is too early to draw 
concrete conclusions (Loibl, Han, and Amant 2012)(Peccatori et al. 2013)(Reichman, 
Eldar-Gava, and Paltiel 2016). Case reports of less frequently occurring cancers suggest 
that pregnant women might have a very poor prognosis in case of colorectal cancer 
(Jeppesen and Østerlind 2011)(Araujo Júnior et al. 2012)(Toosi et al. 2014), bronchial 
carcinoma (Kochman et al. 2001) and gastric cancer (Yoshida, Matsuda, and Furuya 2009) 
due to delayed diagnosis and also rapid progression which theoretically could be induced 
by pregnancy. Moreover, some malignancies (e.g. ovarian cancer) diagnosed and treated 
during pregnancy might be prone to reoccurrence (He et al. 2012) and also are known to 
have poor outcomes if diagnosis is delayed (Serkies, Węgrzynowicz, and Jassem 2011).  
One more point of a concern is that women diagnosed with cancer in the first year 
post-partum have worse chances of survival30 (Bladström, Anderson, and Olsson 2003) 
                                                 
30 This could also be related to immunology changes induced by post-partum depression but while it is 
known that cancer patients who experience depression have worse treatment and survival outcomes (Kanani 
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and recent birth is considered to be an adverse prognostic factor among young women 
diagnosed with breast cancer (Whiteman et al. 2004).  A study from Spain including 25 
breast cancer patients, who were diagnosed in the course of their pregnancies, reports that 
these patients, developed numerous complications unrelated to cancer treatment (Córdoba 
et al. 2013). It is of a concern because it might compromise general wellbeing of these 
women and their foetuses and also have an effect on their ability to take care of themselves 
and their children.  
Overall, despite high cure rates, long-term cancer survivors have an increased 
mortality rate (Follows et al. 2014), are hospitalized more often (Richardson et al. 2015) 
and young survivors (e.g. breast cancer) have poorer prognosis than older women 
(Whiteman et al. 2004). In addition, it is known that pregnancy rates are about 40% lower 
among cancer survivors as compared to general population (Peccatori et al. 2013) 
including the 44% higher rates of  abortion among the survivors (Lambertini et al. 2013), 
which suggests that even if prognosis is good, the reality that patients have to face might 
be slightly harsher.  
During the course of maternal cancer treatment no specific interventions exist to 
protect the foetus from the adverse effects. One exception is pelvic area shielding in case 
of radiotherapy, which protects the foetus from external scattered radiation but internal 
scatter cannot be prevented (Syleny N Han 2015).  
The most recent studies investigating the foetal, neonatal and paediatric outcomes 
after gestational exposure to chemotherapy are very much reassuring (Cardonick et al. 
2015)(Amant, Vandenbroucke, et al. 2015)(Peccatori, Corrado, and Fumagalli 2015) 
unanimously suggesting that children, born to mothers with cancer who have undergone 
chemotherapy, are developing without any major health problems which could be 
                                                                                                                                                    
et al. 2015; Vodermaier et al. 2014), it is not known what role post-partum depression plays in relation to 
post-partum cancer occurrence and diagnosis.  
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attributed to maternal cancer treatment. Hence, despite reassuring data that a good number 
of cancer treatments can be given to pregnant women without causing detrimental effects 
for the foetus, it is expected that babies born after exposure to chemotherapy are of lower 
birth weight, might experience intrauterine growth restriction (IUGR), and premature birth 
(Rizack et al. 2009)(Peccatori et al. 2013)(Amant, Vandenbroucke, et al. 2015) which 
might have unfavourable health-related consequences later in life. Not all studies yield the 
same results. For example, one study found that congenital anomalies, preterm delivery, 
and growth restriction were not increased when exposure to chemotherapy occurred after 
the first trimester (Cardonick, Usmani, and Ghaffar 2009).  
Gestational exposure to chemotherapy needs to be carefully planned, however. The 
optimal delivery timing is three weeks after the last round of chemotherapy due to 
expected foetal bone marrow depression, potential bleeding and increased risk of infections 
(Walfisch 2011). Some remaining concerns on potential foetal complications, even if they 
do not seem to be occurring regularly, are the possibility of impaired cognition (Nulman, 
Tobias, and Uleryk 2011)(Amant et al. 2012), cardiac toxicity (Gziri, Amant, et al. 
2012)(Gziri, Debiève, et al. 2012), renal toxicity31 (Gottschalk et al. 2011), future 
infertility (Hahn et al. 2006), premature menopause in female offspring32 (Stefansdottir et 
al. 2016) and hearing loss33(Shuai Hao et al. 2011). As already mentioned, it has to be 
noted that current state of knowledge suggests that these complications are rather 
                                                 
31It was reported after exposure to trastuzumab. Therefore, after accidental exposure close monitoring of the 
foetus with particular attention to amniotic fluid and the foetal bladder volume is recommended as they 
reflect foetal renal function. Low volumes of amniotic fluid could lead to foetal pulmonary problems. 
32 This was observed in mice when using chemotherapy drug etoposide; mice foetuses exposed to a study 
drug before follicle formation reportedly had 90 percent reduction in a number of follicles. However, 
exposure to the same drug after foetal follicles were formed did not seem to affect future fertility of the 
offspring.  
33 This has only been observed in guinea-pigs when using cisplatin. 
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theoretical than evidence-based but caution is still warranted (Reichman, Eldar-Gava, and 
Paltiel 2016). Overall, experts consider the observational results on foetal outcomes to be 
reassuring and suggest that gestational exposure to cancer treatments is not associated with 
increased risk of congenital abnormalities, cognitive or cardiac impairments when adjusted 
and compared to healthy controls (Cardonick et al. 2015)(Peccatori, Corrado, and 
Fumagalli 2015)(Amant, Vandenbroucke, et al. 2015). 
As already noted, caution when interpreting the above results is warranted, mainly 
due to the rarity and diversity of the condition. Currently available data still has some 
limitations such as small sample sizes, data being collected from various registries with 
lack of valid controls, which is often done retrospectively, without rigorous systematic 
approaches and sometimes with methodological deficiencies (Greene and Longo 
2015)(Reichman, Eldar-Gava, and Paltiel 2016). It is important to note, however, that 
cancer therapies are constantly changing as new are being developed. Therefore, this 
makes it difficult to have a long-term data on new therapies. For the time being the most 
knowledge on cancer treatment during pregnancy comes from retrospective studies which 
use cancer registries to study birth outcomes (Cardonick, Usmani, and Ghaffar 
2009)(Loibl, Han, and Amant 2012), maternal survival and prognosis (Amant et al. 2013), 
and long-term outcomes for children who had gestational exposure to chemotherapy 
(Amant, Vandenbroucke, et al. 2015). Some attempts to conduct systematic prospective 
studies on foetal cardiac function after exposure to chemotherapy are reported as well 
(Gziri, Debiève, et al. 2012). 
Overall, there are still uncertainties remaining about cancer treatment effect on 
maternal cancer, its prognosis and risks it is posing to the developing foetus. There is also 
only limited data available on the effect that a subsequent pregnancy might have on cancer 
reoccurrence in cancer survivors. Concerning less frequently occurring cancers the 
evidence remains scarce and in some cases treating pregnant women with cancer still 
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might be regarded more as a research than a consolidated medical practice. In addition, not 
all cancer treatment regiments have been researched explicitly for cancer during pregnancy 
context and a significant body of knowledge still comes from animal studies such as 
baboon (Van Calsteren et al. 2010) and mice models (Van Calsteren et al. 2011). 
Moreover, the largest studies on maternal and foetal outcomes have been conducted with 
patients affected by the most common cancers which are breast (Loibl et al. 2012)(Amant 
et al. 2013) and gynaecologic malignancies (Amant et al. 2014). Therefore, it is not 
immediately apparent, what are the outcomes when different cancers and treatment 
regiments are compared.  
1.4. Special circumstances  
 
Foetuses developing the congenital tumours independently from maternal tumour 
status are also rare occurrences. Most common are foetal brain tumours, neuroblastomas 
(Reif et al. 2014), teratomas and gliomas (Vibert-Guigue et al. 2008)(Milani 2015). In the 
majority of cases prognosis is poor, recommended treatment includes neurosurgical tumour 
resection and chemotherapy (Milani 2015). Malignancies of foetal origin which 
metastasise to the placenta or maternal body organs are extremely rare. There have only 
been a few cases reported in the literature which involved tumour transmission from the 
foetus to the maternal part of the placenta or maternal organs (Reif et al. 2014).  
Prolonging maternal life for the benefit of the foetus is a very challenging situation 
from numerous perspectives. The goal when putting a critically ill pregnant woman on a 
life support by allowing her somatic functioning to continue is to deliver a viable and 
healthy infant with a beneficial long-term outcome (Esmaeilzadeh et al. 2010). One of the 
largest systematic reviews on the management of pregnant brain-dead women found that 
out of 30 cases reported between 1982 and 2010, 12 viable infants were born and survived 
a neonatal period (Esmaeilzadeh et al. 2010). To date most reports come from patients who 
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experienced a fatal injury but otherwise had healthy pregnancies. Common medical 
problems occurring in brain-dead pregnant women include adrenal insufficiency which 
could lead to hypotension causing foetal hypoxia. It is also very important to maintain 
maternal body temperature as hypothermia might lead to intrauterine growth restriction 
(IUGR) and take all precautions to prevent infection (Said et al. 2013). Clinical 
recommendations suggest that there are no clearly indicated lower limits for gestational 
age which would restrict the medical efforts to support brain-dead mother and her foetus 
(Esmaeilzadeh et al. 2010).  
 1.5. Summary  
 
Overall, currently available studies give an optimistic message, suggesting that 
chemotherapy (and some other treatments) can be safely given to the pregnant patients in 
the second and third trimesters, pregnancy termination does not improve maternal survival 
and that children who experienced gestational exposure to chemotherapy are developing 
fine (Cardonick et al. 2015)(Amant, Vandenbroucke, et al. 2015). Radiotherapy is also 
thought to be possible in the second trimester with some limitations due to the radiation 
field without compromising healthy foetal development (De Sanctis et al. 2012)(Syleny N 
Han 2015) while there is very little data on the use of targeted therapies.  
The remaining challenges include timely diagnosis of maternal disease, choice of 
optimal treatment and management of advanced maternal cancer during the course of 
pregnancy. Speculations are still made that pregnant women have worse survival outcomes 
for some cancers (e.g. colorectal cancer, thyroid cancer, melanoma). Moreover, cancer 
survivors in general are known to have higher hospitalization rates and more health 
problems not necessarily related to cancer and/or its treatment. In addition, some studies 
report that pregnancy rates among cancer survivors are about 40% lower as compared to 
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the general population (Peccatori et al. 2013) and that up to 44% of breast cancer survivors 
who get pregnant, choose to terminate their pregnancies (Lambertini et al. 2013).  
Furthermore, maternal tumour spreading to the placenta or the foetus are rare events, 
just as it is very rare that independently developed foetal tumours would spread to the 
placenta and maternal organs. There are also case reports suggesting that brain dead 
pregnant women could be kept on life support in order to allow foetal maturity 
(Esmaeilzadeh et al. 2010). 
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Chapter 2. Cancer care during pregnancy: ethical issues 
 
2.1. Maternal-foetal conflict34  
 2.1.1. Definition of the conflict  
 
 Looking from a clinical perspective this type of conflict occurs when optimal 
treatment for a pregnant woman is not compatible with a healthy development of her 
foetus. Historically, in the oncology context one of the most common problems was the 
uncertainty about maternal treatment effect on the developing foetus and future child the 
foetus will become. Sometimes it was presented as a choice between life and death or 
choice between two lives. In clinical and ethics literature it is referred to as a maternal-
foetal conflict (Weisz, Schiff, and Lishner 2001)(Moran et al. 2007)(Patni et al. 2007) due 
to a potential harm that maternal treatment can cause to the developing foetus.  
One of the most widely discussed conflicts is that appropriate and timely treatment 
for the cancer affected mother can pose high risk for the developing foetus (Weisz, Schiff, 
and Lishner 2001)(Backes, Moorehead, and Nelin 2011)(Del Pup et al. 2012)(Morice, 
Uzan, and Uzan 2012). Therefore, traditionally the view was held, that cancer treatment 
during pregnancy was not compatible with normal foetal development (Backes, 
Moorehead, and Nelin 2011) leading to either under treating a pregnant cancer patient due 
to a fear of foetal harm or offering inadequate therapy, which increased foetal morbidity 
and mortality (Oduncu et al. 2003)(Azim and Peccatori 2011). However, as it was 
mentioned previously, research data suggest that from a medical point of view a conflict 
                                                 
34 The term “maternal-foetal conflict” is widely used but not everyone agrees with such usage and propose 
another formulation “ethical dilemmas that arise in the care of pregnant women” (Flagler, Baylis, and 
Rodgers 1997). Referring to maternal-foetal conflict I mean a conflict between the pregnant woman’s 
autonomy and/or beneficence and the best interest of the foetus.  
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concerning cancer treatment and pregnancy is not so severe anymore and it might be 
considered a compromise rather than a choice between life and death. There is a growing 
body of evidence suggesting that in many cases of early cancer, the treatment in the course 
of pregnancy is possible without adverse effects on the foetus and compromised survival of 
the mother (Amant, Vandenbroucke, et al. 2015). This, however, is an ideal general 
scenario while in reality there can be numerous factors affecting maternal and foetal 
outcomes in individual cases as well as future implications such as for example more 
frequent hospitalisations of cancer survivors (Richardson et al. 2015). The compromise 
solution when pregnant woman is critically ill is also recognised by ethics scholars 
suggesting that perimortem decisions should take into consideration the wishes of the 
pregnant woman, foetal viability, health status of the foetus, and the views of her partner 
and family (van Bogaert and Dhai 2008).  
It has to be acknowledged that maternal treatment usually does not have any direct 
or active health-related benefit to the foetus other than increasing the maternal chances of 
survival. Hence, in some cases prolonging mother’s life is of crucial importance to foetal 
development and survival, but under some other circumstances the optimal solution for the 
foetus would be postponing maternal cancer treatment until after the full-term delivery. 
Generally experts aim to save two lives by urging to seek compromise and favourable 
treatment solution for a pregnant woman affected by cancer and her foetus. However, if 
such compromise is not possible, some favour maternal health-related benefit (G. Koren et 
al. 2013)(Follows et al. 2014)(Amant et al. 2014) while just a few express restrictive 
position on pregnancy termination in case of maternal cancer (Papini et al. 2010)(De Haan, 
Verheecke, and Amant 2015)35. The results of a systematic review of clinical practice 
                                                 
35One of the leading researchers in Europe F. Amant, in an interviews with Cancer World expresses the 
position that cancer should not be seen as a reason to terminate the pregnancy and developing baby has a 
right to live arguing that this ethical position is based solely on clinical evidence without any influence of his 
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guidelines concerning cancer management during pregnancy reveal that ethical views 
embedded in such guidelines are diverse but leaning to giving preference to maternal 
beneficence (Chapter 3).  
Maternal-foetal conflict can also occur in circumstances where disagreements arise 
between a pregnant woman and her treating physician, entire healthcare team or some of 
the relatives. In such situations pregnant woman’s interests, as defined by her, might clash 
with the interests of her developing foetus, as defined by her treating physician (Fasouliotis 
and Schenker 2000) or other parties involved. On one hand, it can be a maternal-foetal 
conflict in a light of disagreement towards medical treatment options but on the other, it 
could also be a conflict between a pregnant patient and her physician and/or relatives, 
when defining and balancing maternal and foetal benefits not necessarily limited to health-
related benefits. In such circumstances some scholars suggest to make a distinction 
between clinical and ethical decision-making (Boniolo and Sanchini 2016). Such decisions 
extend further and above health related decisions and might include the welfare of the 
future child the foetus will become, welfare of pregnant woman’s family members and/or 
other relatives who might not be in a position to take care of the future child if the patient 
dies after the baby is born (Linkeviciute and Peccatori 2016). Furthermore, it can be argued 
that becoming an orphan at an early age could also compromise child’s welfare. Hence, 
such concerns are not solely specific to cancer and losing one’s parent or parents due to a 
disease does not necessarily constitute a life which is not worth living for an orphaned 
child.  
Such disagreements might also be loaded with heavy emotions, which can be 
influenced by social expectations, cultural and religious beliefs. In addition, it is important 
to note that the pregnant cancer patient and her care providers might be facing ethical 
                                                                                                                                                    
personal religious beliefs: “Frederic Amant: Building the evidence base for saving mother and child” by  
Mark Beishon in July-August 2015. No 67. http://issuu.com/cancerworld/docs/cw67_complete_issue 
[accessed 2015-09-24]. 
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dilemmas36 which are not necessarily the same (Morice, Uzan, and Uzan 2012). Emotions 
and feelings are known to play an important role in our moral life. They also play a crucial 
role in moral judgments we make. However, relying on emotions might not be the most 
efficient way to reaching satisfying solutions to ethical problems. Therefore, it is argued 
that recognition of emotions together with reason-giving could serve better in deciding 
which course of action best conforms with one’s goals, beliefs and values (Annoni 2016), 
which in this work is understood as personal philosophy, which implies that patient’s 
views and beliefs play an important role in decision-making and should be addressed 
(Linkeviciute et al. 2015)(Boniolo and Sanchini 2016).  
 2.1.2. Models of pregnancy 
 
 The relationship between pregnant woman and her developing foetus is unique. 
Explicit understanding of maternal-foetal conflict requires explanation on how pregnant 
and non-pregnant women are similar and also different, and how foetuses are unique 
entities, which are potential human beings, but as of yet not independent. Therefore, in 
order to address ethical, social and legal issues arising when medical interventions are 
required during the course of pregnancy calls for clarification on how physical and 
metaphysical relationship between pregnant women and their foetuses is understood and 
used in medical and ethical decision-making processes.  
                                                 
36 Ethical dilemma arises in the situation where moral principles and personal values are compromised 
because the agent is expected to do each of two (or more) actions but can only do one which presupposes that 
no matter what choice the agent makes, she will fail to do something what she ought to do (Stanford 
Encyclopedia of Philosophy) http://stanford.library.usyd.edu.au/entries/moral-dilemmas/ [accessed 2016-03-
25; last updated 2014-06-30]. For example, a doctor might feel obliged to treat maternal cancer and to protect 
the foetus; pregnant woman might feel that she has to do everything possible to overcome her disease but 
also avoid harming the foetus. 
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Pregnant woman’s relationship to the foetus is still subject to clarifications due to 
numerous speculations concerning pregnancy, motherhood and bearing of children in 
general. Some distinguish self-sacrifice and self-defence models of motherhood/pregnancy 
arguing that the first one is a traditional model which limits our insights to an entire debate 
of pregnancy and pregnancy termination, while the second one is overlooked equally by 
pro-life and pro-choice proponents (McDonagh 2002). Self-sacrifice model presents a 
pregnant woman as agreeing to give up some of her interests for the benefit of her foetus 
while self-defence model suggests that pregnant women should have a right and means to 
defend themselves from pregnancies which threaten their health and might result in 
significant injury. Meanwhile, others argue that parental relationship in itself presupposes 
special responsibility to a child where parents have to be ready to make certain sacrifices, 
no matter the circumstances (Lee and George 2005) and therefore self-defence model is 
not valid alternative.  Hence, I do not take a stand that pregnant woman and her foetus are 
in a fight against each other. My view is that in cases of maternal-foetal conflict protective 
and nurturing role of a would-be-mother is compromised by various circumstances 
pregnant woman finds herself in, be it malignant disease, financial hardship or certain 
expectations from her family and/or society. Therefore, disagreement or conflict per se is 
not strictly between a pregnant woman and her foetus, it could extend to a pregnant woman 
and her environment, particular social circumstances, health condition, and availability of 
resources.  
Solutions to maternal-foetal conflict, however, could strongly depend on the views 
on pregnancy and maternal-foetal relationship. Moreover, such solutions might be 
influenced by societal, cultural and religious views but will mainly affect a pregnant 
woman and her foetus, not the society at large. Two often conflicting positions are centred 
on maternal autonomy and protection of the foetus (or the unborn child). The maternal 
autonomy centred approach could be said to be predominant in most legal systems and 
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ethical debates (Shanner 1998)(Fasouliotis and Schenker 2000)(ACOG Committee on 
Ethics 2005). Hence, there have been some cases in the USA where pregnant women were 
found guilty of “foetal abuse” due to their addition to alcohol or illegal substances (e.g. 
cocaine) while some pro-life thinkers also reject the term “unborn” suggesting to replace it 
with “pre-born” attributing higher moral value and more protection to the foetuses (Ruth 
Macklin 2014). Some have also suggested to address foetus as a patient (Chervenak et al. 
2004)(Chervenak, McCullough, and Brent 2011) establishing a prematernal duty to the 
unborn child, which presupposes that a pregnant woman should care for her unborn child 
(Yeast 1995) and be ready to make certain sacrifices once she accepted to carry the 
pregnancy to term37 (Torres and De Vries 2009) while others go even further suggesting 
that any burden or sacrifice a pregnant woman makes cannot be compared to the harm 
caused by terminating the pregnancy (Lee and George 2005).  
 The proponents of foetal patienthood argue that maternal autonomy plays a major 
role only until foetal viability is reached. Up till then a pregnant woman is free to decide if 
she wants to present the foetus as a patient to the physician and she can also change her 
mind and withdraw previously attributed patienthood status all the way until the foetus can 
be considered viable38. During the time before foetal viability physician has autonomy and 
beneficence-based obligations to the pregnant woman but not beneficence-based obligation 
to the foetus if pregnant woman did not present it as patient to the physician. Meanwhile, 
after viability physician has beneficence-based obligations to the foetus as well as to a 
pregnant woman and therefore should protect foetal health-related interests when caring 
                                                 
37 This point, however, is only valid for the societies where an individual woman has a freedom to decide 
when and with whom she has sexual intercourse, access to reliable contraception and pregnancy termination.  
38 It remains unclear, however, what are physician’s duties to pre-viable foetal patient when pregnant woman 
presents her foetus as patient and then changes her mind. Relationship between pre-viable foetal patient and a 
physician appears to be tentative and does not seem to require protection of the best interest of the foetus if 
pregnant woman withdraws foetal patient status from her pre-viable foetus. 
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for a pregnant patient (McCullough and Chervenak 1994)(Fleischman, Chervenak, and 
McCullough 1998)(Chervenak et al. 2004)(Chervenak, McCullough, and Brent 2011). 
 Referring to the foetus as a patient suggests that pregnant woman and a foetus can 
be seen as two separate entities. Separation of maternal-foetal unit is presented as one of 
the major critiques when addressing foetus as a patient topic (Brown 2008)(Lyerly, Little, 
and Faden 2008)(Rodrigues, van den Berg, and Düwell 2013).  Debates separating 
pregnant women and their foetuses also tend to concentrate on balancing rights and 
interests of two parties but some argue that such attempts are deemed to fail as pregnant 
woman and her foetus cannot be separated from each other (Shanner 1998). Therefore, 
well known “violinist example” (Thompson 1971) or Thompson’s argument39 is argued to 
be irrelevant analogy to maternal-foetal relationship (Shanner 1998). Some feminist 
authors suggest that medicalisation of pregnancy (e.g. ultrasound technology) contributed 
to the perception that foetus is a separate individual who “unfortunately” is imprisoned in 
maternal body (Mullin 2005)(Watt 2016). Hence from biological and physiological point 
of view it is obvious that foetus is dependent on the pregnant woman and it is known that it 
is in the best health related interest of the foetus to gestate inside of the uterus until full-
term is reached. This presupposes that even if the foetus can survive outside of maternal 
body, its health could be significantly compromised if pre-term delivery is induced. 
 Furthermore, the foetal patienthood concept has another problem when applied to 
cancer during pregnancy cases. As the authors of the concept explain, being a patient has 
                                                 
39 In her classical paper “A defence of abortion” Judith Jarvis Thompson invites her reader to imagine that a 
famous violinist is dying of a rare disease and the only way to save him is to attach his circulatory system to 
another person for nine months. Furthermore, Thompson speculates that should someone be kidnapped by 
the Society of Music Lovers and find herself in the hospital hooked up to the violinist in order to provide him 
with a metabolic support, she has no obligation to remain in a hospital bed next to the famous violinist for the 
next nine months even if unplugging herself from the violinist’s circulatory system would result in his 
immediate death (Thompson 1971).  
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two components: 1) human being is presented to the physician; 2) clinical interventions 
exist that are reliably expected to clinically benefit that human being (Chervenak, 
McCullough, and Brent 2011) but in cancer during pregnancy cases the foetus does not 
necessarily need an intervention for its own health benefit. On the contrary, foetus might 
benefit (especially concerning health-related benefits) if no medical interventions are 
carried out on its mother. Therefore, foetus is presented to the physician as a part of 
pregnant woman who needs treatment, but not as an entity requiring specific intervention 
for itself. This means that if cancer is diagnosed during pregnancy, it is a pregnant woman 
who needs treatment and, therefore, is a patient, while foetus has to bear the adverse effects 
not necessarily getting any kind of benefit other than remaining in a functioning maternal 
body until the end of its gestation. However, the later aspect is a very important benefit for 
both viable and pre-viable foetuses as gestating as close as possible to term has been 
observed to have health benefit (Loibl, Han, and Amant 2012) and could be viewed as a 
trade-off. Some call the notion of foetus as a patient a cautionary concept intended to 
prevent the injury to the foetuses and to spare families the distress of finding out that 
treatment choices made in a good faith by unfortunate oversight cause birth defects or 
other injuries to the future children that foetuses are due to become  (Dickens and Cook 
2003). The later interpretation, however, does not focus on the way how a patient is 
presented to the physician or direct interventions designed for the foetal benefit 
specifically. 
 Therefore, the pregnancy embodiment model40 is suggested in order to address 
potential conflicts better (Shanner 1998). Embodiment model recognises that pregnancy is 
                                                 
40 This view is gaining more recognition recently with attempts to clarify the metaphysical relationship 
between the pregnant woman and her foetus, especially concerning the ‘parthood’ rather than separation of 
the two. One such project is ‘Taking Pregnancy Seriously in Metaphysics, Ethics and Epistemology’ run by 
the University of Southampton in the UK 
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both unity and duality; that mother and foetus are not identical entities but also inseparable. 
It transcendences, which means that a pregnant woman is experiencing a change during 
which she is becoming something more than her previous self or transcending the usual 
boundaries of self. According to this model pregnancy is seen as a gradual process where a 
pregnant woman is herself and another person at the same time but at birth the “other” 
individual fully emerges and the woman returns to a non-transcendental, non-pregnant 
state where she returns to be being herself alone again. Moreover, pregnancy is seen as an 
active state (in opposition to passive)41 which requires a recognition and respect for the 
commitments, sacrifices, and contributions a pregnant woman undertakes in carrying a 
pregnancy (Shanner 1998). 
As already noted, maternal-foetal conflict does not have to entail a fight for 
survival between the mother and her foetus.  Occurrence of malignant disease in the course 
of pregnancy can compromise numerous plans, wishes and desires a pregnant woman was 
cherishing such as to be a parent, take care of one’s children, and provide her children with 
welfare. Therefore, even if medical aspects concerning cancer treatment during pregnancy 
allow uncompromised foetal development, there are also other factors to be taken into 
consideration. For example, financial and childcare arrangements, family situation, care 
required for pregnant cancer patient and her cancer care after giving birth. There are 
numerous everyday aspects to be thought about when addressing reproductive issues in 
oncology (Rodriguez et al. 2013). Hence, the view I am defending in this work is that 
pregnant cancer patient should not be forced into any kind of the decision while reasonable 
                                                                                                                                                    
http://www.southampton.ac.uk/philosophy/research/projects/taking-pregnancy-
seriously.page#project_overview [accessed 2016-03-25; updated: no info; attended workshop: 2015-09-18]  
41 Some feminist philosophers, as for example Catriona Mackenzie, argue that causal responsibility for 
pregnancy is shared equally by males and females but it cannot be equated to moral responsibility for 
pregnancy continuation because it is uniquely shouldered by females (Mackenzie 1992).  
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evidence-based measures are being taken to protect the welfare of her foetus and a future 
child this foetus will potentially become. 
There have been attempts to offer theoretical justification for late and even “after 
birth abortion” on the grounds that the mother cannot take care of the child and has to give 
it up for adoption. Giubilini and Minerva argue that concerning maternal welfare it might 
be better to kill a healthy newborn than give it away for adoption due to stress and guilt the 
mother will be experiencing because of separation with a child42 (Giubilini and Minerva 
2013). Such stand would allow waiting and seeing at birth if a newborn has been affected 
by maternal cancer treatment regiment and could be killed if adverse effect has been 
significant. Such practices could be permissible under the Groningen Protocol which 
allows performing euthanasia for severely ill infants43.  On the other hand, if mother was 
dying and did not want to leave an orphan child in the world, the child could also be killed 
after birth to spare the suffering for the mother, who will not be present while a child is 
growing up and also the suffering a child might experience by to not having a parent 
present while growing up. Hence such practice would also face legal challenges as in most 
jurisdictions one acquires legal status at the moment of birth which attributes the right to 
                                                 
42 It has to be stressed that these philosophical speculations are highly theoretical and rather serve as an 
intellectual exercise than a proposal for any practical solution! The proposal by these authors was met by a 
public outrage in many countries. In response the authors said that their philosophical argument was not 
meant to be read by lay audiences and was directed only to other bioethicists without any suggestions on 
what should be done or implemented as a public policy: http://blogs.bmj.com/medical-ethics/2012/03/02/an-
open-letter-from-giubilini-and-minerva/ [accessed 2016-03-29].  
43 Reports from the Netherlands suggest that applying the Groningen Protocol did not lead to the ‘slippery 
slope’ situations and shaped the medical practices towards more prenatal screening and pregnancy 
termination in case of foetal deformities (Verhagen 2013). However, the Groningen Protocol is still highly 
criticised claiming that it lacks grounding in firm moral principles (Vizcarrondo 2014).  
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bring up legal suit on behalf of the newborn where attempts to actively kill it would be 
treated as an assault.  
 2.1.3. Maternal death during or shortly after the pregnancy 
 
Some women in advanced stages of malignant disease might be expressing a wish 
to be left alone and spared from any interventions trying to save the foetus. One of such 
examples is the case of Angela Carder44, where 27 weeks pregnant woman with a terminal 
cancer refused Caesarean section but was obliged to have it by the court order. This case 
served as a landmark in establishing the priority which is given to maternal autonomy 
concerning medical interventions for foetal benefit. It presents a tragic scenario faced by a 
cancer survivor who achieved a subsequent pregnancy following her recovery but was 
confronted by cancer reoccurrence before reaching the end of gestation.  In this case a 
terminally ill patient refused any attempts to prolong her life despite previous plan to 
continue the pregnancy until 28th week in order to reach foetal viability, and requested for 
palliative care at 27th week of her pregnancy due to her fast deteriorating condition. One of 
the reasons why hospital administration sought the court order for Caesarean section in 
Angela’s case was that clinical knowledge, available at that time, suggested that premature 
babies born at the 27th week of gestation had approximately 60% chance of survival. This 
presupposes that hospital had reasons to believe that 6 out of 10 babies in a similar 
situation would have survived and therefore, felt obliged to take extended measures to try 
to give Angela’s baby a chance to live. Given the fatal outcome, Angela’s family appealed 
and three years later, the court order was vacated dismissing the claims for the protection 
                                                 
44 This case occurred in 1987 in the USA: http://www.nytimes.com/1990/12/08/opinion/the-fruit-of-angela-
carder-s-agony.html [accessed 2015-08-30; short description of the case]; 
https://www.nymc.edu/Clubs/quill_and_scope/volume2/murphy.pdf [accessed 2015-08-30; detailed case 
study]; (Pinkerton and Finnerty 1996)(Dickens and Cook 2003). 
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of foetal rights. This case became a milestone in establishing a priority that maternal 
autonomy holds in clinical decision-making surrounding pregnancy care.  
But let’s speculate that Angela’s case unfolded in a slightly different way and her 
baby survived. It would be hard to imagine that Angela’s family would have appealed 
against the enforced surgery decision if the baby lived. It also might be disturbing to think 
about the court, which would rule that attempts to save the baby under given circumstances 
were wrong when the baby is alive and developing fine. To add more complexities to the 
potential narratives of similar cases, we can try to imagine, how we would judge the same 
case if the premature baby survived but had to live with disability, which required 
expensive healthcare services and there were no family members, who could afford the 
time and resources to look after this child. This illustrates, that in addition to clinical 
knowledge, socio-economic circumstances and emotions also might play a significant role 
in decision-making process (Kanate, Auber, and Higa 2009)(Azim, Peccatori, and Pavlidis 
2010a) which could present further hurdles for reaching a well-reasoned and ethically 
justified decision. 
The case of Susan Torres 45 unfolded in a slightly different way. It happened in 
2005 and there was no legal battle involved. Susan survived melanoma, when she was 17, 
after combating her disease she got married, fell pregnant and gave birth to a healthy boy. 
Her disease returned 10 years later and struck her at the time of her second pregnancy. 
Unfortunately, doctors were not able to identify the exact cause of her disease on time and 
at the 17th week into her pregnancy she collapsed at home and was declared brain-dead 
                                                 
45http://usatoday30.usatoday.com/news/nation/2005-06-15-saving-baby-cover_x.htm [accessed 2015-08-30; 
reports the mother being on life support]; http://www.lifenews.com/2005/08/03/nat-1507/ [accessed 2015-08-
30; celebrates the birth of the baby]; http://www.nbcnews.com/id/9314586/ns/health-womens_health/t/baby-
girl-born-brain-dead-woman-dies/#.VeLLGCXtmko [accessed 2015-08-30; reports the death of the baby]; 
(Gregorian 2010). 
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upon arrival to the emergency room. Since Susan was pregnant, she was put on the life 
support in a hope that the foetus could reach viability and survive46. The foetus reached 
27th weeks of gestation and Caesarean delivery was performed. A premature baby girl 
required numerous surgeries but died two months later. A two-year old boy was left an 
orphan, which might raise questions about parental responsibilities towards already 
existing children, when planning their reproductive lives and proceeding with new 
pregnancies. There was also a significant amount of money involved47 which was later 
collected by Christian charities to cover the medical care expenses. Susan was kept on life 
support for 10 weeks while brain-dead in order to try to give her developing foetus a 
chance to mature. 
Increasingly it becomes possible to keep pregnant patients on life support to allow 
foetal maturity but it also raises numerous ethical issues. Currently in case of post-mortem 
pregnancy, just as in ethical frameworks recognising the foetus as a patient (Chervenak et 
al. 2004), foetal viability plays a major role in determining the level of protection which 
the third parties owe to the foetus (Gregorian 2010). Meanwhile, legal scholars argue that 
pregnant woman’s wishes should always be respected whatever the consequences for the 
foetus because enforcing actions, which are for the benefit of the foetus but in conflict with 
pregnant woman’s wishes would sacrifice the fundamental woman’s rights to bodily 
integrity and self-determination for the benefit of the foetus, who does not have the same 
moral and legal status as a pregnant woman (Lemmens 2010). However, proponents of 
maternal autonomy also recognise that attempts should be made to let the foetus to be born 
alive.  
                                                 
46 Some USA states require to provide the pregnant patients with life sustaining  treatment as long as they are 
pregnant, notwithstanding contrary instructions in patient’s living will, advance directive or from a surrogate 
decisions maker (Mayo 2014).  
47Above mentioned sources quoted USD 400 000. 
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2.2. Foetal interests in a light of prenatal harm 
 2.2.1. Approaches to foetal interests 
 
Foetal interests can be considered from various perspectives such as foetus as a 
foetus, foetus as a potential person, foetus as a person in an early developmental stage, 
foetus as a patient, foetus as a future child. In this section my main focus will be on the 
interests of a future child that the foetus will potentially become. However, not all foetuses, 
who are potential future children, will become actual future children (Callhan and Knight 
1992). It can be said, however, that any future child, potential or actual, has an interest to 
be born healthy and have access to a reasonable welfare, which includes availability of 
food, clothing, safe, caring and stimulating environment. For example, reasonable welfare 
argument is further elaborated by some oncofertility scholars, who argue that  cancer 
patients should only be required to provide the same level of welfare to their children as it 
is expected from the general population (Pennings et al. 2006)(Pennings and Mertes 2012). 
Furthermore, some extensive studies have been carried out exploring ethical, legal and 
social problems relating to the care of the unborn in the context of maternal-foetal surgery 
(Health Council of the Netherlands 2009). In current state of affairs it does raise more 
questions than answers but the very important aspect for this work is that we need to 
distinguish when we speak about the foetus as a foetus and when we refer to the foetus as a 
future child. This closely echoes with the above mentioned notion of potential and actual 
future children.  
Moreover, there are numerous disagreements about the moral status of the foetus. 
One possible solution is graded moral status which can be presented by using two different 
models (DeGrazia 2008). The simpler one is two-tier model including two classes of 
beings with full moral status and those with lower level of moral status. The sliding scale 
model allows any number of degrees of moral status. Others, especially proponents of 
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seeing foetus as a patient, suggest that using the concept of moral status is futile because it 
does not offer any practically applicable solution and therefore, it should be abandoned 
(Fleischman, Chervenak, and McCullough 1998).  
Whether we accept or reject the applicability of moral status for determining the 
foetal interests, in any case it could be argued that foetuses have an interest to continue to 
exist unless their life prospects as future children could be defined as a life not worth 
living48. According to this line of reasoning terminating pregnancy because of feared side 
effects of maternal cancer treatment could almost never be justified unless side effects are 
so severe that the life of the child born is full of unbearable suffering49 that it is better for 
such child not to have existed at all. There can be many speculations concerning the 
individual interests of existence and non-existence. However, most philosophers and 
ethicists accept that existence is better than non-existence (Hope 2004). Therefore, the 
standpoint in this work is that foetuses have health and welfare related interests which 
deserve some level of protection50. 
 2.2.2. Problems with moral status of the foetus 
 
 Creators of a framework based on the concepts of “foetus as a patient” suggest to 
replace the moral status with the “foetal patient” where practical decisions in maternal-
                                                 
48 This is called non-identity problem, a concept developed by Derek Partif and commented upon by many 
other authors http://plato.stanford.edu/entries/nonidentity-problem/ [accessed 2016-03-25; updated 2015-09-
25]. 
49 This concept is mainly used in debates surrounding euthanasia and usually entails terminal illness, severe 
pain and no prospects of getting better; in reproductive ethics it is used when discussing welfare of children 
to be but is less defined and subject to the need of further specifications.   
50 This work does not have an ambition to answer the question if foetuses have a right to live. It seeks to 
provide a framework which would hopefully serve as guidance in finding an ethically sound balance in most 
cases.  
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foetal medicine are concerned (Chervenak et al. 2004)(Chervenak, McCullough, and Brent 
2011). They are not alone. Some other scholars also acknowledge the view that focusing 
on moral status might be blinding to the range of features that are morally relevant in 
decision-making (Beauchamp and Childress 2013).  
 There are five main stream theories identified in the bioethics literature which 
could be used for attributing moral status for beings in question. However, it has to be 
recognised that none of these theories by themselves can resolve the questions about moral 
status. Hence, if taken collectively, they can provide a general framework for addressing 
some of the problems (Beauchamp and Childress 2013).  
 The first such theory focuses on biological human properties, where a necessary 
and sufficient condition for moral respect is being a living member of Homo sapiens 
species. The second theory puts emphasis on cognitive properties that distinguish higher 
level beings from lower level beings. One of the major problems with this theory is that it 
does not ensure that vulnerable human beings with cognitive deficiency will be morally 
protected. The third theory attributes moral status to those who can exercise moral agency 
by demonstrating capacity of making moral judgements on what is right or wrong and 
possess individual motives, which can also be morally judged. Just as the second theory 
based on cognitive capacities, this theory leaves those with cognitive deficiencies without 
the moral status. The fourth theory is based on having consciousness, which is understood 
in the form of feeling pain and pleasure and experiencing the suffering. This view 
distinguishes consciousness as 1) having capacity to perceive and think and 2) being 
sentient. From the perspective of this theory, all entities that have capacity to experience 
pain and suffering are considered to have a moral status because they can be morally 
wronged when others infringe pain and/or suffering on them. The fifth theory considers 
relationships between parties as a basis for attributing moral status. Primarily it focuses on 
relationships which establish roles and obligations. For example, it could be argued that 
human foetuses and newborns come to have a significant moral status through special 
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social relationships. However, some authors consider that the claim for moral status could 
be weaker depending on the degree of social relationships (social matrix) that foetus is a 
part of (Strong and Anderson 1989). Some philosophers elaborating relational theory call it 
a modal-relationalism where a being is considered to have a moral status if it is capable of 
having a certain causal or intentional connection with another being (Metz 2012).  This 
fifth theory echoes with a view presented by Chervenak and McCullough (Chervenak et al. 
2004) where foetal patienthood status can only be determined by a pregnant woman upon 
her decision to continue her pregnancy. But once foetus is considered to have reached the 
viability, patient status is granted automatically and pregnant woman cannot withdraw 
patient status from the foetus at her discretion anymore. Therefore the framework offered 
by Chervenak and McCullough (Chervenak et al. 2004) seem to employ relational (mother 
and foetus, clinician and foetus) together with biological and sentience properties. Even 
though they claim that the criteria of moral status is not of help in addressing the ethical 
problems in maternal-foetal medicine (Fleischman, Chervenak, and McCullough 1998), 
they appear to recognise the grading of moral status, attributing higher moral status and 
protection for viable foetuses (Chervenak et al. 2004)(Chervenak, McCullough, and Brent 
2011).  
 It seems that foetal patienthood debate echoes closely with the concept of graded 
moral status in regard to what level of protection to foetal beneficence has to be attributed 
by the physician. It allows attributing moral status in the degrees increasing it with the 
stage of development, which is called a “principle of unequal consideration” and referred 
to as “balancing approach” (Beauchamp and Childress 2013). Based on the balancing 
approach pregnant women might be considered to have more rights, as well as higher 
moral status as compared to their foetuses, at least at early stages of foetal development. 
However, this raises the problem in the situations where foetal interests are compromised 
in the early stages of the development (e.g. substance abuse, which could result in 
permanent damage; cancer therapies administered to the mother in the first trimester). 
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Therefore, some pose very legitimate question of why we only offer protection to the 
foetuses who reached viability while pre-viable foetuses can also experience harm and in 
some cases it might even be more severe and life lasting in children into whom pre-viable 
foetuses will potentially develop (Health Council of the Netherlands 2009). The latter is 
discussed in more detail below concerning the paradox of prenatal harm and pregnancy 
termination.  
 2.2.3. Foetal interests in pregnancy termination debates 
 
Two major accounts defending foetal interests can be distinguished in 
contemporary philosophy works concerning the termination of pregnancy which results in 
foetal death. 
Time-relative interest account of the wrongness of killing (McMahan 2002) 
suggests that we need to consider not only the total amount of future value that the victim 
would be deprived of by death, but also the extent to which the relation of psychological 
unity would have held between the victim at the time of death and herself at a later time if 
she had not died. Such interests are determined by two factors: 1) the total value of the 
future, of which one is deprived and 2) the degree of psychological unity that would have 
been obtained between oneself at some later time. According to this account the worst time 
to die is a young adult while in cases of foetuses there would not be much of psychological 
unity with their later selves.  
Future like ours account holds that abortion deprives the foetus of a valuable future 
(Marquis 1989). Marquis is seen to believe that the future of “standard foetus” includes a 
set of experiences, projects, activities, which are identical with the futures of adult human 
beings and are also identical with the futures of young children. It is because of the identity 
relation that holds between the foetus and the later adult that the foetus now possesses the 
future like ours. According to this account abortion deprives a foetus of its own future. 
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Therefore, Marquis contends that the loss of a future of value is a sufficient condition for 
the presumption that it is wrong to kill a being with such a future. 
Some authors think that the fact that abortion prevents foetal future interests from 
occurring also means that it does not frustrate those interests. Hence both accounts are 
subject to critique, further developments and clarifications (Nichols 2012). Furthermore, 
other lines of argumentation extend to attempts to clarify if foetus is a person. On one side 
of the debate personhood is denied to the foetus because it is not aware of itself due to the 
lack of higher mental capacities or function; opponents of such view respond that 
definition if foetus is a person and therefore has a right to live, should not depend on its 
developmental stage, age or place (Lee and George 2005).  
One of the major concerns in cancer treatment during pregnancy is the possibility 
that foetal health-related interests might be compromised. The extent of such harm, 
however, might not become apparent until foetus becomes a child or even an adult in the 
future. It is also difficult to predict the concrete outcomes as the probabilities of harm 
remain undetermined while currently available data offers assurance (Amant, 
Vandenbroucke, et al. 2015)(Cardonick et al. 2015) caution due to remaining uncertainties 
is warranted (Reichman, Eldar-Gava, and Paltiel 2016). 
As it is discussed in Chapter 1, some cancer therapies can be administered to 
pregnant cancer patients without significant side effects to the children they carry (Amant, 
Vandenbroucke, et al. 2015) but IUGR51, lower birth weight and preterm labour have been 
continuously observed (Cardonick, Usmani, and Ghaffar 2009)(Peccatori, Corrado, and 
Fumagalli 2015). Therefore, the question still remains if terminating the pregnancy is a 
                                                 
51 Intrauterine growth retardation/restriction is a condition where the foetus is not growing at the normally 
expected rate inside of the uterus. IUGR is associated with certain health problems during pregnancy, 
delivery and after birth, including low birth weight, decreased oxygen levels, low resistance to infections, etc. 
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morally justified way of action for preventing prenatal harm, which maternal cancer 
treatment can cause to the foetus. 
 2.2.4. Complexities of prenatal harm 
 
As it has been shown so far, cancer treatment might have an effect on the 
developing foetus. It does not usually cause severe deformities or impairing health 
conditions but could be associated with negative effect on future health as for example 
prematurity is known to correlate with cognitive capacities later in life (Amant et al. 2012). 
Many people would object the permissibility of causing foetal injury which will affect the 
health of the future child, even if they would justify pregnancy termination by the appeal to 
pregnant woman’s interests. The later has been presented as a paradox of abortion and 
prenatal injury (McMahan 2006) because if we say that injuring the foetus is wrong then 
abortion to prevent the injury must be even more objectionable, since killing is usually 
more seriously objectionable than just causing an injury. Furthermore, some argue that it is 
justifiable to exclude pregnant women from participation in clinical trials due to a potential 
harm for their foetuses (Allesee and Gallagher 2011). It appears more difficult to justify a 
significant prenatal injury than it is to justify abortion because pregnancy termination and 
prenatal injury compromise present interests of the foetus but only prenatal injury 
compromises future interests of the child a foetus will become (McMahan 2006). 
Some maternal-foetal conflicts concerning treatment incompatibilities with the best 
outcome for a mother and healthy development of the foetus can be at least partially 
resolved applying the doctrine of double effect (sometimes referred to as a principle or 
rule). The doctrine of double effect is used to justify the actions which have one good 
effect (e.g. saving a woman’s life) and one harmful effect (e.g. terminating the 
pregnancy/causing an injury to the foetus). For a harmful effect to be permissible four 
conditions have to be satisfied: 1) the nature of the act must be good or neutral; 2) only 
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good effect must  be intended while bad effect can only be foreseen, tolerated or permitted; 
3) the bad effect must not be a means for the good effect; 4) there must be a proportionality 
between the good effect and the bad effect (Boyle 1991).  In cancer care during pregnancy 
foetal deaths could possibly be justified by the proportionately grave reasons for saving the 
pregnant woman’s life but only if foetal death occurs as a side effect of cancer treatment 
and is not used as a means to treat the mother (Beauchamp and Childress 2013). For 
example, a miscarriage or a foetal death could be justified if it occurs as a side effect of a 
treatment given to a mother. This also includes quite often presented case of hysterectomy 
where cancerous uterus has to be surgically removed from the maternal body therefore 
preventing the foetus from further development. 
Terminating the pregnancy prior maternal cancer treatment initiation cannot be 
justified by the doctrine of double effect because pregnancy termination serves as a means 
(which could be seen as bad means) to achieve good ends (treat maternal cancer). The use 
of this doctrine remains controversial, especially when it comes to determining a practical 
way for distinguishing the intended effects from those which are merely foreseen 
(Beauchamp and Childress 2013). Some suggest to use the criterion of desire of bringing 
about the bad effect which would help to determine the responsibility for the bad effects 
caused (Chan 2000).  
As it is illustrated above the doctrine of double effect does not offer clear cut 
practical guidance for clinical decisions due to uncertain distinction between intending and 
foreseeing the bad effect. Hence, it seems to lay a background for justifying the occurrence 
of prenatal harm as a result of maternal cancer treatment but not pregnancy termination to 
prevent prenatal injury of occurring. A debate on permissibility of prenatal injury versus 
pregnancy termination still continues and speculations on possible legal implications are 
still being made (McMahan 2006). However, the most common normative stand is that 
even though maternal-foetal relationship attributes certain moral rights to the foetus and 
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obligations to the expectant woman, such rights should not be equated to legal rights and 
responsibilities which could be enforced by legal structures (Post 1996). 
 2.2.5. Mother and foetus: socially embedded relational unit 
 
As already discussed, pregnancy can be viewed as an embodiment, which also 
involves some significant costs52 for a pregnant woman and (in some cases) to her partner. 
It entails emotional and intimate relationship between the developing foetus and its parents 
(Watt 2016). In this light a pregnant woman and her foetus are viewed as a larger 
relational unit, where inter-subjectivity plays a key role for mutually empathetic 
relationship between a mother and her child to be. Such relationships are not build on 
individual autonomy of the mother but require the competence to create and sustain a 
relationship of mutual inter-dependence (Held 1993). Therefore, it can be said that 
emphasis on individual autonomy carries a risk of disrupting the interpersonal relationships 
discarding the relational aspect of woman’s identity. Hence, a vast amount of potential 
solutions have been offered in the feminist literature, which could be collected under the 
umbrella term of relational autonomy (Mackenzie and Stoljar 2000). A relational 
autonomy account is considered a female-friendly account of autonomy involving the 
possibility to choose and live according to standards and values that could be considered 
one’s “own”, which closely relates to the concept of personal philosophy53 (Linkeviciute et 
al. 2015)(Boniolo and Sanchini 2016).  
Moreover, “socially situated” person can take responsibility for events that extend 
beyond her individual agency (Lloyd 2000) and can also choose not to exercise autonomy 
under certain conditions (Mackenzie and Stoljar 2000) because sometimes healthcare 
decisions are made in a state of confusion, where a patient is influenced by numerous 
                                                 
52 Here I mean the costs in a broad sense such as physical, psychological, emotional, financial, etc.  
53 The dangers which could compromise the expression of personal preferences in a relational autonomy 
context and ways to defeat them are discussed in Chapter 6. 
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internal and external factors such as pain, discomfort, worry, and concern for others 
(Dodds 2000).  
The later also indicates relational features of responsibility a pregnant cancer 
patient might choose to take. In practice, acknowledgement of relational autonomy 
requires to expand our perception of respect for patient’s autonomy as informed consent 
which is free from ignorance, coercion and impediments for decision-making capacity 
(Beauchamp and Childress 2013) by enriching it with social circumstances and power 
relationships, which might affect the patient’s choices (Dodds 2000).  
Even though the proposal of foetal patienthood advocates for the protection of 
foetal interests after the viability (Chervenak et al. 2004), it cannot not be protected as a 
separate entity independent from the pregnant woman. In addition, pre-viable foetuses are 
also subject to protection (Health Council of the Netherlands 2009), which can only be 
achieved if pregnant woman is willing to collaborate. However, it is important to note that 
when pregnant woman is facing a potentially lethal disease, her relationship with a 
developing foetus might be compromised by numerous other circumstances such as 
commitments to other children and/or relatives, stage of the disease, prognosis and 
available treatments.  
2.4. Summary 
 One of the major conflicts in cancer care during pregnancy is the choice of 
treatment for a pregnant woman as it can have some adverse effects on the foetal 
development and therefore the child foetus will become.  
In order to frame potential conflicts metaphysical definition of motherhood and 
pregnancy might be helpful. There have been some attempts to do so by distinguishing 
self-sacrifice and self-defence models of motherhood while also defending the embodiment 
model of pregnancy. The later is defined as a dynamic, transcendent and most importantly 
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active state of being, which requires recognition and respect for the commitments, 
sacrifices and contributions a pregnant woman undertakes in carrying her pregnancy.  
Foetal interests are well pictured by two philosophical accounts: time-relative 
interest account and future like ours account. Both of them suggests that unless a life of a 
future child the foetus will potentially become is not worth living because it will be filled 
with unbearable suffering, it is in the best interest of the foetus to gestate to term and be 
born, even if in the course of gestation some prenatal harm will occur. 
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Chapter 3. Cancer and parenthood: views of affected stakeholders 
3.1. Moral and social significance of having children 
 
Overall ethical debates surrounding human reproduction seem to presume a right to 
genetic parenthood (Goold and Savulescu 2009)(Petropanagos 2010) and offering fertility 
preservation for young children and adults is argued to serve as an open future guardian 
(Quinn et al. 2012)(Satkoske and Parker 2013). On the contrary, some argue that value of 
genetic parenthood is often overemphasized in fertility related debates leading to stress, 
anxiety and inadequate attempts to conceive or maintain the pregnancy by people affected 
(Sparrow 2014).  
Nevertheless, oncofertility scholars explicitly emphasize the importance that 
pregnancy and motherhood play in many women’s perception of identity, which is formed 
by social expectation that women should bear and rear children (Quinn et al. 2012). They 
argue that fertility and/or pregnancy loss due to cancer, even if not visible directly like hair 
loss or surgical breast removal, can affect cancer survivor’s sense of self as well as quality 
of life (Campo-Engelstein 2010)(Quinn et al. 2012). It can be associated with low self-
esteem because of a perception that having no children or losing the ability to bear them 
diminishes the social value of affected women (Penrose et al. 2012).  
Meanwhile, some cancer treatments are known to induce spontaneous abortions 
(Peccatori et al. 2013) and could lead to long lasting regret, guilt and remorse, especially in 
cases where pregnancy loss occurs due to a malignancy or its treatment and is 
accompanied by subsequent inability to conceive and bear children. However, social 
expectation to bear children does not necessarily mean that parenthood should be sought or 
maintained by any means. Some cases studies suggest that cancer survivors might feel 
under pressure to pursue parenthood because of social expectation to do so (Sender 2010) 
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while they might not have even considered having children if they were not affected by 
cancer. It certainly is a great goal for all cancer patients to be informed about treatment 
effects on their fertility and fertility preservation options. Hence, it should not be forgotten 
that some cancer patients and survivors might prioritize survival over ability to have 
children (Goncalves, Sehovic, and Quinn 2014) and not all place the same value on 
preserving their reproductive capacities. 
Some reports conclude that cancer survivors place a very high value on having a 
family (Schover 2005) and, in case of pregnancy, protecting the foetus from potential harm 
which cancer treatment might induce (Hauenstein et al. 2010). In addition, some patients 
might see a therapeutic value in fertility preservation and the future prospect of becoming a 
parent (Goncalves, Sehovic, and Quinn 2014). It is argued that fertility preservation helps 
patients stay optimistic and see the future after cancer treatment but its cost and low 
effectiveness as well as sometimes poor prognosis indicate that it might lead to false hopes 
(Pennings and Mertes 2012). Moreover, the hype about fertility preservation sometimes 
tends to promote the view that alternatives to the genetic parenthood are only second best 
option (Petropanagos 2010).  
Furthermore, the choice and use of contraception is also an important aspect to be 
discussed with cancer patients and survivors as some of them might presume that cancer 
treatment left them sterile while this does not necessarily happen to every patient (Sileny N 
Han et al. 2015). Therefore, patient counselling should include both fertility preservation 
options, including alternative options to genetic parenthood (e.g. adoption, foster 
parenting), and a discussion on contraceptive measures to prevent unwanted conception. 
3.2. Parenting while facing cancer  
 
While some cancer patients demonstrate enthusiasm (Geue et al. 2014), clinicians 
are reported to have reservations based on both clinical uncertainty and personal bias 
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towards fertility preservation procedures (Adams, Hill, and Watson 2013)(Küçük et al. 
2013)(Linkeviciute et al. 2014). Despite the  positive attitudes to preservation of future 
fertility, induced abortion rates for pregnancies after breast cancer range as high as 44% 
(Lambertini et al. 2013), calling for additional patient support and reproductive counselling 
services in the course of treatment and after cancer has been treated. 
Meanwhile, there does not seem to be sufficient data showing that children born to 
cancer survivors are of poorer health, other than the possibility that they might have a 
genetic predisposition to cancer54. Still some cancer survivors have reservations towards 
prospective parenthood due to health-related concerns and their future ability to care for 
their children. This later point is also relevant to patients who have not been affected by 
cancer directly but have a genetic or familiar predisposition to cancer and sometimes are 
called cancer previvors (Shulman and Dungan 2010)(Werner-Lin et al. 2014). In addition, 
the decision to use fertility preserving biomaterial for proceeding with conception and 
pregnancy can be surrounded by new uncertainties, such as fear of cancer reoccurrence and 
implications that an attempt to have a child will have on the partner, family and child to be 
born (Linkeviciute and Peccatori 2016).  
Addressing the needs of existing or potential children that cancer patients feel 
responsibility to take care of is not usually conceived as a routine cancer care, even though 
the estimation is that about 24% of cancer patients in treatment have children living at 
home (Rauch and Muriel 2004). Meanwhile, qualitative studies show that parents with 
cancer tend to describe their potential death as an abandonment of their children 
(Elmberger et al. 2008) and cancer affected women see it as a breach of moral 
                                                 
54This problem can potentially be resolved by resorting to artificial reproduction technologies. Prenatal 
genetic diagnosis (PGD) can be employed for selecting embryos which are free of gene mutations associated 
with cancer. Hence, using assisted reproduction technologies are known to have some negative health-related 
effects on future children such as increase in mental health problems (Svahn et al. 2015) and imprinting 
disorders (Lazaraviciute et al. 2014). 
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responsibility in mothering (Elmberger, Bolund, and Lützén 2005). Therefore, there seems 
to be a growing need to understand how being a parent or expecting to become one affects 
individual treatment decisions and quality of life assessment. It is especially relevant in 
order to overcome the barriers (e.g. time constraints and perceived lack of knowledge for 
relevant recommendations), which clinicians face when addressing parenting concerns by 
adult oncology patients,  (Rauch and Muriel 2004).  
Overall, most studies focus on women’s experience while facing cancer and 
juggling parental responsibilities. Experiences and support for partners who share parental 
responsibilities with a woman affected by cancer are poorly researched with very few 
studies reported (Corney, Puthussery, and Swinglehurst 2016). Inclusion of the partner 
appears to be abandoned area in practice as well as research.  
3.3. Provisional views of affected stakeholders 
 3.3.1. Clinicians’ perspectives 
 
Just recently high numbers of physicians had reservations about treating cancer 
during the course of pregnancy (Sileny N Han et al. 2013) and were advising their patients 
to have an abortion based on fears that treatment might harm the foetus and that pregnancy 
might compromise maternal outcome (Weisz, Schiff, and Lishner 2001)(Morice, Uzan, and 
Uzan 2012). Delivery before initiation of maternal treatment was considered an ethical 
approach when managing cancer during pregnancy cases (Oduncu et al. 2003). Concerns 
surrounding fetal safety and maternal prognosis are still relevant today but there is also 
more scientific assurance concerning the outcomes when cancer is treated during the 
course of pregnancy (Amant, Vandenbroucke, et al. 2015). Common agreement among the 
leading experts is that pregnancy termination does not have a survival benefit for the 
mother (Marsden et al. 2010)(G. Koren et al. 2013) but some reservations are still held due 
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to the “healthy mother effect”55 (Royal College of Obstetricians and Gynaecologists 
2011)(Andersson et al. 2015).  
One study exploring the attitudes and practices of the European oncologists found 
that out of 142 physicians working in cancer and/or pregnancy care 44% would prefer 
pregnancy termination if cancer was diagnosed in the first half of pregnancy, 58% would 
delay maternal treatment and initiate early delivery if cancer was diagnosed in the second 
half of the pregnancy and 37% would not give chemotherapy or radiotherapy during 
pregnancy (Sileny N Han et al. 2013). 
Few insightful reports can be found in fertility preservation for cancer patients’ 
studies done by oncofertility scholars. Despite existing guidelines and fertility preservation 
methods as well as recorded wishes of cancer patients to be informed about fertility 
preservation options available to them, significant numbers of physicians worldwide still 
choose not to include discussion about reproduction in their consultation (Linkeviciute et 
al. 2014). We reviewed physician survey studies from the UK, Japan, Saudi Arabia, 
Turkey, Iran and the USA, which reported fertility preservation practices and factors 
influencing physicians’ decision to discuss reproductive issues with cancer patients. Our 
review found that only British and American physicians include a discussion about 
patient’s reproductive concerns in their consultation. Moreover, some physicians have 
numerous biases concerning the initiation of a conversation concerning fertility and cancer. 
Such biases are based on social issues, patient’s age, gender, race, sexual orientation, 
marital status, existing children and medical prognosis, and in some cases religion 
                                                 
55‘Healthy mother effect’ implies that only those women who feel healthy and are able to cope with a disease 
continue with pregnancy after cancer diagnosis or seek pregnancy after cancer was cured, agree to be in the 
registries and participate in follow-up programmes, while those who have health problems are less 
enthusiastic and get lost in the follow-up. Recent study reports that only 37% of young breast cancer patients 
were interested in a study of endocrine therapy interruption to allow pregnancy (Pagani et al. 2015). 
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(Linkeviciute et al. 2014). Overall, general tendency in most studies appears to be that 
physicians are concerned about patient prognosis and type of cancer which make them 
reluctant to allow any treatment delays if patient decides to explore fertility preservation 
options. In addition, the British, Japanese, Turkish and Iranian doctors report that the lack 
of knowledge about reproductive issues in oncology and consultation time constraints are 
among the reasons why they do not bring fertility preservation to the patient’s attention 
(Linkeviciute et al. 2014). Similar trends are reported in previously described study 
exploring physician’s attitudes towards cancer treatment during pregnancy by Han and 
colleagues (Sileny N Han et al. 2013). 
Another interesting study from the USA explores physicians’ attitudes towards 
conscientious objection towards medical procedures which are legal but not in line with 
physician’s moral values and beliefs. Out of 1144 American physicians representing 
different specialties 86% believed that physicians are obliged to present all available 
treatment options for their patient but only 71% agreed that in case of moral objections the 
physician should refer the patient to another physician (Curlin et al. 2007). The later 
suggests that depending on moral convictions which the physician harbours, her patients 
might not be referred to another physician and the treating physician might consider this to 
be an ethical practice. 
Furthermore, cancer care during pregnancy is complicated by the fact that 
multidisciplinary team has to be involved. Therefore, perspectives of other specialty 
doctors are also very important. For example, an Australian study reporting attitudes and 
beliefs of 336 midwives and doctors conclude that they are inconsistent in their responses 
concerning pregnant women’s right to take a final decision in regard to their care (Kruske 
et al. 2013). Same study also found that doctors hold different attitudes as compared to 
midwives concerning the competency to make the final decision, which could possibly be 
closely related to legal accountability attached to medical decisions. However, some 
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healthcare providers tend to believe that they are legally and morally responsible for the 
foetus, which could be used as a justification to override the needs of a pregnant woman 
(Kruske et al. 2013). Meanwhile, from a legal point of view it has been established that 
maternal autonomy should prevail concerns about the foetus because until it is born, foetus 
is not considered a legal entity in most jurisdictions. 
 3.3.2. Patients’ perspectives 
 
Unfortunately, to date there are no systematically collected empirical data reporting 
experiences, attitudes and choices of the patients who experienced cancer and pregnancy at 
the same time. However, there are two studies conducted in the UK reporting patient 
experiences from participation in ORACLE (Kenyon et al. 2006) and Magpie Trial (Smyth, 
Jacoby, and Elbourne 2012)56. 
Both studies explored the experiences of pregnant women who took part in 
randomised clinical trials for the critical conditions, which posed medical risks to 
themselves and their foetuses. The ORACLE investigated the possibility that treatment 
with broad spectrum antibiotics prolongs labour and improves neonatal outcomes in 
women who are less than 37 weeks pregnant and experiencing either pre-term labour or 
premature rupture of membranes (Kenyon et al. 2006). The Magpie Trial investigated a 
prophylactic use of anticonvulsants (magnesium sulphate) for women with severe 
preeclampsia, which also run the QUOTE (Qualitative Understanding of Trial Experience) 
Study (Smyth, Jacoby, and Elbourne 2012). After interviewing the ORACLE participants, 
the researchers found that participants attributed a high value to interaction with healthcare 
professionals and also put a lot of trust on them when making a decision to joining the trial. 
Moreover, most ORACLE participants expected that by joining the trial their babies might 
                                                 
56 I am also aware of some ongoing studies exploring experiences and attitudes of pregnant cancer patients, 
but at the time of thesis submission, none of the findings have been published yet. 
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benefit and this was a pre-condition for altruistic motivation to benefit others who might be 
in a similar situation in the future (Kenyon et al. 2006). The second study, which 
interviewed the participants of a Magpie Trial, found that self-interest was a key 
motivating factor to participate in clinical trial. Major motivating factors were identified as 
self-benefit (trial might help to treat preeclampsia), benefit to their child (treatment might 
minimise the associated risks of preeclampsia to the unborn baby) and altruism 
(participation might help future women or is for the good of medical science). This study 
also showed that although some women sought the opinion of family members and friends, 
they had little involvement or influence on the women’s decisions. Partners played a role 
in providing a second opinion for many women but study participants dismissed the idea 
that their relatives or friends were in the position to influence their decision (Smyth, 
Jacoby, and Elbourne 2012).  
Two studies offer just a provisional insight to pregnant women’s experiences, when 
they face critical conditions, because both of them were conducted in the same country (the 
UK) and focused on participation in randomised controlled trials rather than therapeutic 
treatment decisions. This, however, is very much relevant to cancer management during 
pregnancy because it might be reasonable to think that women being treated for cancer 
during pregnancy should be asked to take part in clinical trials and/or enrol in registries, so 
clinical knowledge about this rare co-occurrence could be better consolidated. Hence, it is 
also important to note that above discussed studies show that pregnant women’s decision 
to take part in clinical trials are led by the expectation of self benefit which could be 
considered a therapeutic misconception and require further ethics foresight.  
3.4. Summary 
Parenthood plays an important role in human life but parenting concerns of cancer 
patients remain highly unexplored topic. Physicians are reported to give preference to the 
maternal wellbeing and would also recommend pregnancy termination to avoid prenatal 
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harm, when cancer has to be treated in the course of pregnancy. Meanwhile, studies of 
pregnant patients in critical conditions report that they attribute high value to the 
interaction with healthcare professionals and trust them to guide decision-making process, 
expect that treatment for their disease will also benefit the developing baby, and 
interestingly, it appears that family members and friends play a supportive role but have 
little involvement or influence on decisions pregnant women take. Hence the views, 
attitudes and experiences from pregnant women who were diagnosed with cancer are still 
missing and it remains a significant gap in knowledge required for a development of 
ethical care guidelines. 
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Chapter 4. Clinical practice guidelines: a review of ethics content 
 
4.1. Methodological background 
 In this part of work I use a systematic review of clinical practice guidelines 
concerning cancer management in the course of pregnancy, in order to find out what 
ethical concepts are mentioned and which ethical standpoints adopted in these documents. 
Systematic reviews are common in clinical research but some authors also propose 
to transfer PICO (Population, Intervention, Comparison, Outcome) model used in 
biomedical literature to systematic reviews of reasons in bioethics (Sofaer and Strech 
2012), where “outcome” is supposed to help to evaluate ethical justifiability of chosen 
action (Sofaer and Strech 2011). However, evaluating the reasons or arguments provided in 
normative bioethics literature can be a challenging task because identifying all the relevant 
literature on a particular topic in bioethics can be very time consuming and not always 
possible due to high volumes of grey literature57.  
Therefore, some argue that even though doing the search systematically should be 
maintained in bioethics research, the type of systematic review will depend on the research 
question (McDougall 2015). In some cases, identifying all the literature concerning a 
particular question might not be feasible and even if it is, the time spent will not add 
significant value to the research (McDougall 2014) as “broad brush” approach can yield 
the same information. Systematic reviews can provide a greater variety of reasons or 
arguments but the proponents accept that the review itself does not involve or replace the 
critical analysis of the materials collected (Sofaer and Strech 2012). That is why some 
                                                 
57 The sources referred to as grey literature mainly constitute of books and edited book volumes, which are 
not indexed in major data bases.  
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advocate a turn to critical interpretative reviews which might better serve bioethics 
research purposes (McDougall 2015).   
I took a combined approach. Clinical practice guidelines can be identified using the 
search strategy common in biomedical and clinical literature reviews and then I explored 
the ethics content in these guidelines by adopting a critical interpretative approach. 
4.2. Identification of relevant documents 
 
 A systematic review tools were used in this part of work (McDougall 2014). The 
PubMed, Web of Science and Science Direct data bases were searched in order to identify 
the relevant clinical practice guidelines concerning cancer management in the course of 
pregnancy published in English language without time limits. A string of search terms 
(pregnancy AND cancer AND guideline*) was chosen to be used with an intention to 
identify the documents which healthcare professionals would turn into when in search for 
practical guidance in managing cancer during pregnancy. Therefore, the following 
inclusion criteria were set up: 1) articles and expert meeting reports which clearly state that 
they aim to provide clinical practice guidelines or recommendation for cancer management 
during pregnancy; 2) publications were released, reviewed or endorsed by a professional 
society representing clinicians practicing in a clinical field relating to oncology.  
Reviews stating that their primary objective is to provide guidelines for 
management of tumours diagnosed during pregnancy but not related to any professional 
organisation were excluded due to a potential opinion bias, presuming that guidelines 
relating to professional clinical organisations would present more objective, better 
researched and balanced view. The last search was performed on October 22-23, 2015. The 
search strategy is presented in Figure 4.2., which describes the search findings in a flow 
chart. The initial search in three data bases yielded 1188 articles. Title screen reduced the 
selection to 142 papers which were selected for abstract read and 35 papers meeting the 
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inclusion criteria were selected for full-text read. Discarding the duplicates reduced the 
collection to 21 articles to which 2 articles were added after cross-reference check (snow-
balling). Full-text read revealed that 2 papers were reviews without professional 
organisation affiliation and 4 guidelines did not mention anything what could be 
considered as ethics content. The final collection constitutes of 17 articles which are 
released or endorsed by a professional society or a much focused expert group and offers 
clinical guidelines for cancer management during pregnancy. Summary of these guidelines 
is presented in Table 4.2. 
Figure 4.2. A flow chart of a systematic review 
 
 
Table 4.2. Summary of the clinical guidelines for cancer management during pregnancy  
Reference; Guideline Management 
recommendatio
Patient support Ethical content 
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Organisation description n 
Ali et al. 2015(Ali 
et al. 2015); UK-
based medical 
practitioners with 
expertise in acute 
myeloid 
leukaemia 
(AML),reviewed 
by Haemato-
oncology Task 
Force of the British 
Committee for 
Standards in 
Haematology 
(BCSH), British 
Society of 
Haematology 
(BSH), UK AML 
National Cancer 
Research Network 
(NCRN) 
Offers a 
uniformed 
consensus 
which, due to 
scarcity of the 
literature, is 
mainly based 
on expert 
opinion than 
trials for 
treating AML 
patients. 
Includes grade 
of evidence for 
all clinical 
recommendatio
ns 
Management 
by 
multidisciplina
ry team; 
Pregnant 
patients with 
AML should 
be treated 
without delay 
after full and 
frank 
discussion; 
Beyond 32 
weeks 
gestation it 
might be 
reasonable to 
deliver the 
foetus before 
chemotherapy 
 
The women 
should be fully 
informed about 
the diagnosis, 
treatment of 
the disease and 
possible 
complications ; 
Reasons for 
and against 
elective 
termination 
should be 
discussed with 
a patient; 
Offer parents 
reassurance on 
baby’s health 
by performing 
tests and 
follow-up 
during infancy 
 
Considerations 
should be 
given to the 
health of both 
mother and 
foetus and 
informed 
wishes of the 
patient 
(enabling 
patients to take 
informed 
decisions, 
respect for 
patient’s 
autonomy; 
balancing 
maternal and 
foetal 
beneficence) 
Follows et al 
2014(Follows et al. 
2014); UK-based 
medical experts 
and patients’ 
representatives; 
revised by 
Haemato-oncology 
Task Force of the 
British Committee 
for Standards in 
Haematology 
(BCSH) 
The guideline 
for first line 
management of 
classical 
Hodgkin 
lymphoma 
The priority 
must be the 
health of the 
mother 
and, ideally, 
management 
should be in 
conjunction 
with an 
obstetrician 
experienced in 
high-risk 
pregnancies 
Patient’s 
personal 
priorities 
should be 
taken into 
consideration 
when making 
treatment 
decisions 
Attention to 
patient’s 
personal 
wishes 
(respect for 
patient’s 
autonomy); 
Maternal 
health and 
wellbeing 
should prevail 
(maternal 
beneficence) 
Amant et al 
2014(Amant et al. 
2014); European 
Society of 
Gynecological 
Provides timely 
and effective 
guidance for 
pregnant 
women and 
To maximize 
the maternal 
outcome, 
cancer 
treatment 
Individualizati
on of the 
treatment and 
effective 
Maximizing 
maternal 
outcome 
(maternal 
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Oncology (ESGO) 
task force "Cancer 
in Pregnancy" in 
concert with other 
international 
experts 
health care 
providers to 
optimize 
maternal 
treatment and 
foetal 
protection and 
to promote 
effective 
management of 
the mother, 
foetus, and 
neonate when 
administering 
potentially 
teratogenic 
medications in 
gynaecological 
malignancies 
should follow a 
standard 
treatment 
protocol as for 
non-pregnant 
patients; 
Despite limited 
evidence-based 
information, 
cancer 
treatment 
during 
pregnancy can 
succeed; 
Iatrogenic 
prematurity 
should be 
avoided; 
State-of-the-art 
treatment 
should be 
provided for 
this vulnerable 
population to 
preserve 
maternal and 
foetal 
prognosis. 
psychological 
support is 
imperative to 
provide 
throughout the 
pregnancy 
period 
beneficence) 
Best treatment 
for vulnerable 
population 
[pregnant 
women with 
cancer] 
(protection of 
the vulnerable) 
Peccatori et al. 
2013 (Peccatori et 
al. 2013); 
European Society 
of Medical 
Oncology 
(ESMO), endorsed 
by Japanese 
Society of medical 
Oncology (JSMO) 
Provides 
Clinical 
Practice 
Guidelines for 
managing 
patients 
diagnosed with 
cancer during 
pregnancy and 
provide 
guidance on 
fertility 
considerations 
for women 
desiring 
pregnancy 
following 
cancer 
diagnosis 
(breast, 
cervical, lung 
cancer, 
Referral to 
institution with 
expertise;  
Multidisciplina
ry team; 
Standard 
chemo might 
not be feasible 
in all cases; 
Target full-
term delivery 
whenever 
possible; 
Pregnancy 
termination 
strongly 
discouraged 
Involving a 
partner and 
family in 
decision-
making 
process;  
Multidisciplina
ry care and 
counselling  
Partner and 
family 
involvement in 
decision-
making 
(respect for 
relational 
autonomy) 
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leukaemia and 
other tumours) 
Koren et al. 
2013(G. Koren et 
al. 2013); 
Chemotherapy 
During Pregnancy 
Working Group, 
approved 
by the Society of 
Obstetricians and 
Gynaecologists of 
Canada (SOGC) 
Reflects 
clinical and 
scientific 
advances and 
offers 
recommendatio
ns concerning 
chemotherapy 
use in 
pregnant 
women and 
women if child 
bearing-age 
It is important 
to balance 
maternal and 
foetal risks; 
Decisions 
should be 
made 
individually for 
each patient; 
Multi-
disciplinary 
team, including 
physicians and 
social workers, 
psychologists, 
spiritual 
advisors 
Discuss the 
available 
options with 
pregnant 
patient and her 
family 
Partner and 
family 
involvement in 
decision-
making 
(respect for 
relational 
autonomy); 
Maternal 
health and 
wellbeing 
should prevail 
(maternal 
beneficence) 
Cardoso et al 
2012(Cardoso et al. 
2012); European 
Society of Breast 
Cancer Specialists 
(EUSOMA) 
Position paper, 
recommendatio
ns for treating 
young women 
with breast 
cancer 
Pregnancy 
after breast 
cancer should 
not in principle 
be discouraged 
Issues of body 
image, 
sexuality, 
fertility and 
lactation must 
be discussed 
with young 
women with 
breast cancer;  
Counselling for 
family 
planning and 
contraception; 
Involve the 
partner if 
present 
 
Informing the 
patient about 
treatment 
effects and 
family 
planning 
(enabling 
patients to take 
informed 
decisions; 
respect for 
patient’s 
autonomy); 
Partner 
involvement in 
decision-
making 
(respect for 
relational 
autonomy) 
 
 
Dauer et al., 2012 
(Dauer et al. 2012); 
Society of 
Intends to assist 
interventionalis
ts and their 
Interventions 
should be 
justified with 
Pregnant 
patients should 
Provide 
counselling 
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Interventional 
Radiology and the 
Cardiovascular and 
Interventional 
Radiology Society 
of Europe, 
endorsed by the 
Canadian 
Interventional 
Radiology 
Association 
staff in 
managing and 
counselling 
pregnant 
patients who 
need 
fluoroscopicall
y or CT-guided 
interventional 
procedures  
the aim for 
doing more 
good than 
harm;  
Concern about 
the possible 
side effects of 
ionizing 
radiation 
exposure on 
the conceptus 
[foetus] should 
not preclude 
medically 
indicated 
diagnostic or 
interventional 
x-ray 
procedures 
when the 
medical benefit 
for the mother 
is justifiable;  
Conceptus 
doses lower 
than 100 mGy 
should not be 
considered a 
reason for 
terminating a 
pregnancy 
be counselled 
based on sound 
information 
about the risks 
of radiation 
exposure; 
If possible pre 
and post 
procedure 
counselling 
should take 
place involving 
the mother and 
the father 
 
support to 
patients 
(enabling 
patients to take 
informed 
decisions);  
Abortion is an 
individual 
decision 
affected by 
many factors 
(respect for 
patient’s 
autonomy); 
Partner 
involvement 
(respect for 
relational 
autonomy 
[indirect 
reference]) 
De Groot et al 
2012(De Groot et 
al. 2012); 
Endocrine Society 
Clinical Practice 
Guideline (US), 
reviewed and 
commented on by 
members of The 
Endocrine Society, 
Asia and Oceania   
Thyroid 
Association, 
and the Latin 
American Thyroid 
Society 
Updates the 
guidelines for 
the 
management of 
thyroid 
dysfunction 
during 
pregnancy and 
postpartum 
published 
previously 
No clear 
evidence that 
pregnancy 
worsens the 
survival of 
pregnant 
patient 
 
Information for 
the patient 
making the 
decision about 
breastfeeding 
Provide 
information 
for the 
patient(enablin
g patients to 
take informed 
decisions; 
respect for 
patient’s 
autonomy 
[indirect 
reference]) 
Royal College of Provides Suggests People with Informing the 
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Ob/Gyn, 
2011(Royal 
College of 
Obstetricians and 
Gynaecologists 
2011); Royal 
College of 
Obstetricians & 
Gynaecologists 
clinical 
guidance to 
health 
professionals 
caring for 
women of 
childbearing 
age with a 
diagnosis or 
history of 
breast cancer. 
Green-top 
guideline 
No.12 
auditing the 
referrals and 
outcomes 
cancer should 
be fully 
informed of 
potential 
gonadotoxicity 
before 
treatment, and 
specialist 
psychological 
support and 
counselling 
should be 
available; 
Involve a 
partner in a 
discussion with 
a 
multidisciplina
ry team 
patient about 
treatment 
effects 
(respect for 
patient’s 
autonomy); 
Partner and 
family 
involvement in 
decision-
making 
(respect for 
relational 
autonomy) 
 
Amant et al., 
2010(Amant et al. 
2010); an 
international expert 
Panel 
Provides 
guidance for 
clinicians about 
the diagnosis, 
staging and 
treatment of 
breast cancer 
occurring 
during an 
otherwise 
uncomplicated 
pregnancy  
Serious 
consideration 
should be 
given to 
continuing of 
pregnancy 
whilst treating 
cancer; 
Delivery 
should not be 
induced before 
37 weeks as 
morbidity 
mainly 
associated with 
prematurity; 
Treatment 
should adhere 
as closely as 
possible to 
standard 
protocols; 
Breastfeeding 
shortly after 
chemotherapy 
not 
recommended 
Multidisciplina
ry team should 
provide patient 
with clear 
explanation of 
treatment 
options 
Seriously 
consider 
continuing of 
pregnancy 
whilst treating 
cancer 
(balancing 
maternal and 
foetal 
beneficence, 
protection of 
the vulnerable 
[indirect 
reference]); 
Provide 
information 
for the 
patient(enablin
g patients to 
take informed 
decisions) 
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Marsden et al 
2010(Marsden et 
al. 2010); endorsed 
or had an input 
from U.K. 
Melanoma Study 
Group, the British 
Association of 
Dermatologists, the 
British Association 
of 
Plastic, 
Reconstructive and 
Aesthetic 
Surgeons, the 
Royal College 
of Physicians, 
London, the 
Association of 
Cancer Physicians, 
the Royal College 
of Radiologists, 
London, the Royal 
College of 
Surgeons of 
England, the Royal 
College of 
Pathologists 
(pathology section 
only), the Royal 
College of General 
Practitioners, 
London, and the 
Department of 
Health 
Guideline for 
management of 
cutaneous 
melanoma 
presents 
evidence-based 
guidance for 
treatment, with 
identification of 
the strength of 
evidence 
available at the 
time of 
preparation of 
the guidelines, 
and a brief 
overview of 
epidemiology, 
diagnosis, 
investigation 
and follow up. 
 
Chemotherapy 
does not have 
survival benefit 
in IV stage; 
Melanoma can 
metastasize to 
the placenta 
and foetus 
more 
frequently 
which has poor 
prognosis for 
the mother and 
the baby 
Social and 
family effects 
of developing 
recurrent 
melanoma 
during 
pregnancy 
or after birth 
are great. 
Counselling 
recommended. 
Provide 
support, 
information 
and education 
to patients 
(enabling 
patients to take 
informed 
decisions;  
respect for 
patient’s 
autonomy) 
Papini et al 
2010(Papini et al. 
2010); Joint 
statement for 
clinical practice by 
Italian associations 
on thyroid cancer 
Provides 
guidance to 
thyroid nodule 
and 
differentiated 
thyroid cancer 
management 
in pregnancy 
Most tumours 
are slow 
growing and 
surgery after 
the delivery 
will not change 
the prognosis; 
Pregnancy 
should never 
be interrupted 
Assurance 
about 
prognosis 
should be 
given to the 
affected 
patients 
Never 
interrupting 
the pregnancy 
(foetal 
beneficence 
but also care 
and support 
for the 
expectant 
mother) 
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Pentheroudakis et 
al. 
2010(Pentheroudak
is et al. 2010); 
European Society 
of Medical 
Oncology 
(ESMO) 
Provides a 
guide with 
scientific levels 
of evidence for 
management of 
breast and 
cervical 
cancers, and 
melanoma 
The optimal 
therapeutic 
strategy should 
be jointly 
chosen by the 
medical team, 
patient and 
family and will 
depend on 
gestational age, 
nature and 
stage of cancer, 
treatment 
options and 
patient wishes 
All patients at 
risk of 
infertility who 
have not 
completed 
childbearing 
should discuss 
germ-line 
storage options 
with a medical 
team 
Partner and 
family 
involvement in 
decision-
making 
(respect for 
relational 
autonomy) 
Amant et al., 2009 
(Amant et al. 
2009); 
international 
experts in the field 
Suggests 
models for 
treatment of 
gynaecologic 
cancer in 
pregnancy 
Randomised 
trials and 
prospective 
studies on 
cancer 
treatment 
during 
pregnancy are 
lacking;  
Multidisciplina
ry expertise 
should be 
available;  
It is advisable 
to engage the 
expertise of 
other members 
of the 
healthcare 
team such as 
psychologists, 
social and 
pastoral 
workers 
Counselling 
both parents on 
the maternal 
prognosis and 
foetal risk is 
needed 
The parents 
should be 
informed 
about the 
different 
treatment 
options and the 
possible 
consequences 
for the patient 
and the 
foetus(enablin
g patients to 
take informed 
decisions; 
respect for 
relational 
autonomy 
[indirect 
reference]);  
The prognosis, 
treatment 
modalities, 
gestational 
age, and 
patients 
preference are 
pivotal in the 
decision 
making 
process on 
treatment 
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during 
pregnancy or 
termination of 
pregnancy 
(balancing 
maternal and 
foetal 
beneficence 
[indirect 
reference]; 
respect for 
patient’s 
autonomy) 
Pentheroudakis et 
al., 
2008(Pentheroudak
is, Pavlidis, and 
Castiglione 2008); 
European society 
of Medical 
Oncology (ESMO) 
Provides 
recommendatio
ns for 
diagnosis, 
treatment and 
follow-up 
surrounding 
cancer 
treatment, 
fertility 
preservation 
and cancer 
during 
pregnancy  
Pregnancy 
termination is 
advised in the 
case of 
chemotherapy 
or radiotherapy 
administration 
during the first 
trimester, need 
for radical 
gynaecologic 
surgery, poor 
maternal life 
expectancy 
The optimal 
therapeutic 
strategy should 
be jointly 
chosen by the 
medical team, 
patient and 
family and will 
depend on 
gestational age, 
nature and 
stage of cancer, 
treatment 
options and 
patient wishes.  
Inclusion of 
patient and 
family in 
decision-
making 
(respect for 
relational 
autonomy 
[indirect 
reference]); 
considering 
patient’s 
wishes 
(respect for 
patient’s 
autonomy) 
Loibl et al., 
2006(Loibl et al. 
2006); Internal 
expert meeting 
Offers 
guidelines on 
how to 
diagnose and 
treat women 
with breast 
carcinoma 
during 
pregnancy 
Multidisciplina
ry approach is 
recommended 
including 
psychologist, 
social workers, 
and a chaplain; 
 Ongoing 
psychological 
support during 
treatment and 
delivery should 
be available for 
the patient and 
her family 
A supportive 
patient-
physician 
relationship is 
required, as is 
close 
collaboration 
and feedback 
of all 
disciplines 
involved in the 
patient’s care, 
aiming to assist 
the patient and 
her partner 
towards 
Informing the 
patient about 
the 
options(enabli
ng patients to 
take informed 
decisions); 
involving 
partner in 
consultations 
(respect for 
relational 
autonomy) 
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achieving a 
true informed 
consent and 
commitment to 
treatment 
Helewa et al., 
2002 (Helewa et al. 
2002); Breast 
Disease Committee 
and Executive 
Committee and 
Council, Society of 
Obstetricians and 
Gynaecologists of 
Canada 
Provides 
physicians with 
up-to-date, 
accurate 
information and 
recommendatio
ns regarding 
pregnancy and 
lactation impact 
on cancer risk, 
prognosis, risk 
of reoccurrence 
and feasibility 
of 
breastfeeding in 
women affected 
by breast 
cancer; and 
also offers 
counselling 
recommendatio
ns 
Multidisciplina
ry approach 
should be 
taken;  
Patients should 
be counselled 
regarding the 
effect of 
proposed on 
the foetus and 
on overall 
maternal 
prognosis;  
Termination of 
pregnancy 
should be 
discussed, but 
patient should 
be counselled 
that prognosis 
is not altered 
by termination 
of pregnancy  
Counselling 
support for 
breast cancer 
patients is 
advocated 
Informing the 
patient about 
the options 
(enabling 
patients to take 
informed 
decisions) 
 
 The USA National Cancer Care Network (NCCN) guidelines were not identified by 
the searches in the data bases. Therefore, they were searched manually on NCCN official 
website on 2015-10-24 www.nccn.org with keyword ‘pregnancy’ but no relevant 
guidelines were located. These search results correspond to a previous review comparing 
NCCN and European Society of Medical Oncology (ESMO) guidelines for breast cancer 
care which found that the NCCN guidelines did not fully address pregnancy issues but in 
general supports pregnancy after breast cancer (Zagouri et al. 2015). 
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4.3. Analysis of ethics content 
 
 This work does not focus on judging the ethics content present in analysed 
guidelines. On the contrary, it seeks to understand the standpoints and approaches to 
ethical issues surrounding cancer care during pregnancy through clinical practice 
guidelines. Careful analysis of ethics content in 17 guidelines suggests that three main 
themes can be identified in their texts. That is respect for autonomy, beneficence and 
protection of the vulnerable. The first two are found in classical biomedical ethics texts 
and are known as moral principles (Beauchamp and Childress 2013) while the third one is 
also claiming the status of a principle, especially in the European bioethics (Rendtorff 
1998)(Rendtorff 2002). Hence, it’s conceptualisation, definition and recognition has been 
slow (Sass 2001)(Tavaglione et al. 2013). Just recently it has been suggested to develop the 
concept of vulnerability as a principle of protection of the vulnerable (Hurst 2008) and also 
as a principle of respect for human vulnerability (Ten Have 2015). 
 In biomedical ethics autonomy is defined as a “principle of patient’s autonomy”58 
which implies that physicians should empower patients to make informed decisions about 
their treatment which are of paramount importance in patient care (Blank 2002). It is also 
known as a “principle of respect for autonomy” which involves acknowledging the value 
and decision-making rights of patients by enabling them to make decisions about their 
treatment (Beauchamp and Childress 2013). For the purpose of this work, autonomy is 
perceived as involving the patient in a decision-making process by informing her about the 
                                                 
58 It appears that clinicians tend to refer to the principle of autonomy more often than the principle of respect 
for autonomy. While both of them foster very much the same value attributed to patient’s autonomy, the first 
one is very much clinical practice oriented and was presented by the Medical Professionalism Project as the 
Physician’s Charter (Blank 2002). The respect for autonomy is usually referred to in biomedical ethics 
literature as it has been continuously developed by applied ethics scholars (Beauchamp and Childress 2013). 
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treatment options and taking patient’s wishes into account when determining the disease 
management plan.  
 The developers of principles of biomedical ethics emphasise the importance of 
informed consent and argue that it could not be equated to shared (or joint) medical 
decision-making (Beauchamp and Childress 2013). They argue that shared decision-
making could be misleading by merely allowing patients to participate in information 
exchanges but continuing the legacy of medical paternalism by ignoring patient’s rights to 
approve or reject proposed procedures (Beauchamp and Childress 2013).  
 Proponents of preventive ethics seem to adopt such paternalist approach where 
informed consent is understood as an ongoing dialogue with a patient followed by 
negotiation and respectful persuasion if disagreement occurs (McCullough and Chervenak 
1994). They seem to give higher preferential value to clinically defined foetal and maternal 
beneficence, especially after foetal viability is reached (Chervenak et al. 2004). Whereas 
the fathers of biomedical ethics insist that that “respect for autonomy in health care 
relationships requires much more than avoiding deception and coercion. It requires an 
attempt to instill relevant  understanding, to avoid forms of manipulation, and to respect 
persons’ rights” (Beauchamp and Childress 2013).  
 However, the later sometimes does clash with what is clinically perceived as the 
most beneficial intervention concerning the best interest of the patient and her foetus. In 
biomedical ethics literature it is known as a principle of beneficence, which implies that 
there is a moral obligation to act for the benefit of others. It corresponds with principle of 
utility and principle of  non-maleficence (Beauchamp and Childress 2013) as well as 
principle of primacy of patient’s welfare which is based on serving the interest of the 
patient (Blank 2002). The relevance of this principle is that cancer treatment during 
pregnancy might require a compromise between maternal and foetal health, therefore a 
choice has to be made on whose health-related benefits should prevail. In addition to that 
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patient might have her own ideas and understanding of what constitutes the best interest of 
her own and that of her foetus. It is important to note that again in biomedical ethics 
obligation to do no harm is usually more stringent than obligation to benefit. Therefore, 
even if best utilitarian outcome could be reached by acting beneficently the duty to do no 
harm would override the requirements of beneficence (Beauchamp and Childress 2013). 
That corresponds to the doctrine of double effect as discussed in Chapter 2.  
 Vulnerability can be perceived as a state which is shared by entire humanity 
because we all are subject to disease and death (Ten Have 2015) but for the purpose of this 
work it is more relevant to consider vulnerability of the specific groups such as pregnant 
women, cancer patients, children, who might have reduced capacity, power and control in 
order to protect and defend their interests as compared to others (Mackenzie, Rogers, and 
Dodds 2014). In clinical setting, and especially clinical research, vulnerability can be 
detected in different forms: cognitive, juridical, deferential, allocation and infrastructural 
(Kipnis 2001)(Kipnis 2003). Some proposals were made to consider vulnerability as a 
principle of European Bioethics contrasting it to American principlism ethics (Rendtorff 
1998)(Rendtorff 2002) but this was not met with much of enthusiasm (Sass 2001). Another 
proposal suggested to consider it as a “principle of protection of the vulnerable” (Hurst 
2008). In this work the concept of “protection of the vulnerable” is used under the 
definition which includes providing care and support for those who might be under-
represented, have limited or restricted capacities to represent their interests or not able to 
defend their position, which in case of participation in clinical trials is referred to as “poor 
bargaining position” (Kipnis 2001)(Sheppard 2015). This could include pregnant women, 
cancer patients, foetuses, neonates, and potential future children and existing children. 
 The first two concepts can be specified further. In case of respect for patient’s 
autonomy it can be specified as enabling patients to take informed decisions, respect for 
patient’s autonomy, respect for relational autonomy. In case of beneficence the following 
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specifications can be applied: balancing maternal and foetal beneficence, favouring 
maternal beneficence and favouring foetal beneficence. It is important to note that such 
wording, specific for medical ethics literature, is not usually used in the texts of clinical 
practice guidelines. Table 4.2. illustrates how original wording from the guidelines 
translates to “ethics language”. For example, “attention to patient’s personal wishes” 
(Follows et al. 2014), “abortion is a personal decision” (Dauer et al. 2012) is interpreted as 
respect for patient’s autonomy while “considerations should be given to the health of both 
mother and foetus” (Ali et al. 2015) is regarded as balancing maternal and foetal 
beneficence but “maximizing maternal outcome” (Amant et al. 2014) is translated as 
preference to maternal beneficence. Explanations on what ethical concepts mean and 
which guidelines contain them are given in Table 4.3.  
Enabling patients to take informed decisions and respect for patient’s autonomy 
were distinguished because informed decisions can be limited to providing information 
about the treatments and just asking the patient if she accepts or rejects the intervention 
based on the information provided59. While respect for patient’s autonomy goes one step 
further and in addition to providing patient with information, involves patient in decision-
making process making her an active participant where treatment plans can be modified 
and adjusted to patient’s preferences and wishes. This distinction is not very clearly 
elaborated by the creators of the guidelines (just as in biomedical ethics literature) but 
distinction is important as it has been shown that concerning cancer and reproductive 
issues some clinicians can be reluctant to provide patients with all relevant information 
                                                 
59 According to Beauchamp and Childress, a key aspect in ethical patient care is allowing her to approve and 
authorise the interventions while information exchanges and communication through which patient elects the 
intervention is medical advice, which could be highly paternalist (Beauchamp and Childress 2013).My 
approach to this is that patient should not be left alone to take the decision about medical options available to 
her and in addition to evidence-based medical information, she should also be given space to reflect on 
available alternatives and use counselling services, if required.  
97 
 
about their options (Linkeviciute et al. 2014) and also significant numbers harbour 
conservative attitudes towards cancer and pregnancy compatibility (Sileny N Han et al. 
2013). Furthermore, even if some scholars like McCullough and Chervenak (Chervenak et 
al. 2004) suggest that directive counselling based on scientific evidence, otherwise known 
as respectful persuasion (McCullough and Chervenak 1994) should be allowed in medical 
practice, paternalist approach to patient care is highly criticised practice (Beauchamp and 
Childress 2013). In general there is wide agreement in clinical ethics literature that it is a 
pregnant woman who decides what interventions can be performed on her for the benefit of 
her foetus and herself (Pinkerton and Finnerty 1996)(Shanner 1998)(Fasouliotis and 
Schenker 2000)(Dickens and Cook 2003)(ACOG Committee on Ethics 2005). This has 
become especially evident in medical and ethics literature after the US Supreme Court 
ruling in Angela Carder’s case (Chapter 2). 
 The later is also clearly reflected in the reviewed guidelines. They appear to 
endorse the respect for patient’s autonomy by stating explicitly that wishes of the patient 
should always be taken into consideration and even advancing it further by promoting 
relational approach to autonomy such as respect for relational autonomy, where pregnant 
patient’s partner and/or family are included in the decision-making process. This approach 
is especially relevant in pregnancy care. However, even if some guidelines recognise 
relational aspects of patient care, they do not mention how conflicts between the patient 
and her family should be addressed. Such situations, even if rare, can pose some dangers 
on individual autonomy of pregnant cancer patient if her family members have preferences 
conflicting to hers. Hence limited empirical data suggests that this might not necessarily be 
a relevant concern in practice (Kenyon et al. 2006)(Smyth, Jacoby, and Elbourne 2012).  
 Most guidelines suggest that maternal cancer treatment and healthy development of 
the foetus are compatible and, therefore, advocate for encouraging and supporting the 
patient to continue with pregnancy by balancing maternal and foetal beneficence. Some 
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emphasize very explicitly that pregnancy termination is strongly discouraged (Peccatori et 
al. 2013), serious consideration should be given to continuing the pregnancy (Amant et al. 
2010) or that pregnancy should never be interrupted (Papini et al. 2010). It is clear that 
compromising the maternal outcome by withholding the treatment is not justified and 
maternal beneficence is advocated. Therefore, in cases when optimal balance for both 
mother and foetus is not possible, maternal health is given more consideration (Follows et 
al. 2014)(Amant et al. 2014)(G. Koren et al. 2013) but even very categorical views of 
never interrupting the pregnancy showing preference to foetal beneficence advocate for 
care and support for a pregnant woman (Papini et al. 2010). Moreover, it seems reasonable 
to think that guidelines, which explicitly state that pregnancy termination in case of 
maternal cancer is discouraged, do so based on scientific evidence suggesting the 
compatibility of cancer and pregnancy. 
 Protection of the vulnerable is only mentioned by one group of experts in two 
subsequent guidelines (Amant et al. 2010)(Amant et al. 2014) and it is difficult to speculate 
who is considered as vulnerable. One of the mentioned guidelines also supports the mother 
focused beneficence and advocates for providing the best treatment for the vulnerable 
population of pregnant women with breast cancer (Amant et al. 2014) while the other one 
has only indirect reference encouraging pregnancy continuation by saving the foetus and 
treating maternal cancer (Amant et al. 2010). Just as in the case of beneficence, the concept 
of vulnerability seems to be treated in a light of scientific evidence, protecting the women 
and their foetuses from scientifically unjustified treatment options which might cause harm 
to both of them. 
The major limitations of this systematic review are that data for professional 
guidelines is available from case studies, case study reviews and various registries, which 
are known to have the numerous downsides concerning the level of evidence. This implies 
that sometimes recommendations are based on considered expert opinion rather than on the 
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evidence-based data. It also has to be stressed that clinical guidelines are not expected to 
offer in-depth ethical analyses of clinical conditions they are addressing but including 
ethics components could potentially improve patient care60 and reduce moral distress 
among the healthcare team.  
Table 4.3. Main ethical concepts identified in the guidelines 
Concept Explanation of its meaning Guidelines 
mentioning this 
concept 
Autonomy 
Enabling patients to take 
informed decisions 
Providing patients with the 
information about available treatment 
options, including risks and benefits 
for the mother and the foetus 
(Ali et al. 
2015)(Cardoso et al. 
2012)(Dauer et al. 
2012)(De Groot et al. 
2012)(Amant et al. 
2010)(Marsden et al. 
2010)(Amant et al. 
2009)(Loibl et al. 
2006)(Helewa et al. 
2002) 
Respect for patient’s 
autonomy 
Involving the patient in a decision-
making process by informing her 
about the options and taking patient’s 
wishes into account when 
determining the disease management 
plan. That is a classical principle in 
biomedical ethics 
(Ali et al. 
2015)(Follows et al. 
2014)(Cardoso et al. 
2012)(Dauer et al. 
2012)(De Groot et al. 
2012)(Royal College 
of Obstetricians and 
Gynaecologists 
2011)(Marsden et al. 
2010)(Amant et al. 
2009)(Pentheroudakis, 
Pavlidis, and 
Castiglione 2008) 
Acknowledging the 
respect for relational 
autonomy 
Involving the patient and her 
partner/family in a decision-making 
process by informing about the 
options and taking patient wishes into 
account when determining the 
(Peccatori et al. 
2013)(G. Koren et al. 
2013)(Dauer et al. 
2012)(Royal College 
of Obstetricians and 
                                                 
60 The research of patients’ perspectives on their care is still in its infancy, especially concerning cancer care 
during pregnancy and ethics support services. Therefore, I do not explore in depth the criteria to be used in 
order to evaluate patient care.  
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disease management plan  Gynaecologists 
2011)(Pentheroudakis 
et al. 2010)(Amant et 
al. 
2009)(Pentheroudakis, 
Pavlidis, and 
Castiglione 
2008)(Loibl et al. 
2006) 
Beneficence 
Balancing maternal and 
foetal beneficence 
Considering maternal health 
outcomes and foetal risks when 
determining the disease management 
plan 
(Ali et al. 
2015)(Amant et al. 
2010)(Amant et al. 
2009) 
Maternal beneficence Giving preference to maternal health 
outcomes over foetal risks, if optimal 
balance for both is not possible 
(Follows et al. 
2014)(Amant et al. 
2014)(G. Koren et al. 
2013) 
Foetal beneficence  Giving more weight for protecting 
the foetus and allowing pregnancy to 
continue but offering support for the 
pregnant patient 
(Papini et al. 2010) 
Vulnerability 
Protection of the 
vulnerable 
Proving care and support for those 
who might be under-represented or 
not able to defend their position. 
Could include pregnant women, 
cancer patients, unborn 
children/foetuses, neonates, children 
(Amant et al. 
2014)(Amant et al. 
2010) 
 
4.4. Key recommendations for ethical care 
 
The findings of clinical practice guidelines review reveal that three ethical concepts 
dominate the reviewed guidelines with the most elaboration on respect for patient’s 
autonomy, followed by balanced approach to maternal and foetal beneficence and also 
introducing less often addressed concept surrounding protection of the vulnerable. The 
later concept might serve better for practical ethics approach in cancer during pregnancy 
care as compared to foetus as a patient concept.  
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Overall the reviewed guidelines urge to give consideration to the health of pregnant 
woman and her foetus, promote maternal health and wellbeing, inform the patient about 
available options and offer counselling and support in the process of decision-making. It is 
common to involve the pregnant woman’s partner and/or family in counselling and 
decision-making process. Majority of the guidelines suggest that a multidisciplinary care 
team is formed for determining treatment plans and managing the condition. Furthermore, 
protection of the foetus is also given due attention.  
4.5. Summary 
Clinical practice guidelines for cancer management in the course of pregnancy 
focus on three concepts found in biomedical ethics literature. These are respect for 
patient’s autonomy, beneficence and protection of the vulnerable. In addition some 
guidelines recognise the significance of relationships pregnant cancer patient might be 
inclined to consider when making her treatment choices. Furthermore, experts advocate for 
a multidisciplinary approach to cancer treatment during pregnancy and counselling 
services for patients. 
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Chapter 5. Ethics support services for patients and healthcare 
professionals 
5.1. Methodological diversity 
 5.1.1. The landscape 
 
There are two main stream approaches to ethics support which can be distinguished 
in clinical ethics (Linkeviciute and Sanchini 2016). The first one is known as healthcare 
ethics consultation61 and is predominantly practiced in the USA (Tarzian 2013). The 
second one can be broadly referred to as moral case deliberation and is more prominent in 
Western Europe (Dauwerse et al. 2014)(Stolper, Molewijk, and Widdershoven 2015). 
Healthcare ethics consultation (HCEC) is characterised by the effort to solve conflicts 
through a dialogue between all the stakeholders involved and is expected to conclude with 
a “principled ethical resolution” (Aulisio, Arnold, and Youngner 2000)(Gaucher, Lantos, 
and Payot 2013)(Tarzian 2013). Meanwhile, in the context of moral case deliberation 
(MCD) more emphasis is put on the conceptualization of and reflection on the problem 
rather than on the problem-solving dimension. The MCD is often perceived as a space 
where healthcare professionals can  discuss and share their ideas on troubling ethical 
problems arising in their practice (Dauwerse et al. 2014).  Hence some methods, as for 
example the Nijmegen method (Steinkamp and Gordijn 2003) and Karolinska model for 
ethical analysis (Bartholdson, Pergert, and Helgesson 2014), allow space for exploring the 
possible solutions and their justification. 
 Furthermore, differences between American and European approaches were also 
partly determined by legal system differences in two continents. A historical moment 
marking a milestone in the development of HCEC services was the “Quinlan case” in 1976 
where a legal dispute took place in order to determine if Ann Karen Quinlan’s life 
                                                 
61 Previously it has been known as “clinical ethics consultation” and the term is still in use (Linkeviciute and 
Sanchini 2016).  
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supporting ventilator could be switched off. The Supreme Court of New Jersey ruled that 
ventilator can be removed, and urged the hospitals to form ethics committees which would 
help to resolve similar problems in the future (Tapper 2013). Following this case, the U.S. 
President’s Commission suggested that consultations with ethics committees could be used 
as means to approach ethical disputes in clinical setting (Aulisio, Arnold, and Youngner 
2000). Therefore, the American approach to ethics consultation has a nudge from a legal 
system to act as a guardian, so that ethical decisions can be reached within the hospital 
without resorting to the courts. 
 However, there seems to be a growing interest in using the mediation approaches in 
healthcare ethics consultation (Fiester 2013)(Morreim 2015)(Howe 2016), arguing that 
mediator’s job is to avoid making a recommendation and imposing the solution. Instead 
ethics consultants are invited to engage the conflicting parties in such a way that resolution 
emerges from those in conflict and is not imposed by recommending what has to be done 
(Fiester 2013)(Morreim 2015). Despite the calls to segregate ethics consultation and 
mediation services (Morreim 2015) and widely unanimous agreement that mediation skills 
are essential for ethics consultants (Viafora 1999)(Steinkamp and Gordijn 2003)(Neitzke 
2009)(Larcher, Slowther, and Watson 2010)(Tarzian 2013), it still remains unclear what 
exactly is the end product of ethics consultation. Proposals were made to restructure the 
ethics consultation delivery process by paying more attention to the closure which would 
extend beyond the recommendation or one time solution by calling for more attention to 
the moral distress and negative emotions associated with a conflict (Fiester 2015).  Further 
suggestions are made to assign greater moral weight to the feelings individual patients and 
their families experience (Howe 2016).  
 The European take on ethics consultation is slightly different. While ethics 
consultants in the American setting are expected to participate in a “principled ethical 
resolution” to resolve conflicts and avoid turning into courts, British ethics committees, 
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under recommendation of the Royal College of Physicians, are pictured as offering “ethics 
support and advice” (Gaucher, Lantos, and Payot 2013). French have so called Espaces de 
reflexion éthique, which are not meant to offer decision-making recommendations. Instead 
physicians are advised to pursue ethical reflection regarding troubling issues with the help 
of the ethics committees, but any initiative of sharing decision-making responsibility 
among ethics committees and physicians is discouraged (Gaucher, Lantos, and Payot 
2013). Moreover, MCD is not subject to regulation or standardization and is perceived as 
“learning by doing enterprise” (Stolper, Molewijk, and Widdershoven 2015) being one of 
the resources healthcare professionals could use when faced with difficult decisions. Hence 
it does not share the decisional responsibility with healthcare professionals. However, the 
most data comes from the Netherlands where MCD is the most widely practiced, 
Scandinavian countries, Germany, the UK also have clinical ethics support services but 
they are not unified in structure, goals and delivery methods (Bartholdson et al. 
2015)(Dorries et al. 2014)(Larcher, Slowther, and Watson 2010). Ethics committees in the 
Baltic States (Lithuania, Latvia, Estonia) mainly focus on research ethics and do not offer 
ethics support services in a form of reflection or consultation (Gefenas et al. 
2010)(Dranseika 2011). 
 5.1.2. Methodological approaches to ethics support in healthcare 
 
 The methods used in both approaches to ethics consultation usually have a protocol 
that lists a number of questions to be answered and steps to be followed. The classical way 
to start the ethics consultation is by presenting the case and related problem(s) (Steinkamp 
and Gordijn 2003). This is followed by the gathering of relevant facts and identification of 
the stakeholders involved. Then, it proceeds with the comprehension of the nature of the 
problem, the determination of the values compromised, as well as the arguments in favour 
and against the potential solutions. Depending on the methodology, the concluding part can 
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arrive at a solution, a recommendation, or a list of possible alternatives leaving the final 
decision for those who will be affected by it (Linkeviciute and Sanchini 2016). 
In the American context the four principles of biomedical ethics (respect for 
patient’s autonomy, nonmaleficence, beneficence and justice) are used widely as a point of 
reference for ethical decisions (Beauchamp and Childress 2013). Other attempts to develop 
practically applicable theories for ethical decision making have also been made. For 
example, unified theory where morality is perceived as a public system has been suggested 
to be used as a reference for ethical decision-making (Gert, Culver, and Clouser 2006). The 
concept of common morality is also used by Beauchamp and Childress arguing that four 
principles might be universally applicable (Beauchamp and Childress 2013).  
Some European scholars suggest that a particular method for ethics consultation 
might be best chosen when we know what case we have to approach and depending if 
consultation is done retrospectively or prospectively (Steinkamp and Gordijn 2003). There 
have also been some attempts to propose a list of ethical principles reflecting the European 
ideas and values. These principles include respect for autonomy, integrity, dignity and 
vulnerability (Rendtorff 2002). Dignity and vulnerability remain highly criticized concepts 
(Kottow 2004)(R Macklin 2003) but despite the critique referring to the usefulness and 
relevance of the European bioethics principles (Sass 2001), vulnerability seems to be 
gaining some recognition in medical ethics literature (Sheppard 2015) and the concept of 
respect for human vulnerability is being explored as a potentially new principle in 
bioethics (Ten Have 2015)(Matthews and Tobin 2016). 
One of the first attempts aimed at proposing structured tool for carrying out ethics 
consultation in a clinical setting occurred in 1980.  The Four Boxes Method in a form of a 
pocket guide was created with an intention to be used when addressing ethical issues in the 
clinic. This method focuses on medical indications, patient preferences, quality of life and 
other contingencies as well as incorporates four principles of biomedical ethics (Jonsen, 
Siegler, and Winslade 2010). The four elements constituting this method are the following: 
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1) medical indications concern the evidence supporting therapeutic and diagnostic 
interventions; 2) patient preferences indicate the choices expressed by the patient, based 
both on personal experience, beliefs, values and on the information provided by the 
physician; 3) quality of life describes the features of patient’s life before and after the 
treatment, focusing on a degree of satisfaction that they experience and on the values 
regarding their life and their health; 4) other contingencies refer to the contextual features 
such as familial, social, institutional, financial, legal setting within which the medical 
decision has to be taken (Jonsen, Siegler, and Winslade 2010). This method was developed 
with the aim to help solving practical dilemmas in the clinic, starting with problem-
identification and concluding with possible strategies to manage the problem. This method 
also stresses the importance of using model cases as guides, which could serve as an 
educational resource (Linkeviciute and Sanchini 2016). Another slightly different 
methodology called CASES was developed by the Integrated Ethics project at the U.S. 
Department of Veterans Affairs. The CASES method constitutes of the following steps 
1) clarify the consultation request, 2) assemble relevant information, 3) synthesize 
information, 4) explain the synthesis, 5) support the consultation process.62 
 Most methods are primarily directed to healthcare professionals even if some of 
them allow space for patient participation. Similarly also some European methods are first 
and foremost designed to help clinicians to address and reflect on ethical problems. For 
example, such are the Nijmegen Method (Steinkamp and Gordijn 2003) and the Lanza 
Foundation Protocol (Viafora 1999). Moreover, a Swedish model known as Karolinska 
model for ethical analysis which has been redesigned specifically for oncology setting 
reject patient participation in ethics consultations motivating that such experience might be 
too stressful for the patient (Bartholdson, Pergert, and Helgesson 2014). However, other 
Scandinavian countries report different experiences and positions, for example, users of the 
                                                 
62 The guide specifying further questions and offering further guidance for ethics consultants can be found at 
http://www.ethics.va.gov/integratedethics/ [accessed 2016-03-19]. 
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Norwegian clinical ethics committee model advocate for patient involvement in order to 
achieve better outcomes (Forde and Hansen 2009). Furthermore, a comparative study from 
France, Norway, Germany, Italy and the UK concludes that less patient participation in 
clinical ethics consultation lays better grounding for  protecting patient’s confidentiality 
and allows more objectivity for decision-making while more patient involvement would 
yield enhanced respect for patient’s autonomy and best interest but could lead to 
unbalanced conclusions favouring the patient’s views rather than ethics norms (Fournier et 
al. 2009). 
 5.1.3. Patient focused ethics support methodologies  
 
Methodologies focusing on patients and offering ethics support to patients are less 
frequently mentioned in clinical ethics literature63. Two such examples are Philosophical 
counselling (PC) (Matchett 2015) and  Decisional counselling (DeCo) (Chiavari et al. 
2015). It is important to note that traditionally clinical ethics committees dealt with ethical 
issues surrounding end of life or scarce resource allocation (Linkeviciute and Sanchini 
2016) but increasingly there are different types of ethical problems arising in healthcare 
setting and different approaches to potential solutions are needed (Chiavari et al. 
2015)(Boniolo and Sanchini 2016). This is especially relevant in the healthcare areas 
involving genetic testing, various screening programmes, and use of assisted reproduction 
technologies, which are all common in the oncology and oncofertility settings. Therefore, 
two above mentioned methods are precisely focused on an individual facing troubling 
ethical issue rather than a team of healthcare professionals. They are used to support an 
individual patient (and in some cases her relatives) in decision-making process. 
                                                 
63 Attempts to address ethical issues occur in psychological counselling services for cancer patients (Lawson 
et al. 2015) and increasingly the calls are made to establish closer collaboration between bioethics and social 
work (Brazg, Dotolo, and Blacksher 2015). 
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 Philosophical counselling can be defined as a specific kind of dialogical activity 
where a consultant (or a counsellor) helps a counselee (or a client) to reflect upon his/her 
life troubles by using philosophical concepts, theories and techniques64.  Philosophical 
counselling has been gaining a growing acknowledgement in the clinical ethics field as an 
alternative to dispute resolution because it potentially offers a better “closure” of the case. 
The proponents argue that conflict resolution is not sufficient for a high quality ethics 
consultation and more attention to patient’s perspectives is required. Therefore, a very 
much welcomed feature of philosophical counselling is the space, which this method offers 
for looking more carefully at the specific concepts and patterns of reasoning, which are 
shaping the counselee’s perspective (Matchett 2015). However, the practice of 
philosophical counselling has been subject to extensive critique questioning its place 
within psychological and psychotherapeutic approaches to patient care, whether it is 
therapeutic in its nature and if it qualifies as contemplation or critical thinking activity  
(Šulavikova 2012). Some authors express concerns about theoretical and empirical validity 
of philosophical counselling. For example, Lydia B. Amir raises concerns that 
philosophical counselling might even compromise patient’s wellbeing by the lack of 
agreement how patient’s autonomy should be supported. Further downsides are named as 
blurry boundary between philosophical and psychological counselling and the lack of 
reliable tools for evaluating the effectiveness and preventing potential risks associated with 
this practice (e.g. frustration, confusion, bewilderment, fear, discourage) (Amir 2004). 
Decisional counselling is a method which focuses on patient’s personal values and 
importance that she attributes to the potential benefits, harms and scientific uncertainties 
                                                 
64 It was introduced by a German philosopher, G. Achenbach, who, in 1984, published a book containing 
some lectures he gave on what he defined as a new way of doing philosophy, according to which philosophy 
has to be interpreted as a practical tool to cope with life and its difficulties (Achenbach 1984). It was further 
developed by a Canadian scholar Peter B. Raaber (Raabe 2001), who continues to work actively in a field of 
philosophical counselling http://www.peterraabe.ca/what.html [accessed 2016-05-26]. 
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surrounding her condition, available treatments and choices at hand (Chiavari et al. 2015). 
It focuses on helping patients to think about their choices by presenting which choices 
exist, describing what each of them entails, deliberating about potential options and 
forecasting how they might feel about potential implication and outcomes of the choices 
made. Patient support directed to enhancing their decision-making process can have 
different focus and be directed to value clarification, improving patient experience or 
empowering more disadvantaged groups (Stacey et al. 2012). Decisional counselling 
process is directed by a trained facilitator, who provides the patient with individualised, 
nondirective information but remains neutral concerning the choice on which patient has to 
make a decision. Decision counsellor prepares the patient for the consultation with a 
physician, so patient is better equipped with information concerning her condition, value 
preferences and uncertainties, which can be further discussed and clarified during the 
consultation with physician (Chiavari et al. 2015) 
Ethical counselling (EC) is developed to fit under the umbrella of philosophical 
counselling and offers two distinct methodologies for addressing ethical issues in 
healthcare setting. One methodology is designed for clinicians and serves as space to 
reflect in order to help clinicians to understand patient’s preferences better. The second 
methodology is aimed to serve the patients directly (Boniolo and Sanchini 2016). 
However, in both methodologies a patient is seen as a privileged decision-maker 
concerning the ethical issues occurring in a situation at question, recognising the 
importance of communication, emotions, understanding of probabilities and attributing 
high value to respect for patient’s autonomy (Boniolo and Sanchini 2016). EC is conceived 
as a non-directive method, which serves as an orienteering tool for patients and clinicians 
when thinking about the choices surrounded with ethical questions and uncertainties. Its 
structure is meant to assist a guided reflection process where ethical arguments supporting 
and rejecting each available option can be clarified and evaluated. This method takes 
patient’s personal values and beliefs into particular consideration in order to explore and 
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understand the reasons behind patient’s wishes but does not intend to offer justification for 
one choice over another (Linkeviciute et al. 2015). The developers of EC relate it with the 
MCD approach to ethics consultation as it highlights the importance of clarifying and 
conceptualising the problem rather that offering a solution. Just as HCEC model it 
considers the parties involved recognising the importance of respecting their autonomies 
but it also discards the idea that consensus-building completes ethical reflection. The latter 
is the shared common ground with above mentioned tradition of the Philosophical 
counselling (Linkeviciute and Sanchini 2016)(Boniolo and Sanchini 2016).  
5.2. Standardisation and evaluation attempts 
 5.2.1. Regulation 
 
The American Society for Bioethics and Humanities (ASBH) has been a leading 
institution in making the continuous attempts to promote the professionalization, 
institutionalization and quality assurance of ethics consultation services in the USA.  It 
works towards setting up a HCEC service practice standards which includes ensuring that 
all stakeholders can access HCEC services and receive response in a timely manner, 
transparent service documentation system, established evaluation procedure and 
institutional policy, providing details how all these standards are met (Tarzian 2013).  
This organisation has also introduced the first code of core ethical responsibilities 
for individuals performing healthcare ethics consultation which first and foremost was a 
solid step towards professionalization of ethics consultation practice in the USA (Tarzian 
and Wocial 2015). Elaboration of an ethics code for healthcare ethics consultants also 
serves as a protection of the consultants should their recommendations be challenged in 
court. However, despite establishing the practice standards such as being competent, 
avoiding conflict of interests, respecting privacy of the patients, communicating 
responsibly and promoting just healthcare, the code of ethics for healthcare ethics 
consultants remains highly aspirational (Tarzian and Wocial 2015). Hence, it remains 
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unclear what professional obligations ethics consultants should adopt as their practice is so 
diverse. Some suggest that instead of individual responsibility, ethics consultants should 
share their professional responsibility with an entire healthcare team (Schwab 2016). 
The ASBH is playing directive and regulatory role on how HCEC service delivery 
should be organized in the USA, while its European counterparts such as the UK Clinical 
Ethics Network (UKCEN) and the European Clinical Ethics Network (ECEN) picture 
themselves as supporting and guiding, rather than establishing concrete and binding 
practice requirements for its members or issuing practice licences to individual ethics 
consultants. Therefore, the European organisations play more passive role as compared to 
their North American counterpart.  European bodies tend to build their activities around 
offering education, support and space for reflection but not regulation or strict 
recommendations (Linkeviciute and Sanchini 2016). 
 5.2.2. Expectations from ethics consultants 
 
 Common agreement between European and North American organisations is that in 
order to provide meaningful ethics consultations, ethics consultants are expected to possess 
a number of skills (Linkeviciute and Sanchini 2016). The ASBH offers list of core 
competences, which include the capacities to identify and analyse the disagreements; 
retrieve the relevant ethics literature, policies, guidelines and other documents; collaborate 
with institutional structures; organise formal and informal meetings; report the activities 
and establish follow up processes; communicate and train; represent the views of different 
parties; recognise and find solutions to communication barriers (Larcher, Slowther, and 
Watson 2010)(Tarzian 2013). Furthermore, some cultural competencies are also expected, 
as is the knowledge of moral reasoning, ethical theories and concepts, healthcare systems, 
institutions and clinical contexts, policies, beliefs and perspectives of patients and staff, 
relevant codes of ethics, professional conduct, guidelines and health law relevant to ethics 
consultation (Aulisio, Arnold, and Youngner 2000)(Tarzian 2013).  
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In Britain, the UKCEN has also released a document providing the summary of 
skills and competences required when offering ethics consultation services. The major 
difference is that the UKCEN seems to pay more attention to clinical ethics committees 
and, therefore, its requirements are specifically aimed to the members of such committees 
(Larcher, Slowther, and Watson 2010) while the ASBH puts more emphasis on the skills 
possessed by an individual ethics consultant (Tarzian 2013)(Linkeviciute and Sanchini 
2016). 
It is interesting to note that both the ASBH and the UKCEN emphasise the 
importance of character traits and personal qualities of ethics consultants.   An ethics 
consultant is expected to demonstrate tolerance, patience, compassion, honesty, 
forthrightness, self-knowledge, courage, prudence, humility, and integrity (Aulisio, 
Arnold, and Youngner 2000)(Larcher, Slowther, and Watson 2010). 
The code of ethics for ethics consultants released by the ASBH specifies the core 
responsibilities that ethics consultants should aspire to cultivate in their work. It includes 
maintaining the competence and integrity, managing conflicts of interest and respecting 
privacy, contributing to the field, making public statements responsibly and promoting 
justice in healthcare (Tarzian and Wocial 2015). Hence as it has already been mentioned 
these requirements remain aspirational as there are no solid means to enforce them. This 
particular code has also been criticised as lacking clarity and failing to define role specific 
responsibilities of ethics consultants (Schwab 2016).  
The ways to acquire knowledge and skills for doing ethics consultation are still 
debated. The ASBH is increasingly suggesting examination and licensing, while the 
UKCEN also acknowledges self-directed learning (Linkeviciute and Sanchini 2016). The 
later also applies to the MCD which is even named as “learning by doing enterprise” 
(Stolper, Molewijk, and Widdershoven 2015).  
 In the American setting the ethics consultant have two tasks. Firstly, they should 
help to identify and analyse the nature of the problem. Secondly, the consultant should 
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facilitate the building of a “principled ethical resolution” (Aulisio, Arnold, and Youngner 
2000)(Gaucher, Lantos, and Payot 2013)(Linkeviciute and Sanchini 2016). This means 
“ensuring that all involved parties’ voices are heard, assisting them to clarify their own 
values, facilitating understanding of factual information and recognition of shared values, 
identifying and supporting the ethically appropriate decision maker(s), and ensuring that 
identified options comport with relevant bioethics, medical, and scholarly literature, and 
with laws, pertinent institutional policies and current practice standards” (Tarzian 2013). 
 Concerning the MCD the requirements for the ethics consultants (also called 
facilitators) are not so explicitly defined. Facilitators do not necessarily have to be the 
ethicists as their major role is to moderate the dialogic process (Linkeviciute and Sanchini 
2016). Since Dutch healthcare has a growing interest in MCD, training programmes for 
health care professionals are being developed to enable them to run MCD sessions 
themselves without necessarily depending on (external) ethicists. Teaching programmes 
for MCD include providing the trainees with basic knowledge about ethics, profound 
knowledge about conversation methods, attitude and skills for easing dialogue and 
analytical reasoning. However, each trainee is encouraged to find his or her own style of 
MCD (Stolper, Molewijk, and Widdershoven 2015). 
 Therefore, certification or attestation of ethics consultants remains a grey area 
despite the increasing rigour that professionalization of the practice is to be developed. 
Hence, initially the ASBH held the position which rejected the certification of ethics 
consultants or even accreditation of programmes which prepare ethics consultants (Aulisio, 
Arnold, and Youngner 2000). Recently, however, attempts have been made to develop 
some practical tools for assessing and attesting the individual consultants ability to perform 
clinical ethics consultation (Fins et al. 2016). In addition, assessments tools for 
retrospective evaluation of already performed ethics consultations are being developed 
(Pearlman et al. 2016).  
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 5.2.3. Evaluation of ethics consultation practice 
 
 Evaluation of decisional and/or ethics support interventions is complicated by the 
fact that in many cases there is no singular “best” choice which could be supported by the 
concrete evidence that certain screening, testing or treatment option is better than other 
alternative available (Chiavari et al. 2015). However, the ASBH continuously recommends 
to evaluate HCEC practices (Aulisio, Arnold, and Youngner 2000)(Tarzian 2013) and 
some attempts to develop the evaluation tools have already been made. One example is a 
conceptual framework developed in the USA (Pearlman et al. 2016) for assessing ethics 
consultation quality. This particular framework is perceived as a systematic process 
promoting a shared understanding of ethics consultation services and their quality. The 
evaluation process is presented as “Ethics Consultation Quality Assessment Tool” 
(ECQAT) and, although it is primarily designed to assess the quality of ethics consultation 
services, it also has an aim to promote the accountability of ethics consultation service 
providers. The key elements of ECQAT are ethics question, consultation-specific 
information, ethical analysis and conclusions and/or recommendations (Pearlman et al. 
2016) 
 Pearlman and colleagues (2016) suggest that ethical analysis might provide the 
justification for drawing some decisional conclusions and/or recommendations, when 
adequately structured. However, the choice of the tools for the ethical analysis can be 
biased by some particular world views which could also affect the conclusions and 
potentially serve better for supporting specific solution in line with preferred moral 
conviction (Linkeviciute et al. 2016).  
 There are just a few empirical studies reporting the data from attempts to actually 
evaluate the outcomes of ethics consultation. A recent study from Sweden, which 
employed exploratory and descriptive qualitative approach and interviewed 11 healthcare 
professionals, found that ethics rounds as a way of supporting healthcare professionals is 
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seen as a positive intervention to their daily work which helps to see things from different 
perspectives and gain insights into ethical issues (Silen et al. 2016). However, the same 
study reports that healthcare professionals who participated in ethics rounds did not 
experience any changes in their daily work or thinking due to organisational hurdles. A 
bigger survey study from the USA collected responses from 123 clinicians about their 
views on healthcare ethics consultation (Wocial, Molnar, and Ott 2015) and found that 
60% of respondents  thought that ethics consultations helped to clarify the values of the 
patient and/or their families and also assisted in clarifying their own values. Moreover, 
75% of American respondents said that their confidence in patient’s care plan increased as 
a result of ethics consultation. The later resonates with the view that ethics consultation 
sometimes is perceived as peer-review for the decisions clinicians are making (Neitzke 
2009). Not all studies yield the same results, one more study from Sweden found that 
ethics rounds do not improve the handling of ethical issues and suggests that the outcomes 
of ethics rounds might be directed to the patient outcomes rather than clinicians working 
environment (Silén et al. 2015). This remains a significant limitation of the above studies 
(Wocial, Molnar, and Ott 2015)(Silen et al. 2016) as they do not include patient/family 
perspectives, nor evaluate patient outcomes as a result of ethics consultation.  
 5.2.4. Remaining questions for successful evaluation  
 
 As myself and colleagues have already argued elsewhere (Linkeviciute et al. 2016) 
there are three questions which require clarification in order to establish functioning 
evaluation system for ethics consultation.  
Firstly, we have to appreciate the diversity in which ethics consultation is 
practiced.  In order to understand what could and should be evaluated in ethics 
consultations, we might need to draw a clear distinction between varying approaches to the 
practice of ethics consultation (Linkeviciute and Sanchini 2016) with emphasis 
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distinguishing those which offer a space to pursue ethical reflection, conceptualize ethical 
questions and clarify conflicting ethical positions (Gaucher, Lantos, and Payot 
2013)(Dauwerse et al. 2014)(Boniolo and Sanchini 2016) and those which seek to provide 
principled ethical resolution and offer a recommendation (Aulisio, Arnold, and Youngner 
2000). In this way we could have a more precise idea if the aim is to evaluate the process 
of ethics consultation, its outcomes or both.  
Secondly, even though we know that ethics consultation in European context 
cannot be equated to healthcare ethics consultation models in North America (Gaucher, 
Lantos, and Payot 2013)(Linkeviciute and Sanchini 2016), methods used for actual 
consultations by both approaches are still very heterogeneous and some standardisation 
might be required before evaluation is possible (Linkeviciute et al. 2016). The attempts to 
offer evaluation tools for the European methods might need to focus more on the process 
rather than conclusions reached or recommendations made in case of troubling case or 
situation. However, as discussed above, even the North American approach to healthcare 
ethics consultation is not homogenous and increasingly its outputs and impact is being 
questioned and alterations65 to the existing “conflict resolution” approach suggested 
(Morreim 2015).  
Thirdly, we still have to define what kind of accountability we expect from ethics 
consultants before we can evaluate what they do. The level of accountability would differ 
if consultants are expected to give a concrete recommendation or just moderate a 
discussion (Linkeviciute et al. 2016). Furthermore, there are varying proposals on the most 
                                                 
65 The most broadly discussed alteration is presented as “bioethics mediation”, which is supposed to extend 
beyond recommendation/conflict resolution by taking into account feelings and emotions associated with the 
troublesome situation (Fiester 2015) and also  reducing the distress experienced by the parties involved by 
building patients trust and avoiding hostility to resolutions produced by experts rather than those who will 
actually be affected by the decision (Howe 2016).  
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appropriate model for defining ethics consultant’s responsibility varying form shared 
responsibility among the healthcare team (Anderson-Shaw 2014) to distinguishing role-
based and activity-based models of accountability (Finder and Bliton 2014).  
Therefore, we previously concluded that “depending on the scope, goals and 
methodologies used in ethics consultation, we might need different evaluation criteria to 
make sure that we are judging them adequately. European approaches to ethics 
consultation have less decisive power; do not seek equal status with clinical consultation 
and by virtue offer a space for reflection and advice rather than conflict resolution or 
principled recommendation. This suggests that assessment tools can only partially mirror 
North American experiences and require further developments to be applicable for the 
European context” (Linkeviciute et al. 2016).  
5.3. Summary 
Ethics support services for healthcare professionals and patients take different 
forms and approaches. They can be divided into the North American healthcare ethics 
consultation approach and deliberative approach (e.g. moral case deliberation), which is 
more common in Europe. There is growing interest to professionalise ethics consultation 
practice and evaluate its services. Ethics support aimed at healthcare professionals remains 
a predominant practice while patient focussed ethics support methods are only starting to 
emerge (e.g. decisional counselling, ethical counselling, philosophical counselling) but 
ethical concerns are also addressed in the course of other types of patient counselling such 
as psychological counselling. Meanwhile, there are still many open questions concerning 
the professionalization, standardisation and evaluation of ethics support services. These 
questions could be answered upon the agreement on the role ethics support plays in clinical 
practices. The latter is very much relevant in many European counties. 
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Chapter 6. Framework for ethical care of pregnant cancer patients 
 
6.1. Relational approach to patient care 
 6.1.1. Patient in a relational context 
 
 This section considers the relationships between a patient and the people around her 
whom she finds important to take into account when making decisions about her cancer 
treatment and pregnancy care. It also considers healthcare team in regard to 
accommodating pregnant cancer patient’s wishes aligned with the wishes of her partner 
and/or family.  
 Caring for a pregnant woman with cancer usually requires a multidisciplinary team 
and personalized treatment plan, which usually involves physicians of different specialties. 
It also often requires support from patient’s family members in order to attend 
appointments with specialists, hospital visits for treatment, preparing for the arrival of the 
baby, taking care of a newborn while continuing cancer treatment, etc.  Therefore, all 
parties affected by pregnant patient’s disease could have different interests or might 
delegate themselves to represent the interests of the party or parties that are restricted in 
representing themselves (e.g. foetuses, young children and even pregnant women) and 
therefore, the involvement of various healthcare providers and family members could 
inevitably lead to disagreements (Moore, Engel, and Prentice 2014). Some of the affected 
people might not feel comfortable with the choices of a pregnant cancer patient and 
attempt to influence her decisions. This could come from a family as well as from a 
healthcare team and as it has already been mentioned (Chapter 2 and Chapter 3), the ethical 
questions, which are raised by the healthcare team and patients and/or their families, are 
not always the same. 
119 
 
  Respect for patient’s autonomy being a core principle in modern medical ethics 
(Beauchamp and Childress 2013) requires due attention to the individual patient’s views 
and wishes, as well as their participation in decision-making and being the main decision-
maker in the choice of treatment (Beauchamp and Childress 2013) and ethically troubling 
situations (Boniolo and Sanchini 2016). However, patients do not live in isolation and their 
choices might affect other stakeholders involved, just as their choices can be affected by 
other people or situational and relational factors. Some feminist writers argue that 
suggesting women to exercise autonomy in its individualistic form is against the female 
nature and could only lead to disrupted relationships (Mackenzie and Stoljar 2000). Caring 
for a pregnant cancer patient requires to consider multiple relationships, which this patient 
has, including her perceived relationship with a foetus, her partner, other children (if 
present), parents and other family members, in some cases members of the communities 
pregnant cancer patient identifies with and ethno-socio-cultural and political environment.  
 A review of clinical practice guidelines for cancer management during pregnancy 
also reveals that clinicians are encouraged to pay attention to individual patient and her 
family’s wishes. Moreover, these guidelines also call for a careful balancing between 
maternal and foetal beneficence when administering cancer treatment and protecting the 
vulnerable actors in cancer treatment process (Chapter 4).  
 In this section I mainly focus on patient wishes in the context of her relationships, 
which is also known as narrative identity leading to self-creation, which is not limited to 
having a self-narrative and knowing who we are because we also want our inner story to 
unfold in a certain way by being or becoming a certain kind of person (DeGrazia 2005) 
and/or fulfilling the obligations and meeting the expectations of those significant to one’s 
life. That includes but is not limited to life partner, parents, existing and potential future 
children (Linkeviciute et al. 2015)(Linkeviciute and Peccatori 2016). 
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  Narrative identity could be seen as a connection between pregnant woman’s story 
and stories of people around her (e.g. relationships with a life partner, children, closest 
friends, neighbours, colleagues, religious community members, etc.), even though these 
individuals do not literally form a part of a patient, they might certainly be a part of her 
identity and to some extent their interests are also her interests. Overlapping interests 
indicate that their wellbeing constitutes a part of patient’s wellbeing because if her partner 
and children flourish, she is also better off (DeGrazia 2005)(Goncalves, Sehovic, and 
Quinn 2014).  
 As David DeGrazia explains, a large part of who we are is determined by our 
interpersonal relationships, some of which are central to our identity (DeGrazia 2005). 
Therefore, the ideal that a patient is in charge of her life and at liberty to make her own 
choices, as some feminist authors suggest (Feary 2003), is further complicated by multiple 
identities of pregnant cancer patients and their social embeddedness. Socially constituted 
individuals might also identify themselves through their social roles (e.g. partner, mother, 
friend) and choose to exercise their autonomy in a light of their past experiences, 
expectations and relationships, which they see as part of their narrative identity 
(Mackenzie and Stoljar 2000)(Mullin 2005)(DeGrazia 2005). 
 The later exposes individuals to vulnerability to co-creation such as being 
dependent on others to develop and maintain skills of putting together a life narrative 
autonomously (McConnell 2016). While on the other hand, personal identity is mirrored  
through the relationships with others  (DeGrazia 2005) which eventually is reflected in the 
choices, values and even identity a woman adopts (Mackenzie and Stoljar 2000)(Donchin 
2001). 
 The above indicates that accommodating the need to involve the partner and other 
family members into information, decision-making and cancer care process of a pregnant 
cancer patient might enhance her ability to exercise the relational autonomy rather than 
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restrict it or deprive the patient from making the choices in-line with her wishes, values 
and ways she sees life (personal philosophy). Hence, some safeguards would be necessary 
in order to respect the supremacy of pregnant cancer patient as an individual with her 
genuine personal wishes. 
 Therefore, even though I argue that in cancer care during pregnancy a different take 
on respect for patient’s autonomy is necessary in order to address the needs of the patients 
and their closest relations, this does not mean that respect for individual autonomy should 
be abolished all together.  On the contrary, recognising the importance of the relationships 
would help to empower the patients to exercise their wishes concerning their cancer care in 
a broader context. Relational approach to such care would help to see and recognise the 
patient as socially embedded human being who holds individual views on life.  
 However, respecting and involving others in discussions, decision-making and care 
of pregnant cancer patients could be very intense, emotional and otherwise difficult task. It 
might also require change of attitudes towards the relationship between a patient and the 
healthcare team. While medical paternalism where “doctor knows best” is highly criticised 
approach in modern biomedical ethics (Beauchamp and Childress 2013), under some 
circumstances newly emerging concept of medical maternalism66 might come in helpful 
(Specker Sullivan 2016).  Furthermore, such change in attitude towards the patient could 
also be supported by ethics of care, which is built on compassion, presence, empathy and 
recognition of the patient as a fellow human being (van Heijst 2011). 
 6.1.2. Relational ethics 
 
 The focus of this section is on the relationships between healthcare professionals 
and a patient, requiring cancer care in the course of pregnancy. Relational ethics situates 
ethical action in relationships where acting ethically “involves more than resolving ethical 
                                                 
66 This concept echoes with medical paternalism but clinicians, while taking decisions for their patients, give 
particular consideration to patient’s wishes, preferences and values. 
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dilemmas through good moral reasoning, it demands attentiveness to our commitments, to 
one another, to the earth, and to all living things. Ethics is about interdependency as well 
as freedom, our emotions as well as our reason, and our unique situation as well as our 
human commonalities. It involves finding the fitting responses to our ethical questions” 
(Austin 2008). Ethics of care is developed further by specifying that compassion, presence, 
empathy and recognition of a patient as a fellow human being play a significant role in 
relationship between healthcare professionals and their patients (van Heijst 2011). 
 This approach has been mainly developed in a context of nursing care which could 
be very intense in both oncology and gynaecology/obstetrics settings. Historically nurses 
have been known to care for the patients while doctors just prescribed treatment but would 
not be actively involved in administering it. Currently it is still reported that specialty 
doctors do not always have enough time and sometimes the latest knowledge, expertise and 
resources to involve their patients in informative discussion about treatment options 
available to them, especially concerning fertility preservation for cancer patients 
(Linkeviciute et al. 2014) and cancer treatment during pregnancy (Sileny N Han et al. 
2013). 
  Guidelines for cancer management during pregnancy (Chapter 4) unanimously 
suggest that cancer care during pregnancy should be provided by multidisciplinary teams. 
Hence the guidance is mainly aimed at physicians, just briefly mentioning the involvement 
and role of nursing staff. However, majority of guidelines suggest that pregnant cancer 
patients should be offered counselling in the course of decision-making and also during the 
treatment. Oncology nurses in particular often encounter ethical issues due to complex 
patient care needs requiring expertise from multidisciplinary teams (Moore, Engel, and 
Prentice 2014)(Pollard 2015) and could play a significant role in directing patients to or 
even delivering initial counselling for patients affected by cancer while pregnant.   
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 As I already mentioned at the beginning of this chapter, good caring is not 
reducible to respect for autonomy  (Feary 2003) as it also includes recognition, 
compassion, presence and empathy (van Heijst and Leget 2011). Indeed it is further argued 
that by overvaluing autonomy, healthcare professionals risk rejecting the patient’s need to 
be loved and belong to others (van Heijst 2011). Therefore, a relational context is 
considered to be a basic premise of relational ethics in relationship between a patient and 
healthcare professionals with core tenets of mutual respect, engagement, embodied 
knowledge, environment and  uncertainty (Pollard 2015).  
 Despite primarily focus to care approach coming from the nurses, care approach is 
also increasingly recognised among the practicing physicians67 with some calling it 
professional loving care.  According to the developers of the concept “the idea of 
professional loving care rests on the assumption that professionals have the space, time, 
and ability to react to care-receivers in a way that demonstrates the best possible care” 
(van Heijst 2011). Compassion, recognition and presence are argued to be the key features 
in ethics of care (van Heijst and Leget 2011) and care itself is considered to be a value in 
care ethics (Vanlaere and Gastmans 2011). Care can be perceived as an attitude and also as 
an activity supported by theory of presence (Vosman and Baart 2011), where strong accent 
is put on developing a relationship between the ones who give care and those who receive 
it (van Heijst 2011).  
 In the field of oncology this could even extended to medical maternalism, approach 
where decisions for another person are based on reasonable understanding of that person’s 
own preferences (Specker Sullivan 2016) which would be very relevant for cases where 
                                                 
67 “Fedro Peccatori: teaching the world to care” by Daniela Ovadia in Cancer World, January-February 2016: 
22-26. http://www.cancerworld.org/Articles/Issues/70/January-February-2016/Profile/753/Fedro-Peccatori-
teaching-the-world-to-care-.html [accessed 2016-06-23]. 
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pregnant cancer patient is dying and/or being kept on life support for the benefit of the 
foetus. However, there are concerns that healthcare professionals demonstrate poor 
understanding of their own legal accountability in regard to the rights of pregnant women 
and her foetus (Kruske et al. 2013) and also sometimes fail to notice that things have gone 
wrong for the patient by following the policies to the letter (van Heijst 2011). Therefore, 
using relational ethics approach to patient care does not make decision-making easier but 
possibly more considered and fitting to the situation because it helps to see patients as 
interdependent and connected by challenging the traditional notions of autonomy, equality, 
and the self as an independent entity (Pollard 2015).  
6.2. Protecting individual autonomy in a relational context 
 6.2.1. Evidence-based information disclosure 
 
 Allocating time for informing the patient about her treatment options plays a key 
role when enabling the patient to take informed decisions about her cancer care and 
treatment. Some patients might require time to understand the information and consider 
how options available to them fit to their life narrative and expectations, how it aligns with 
their social roles, relationships their value and personal philosophy they are keen to 
cherish.  
 Considering the time limitations which physicians face in everyday practice, 
additional patient support services (e.g. counselling) could be beneficial68 to patients who 
are diagnosed with cancer during pregnancy. Such counselling could be offered in different 
modes and types with unifying feature of helping patient to understand all relevant 
information, cancer treatment and pregnancy care options at hand, crystallising her own 
preferences, expectations and perceptions on what would count as a desirable outcome in 
                                                 
68 Creating effective evaluation tools for counselling services is still in early infancy and some most current 
problems are reflected on in Chapter 5. 
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her individual situation. Decisional counselling is an excellent example of how cancer 
patients could be helped to understand the complexity of the information about their 
condition and treatment options as well as implications of choosing one over another and 
feelings related to the potential consequences of the choice (Chiavari et al. 2015). Hence, 
patients are different and their needs for counselling vary. Therefore for some, other types 
of counselling might be better suited to their individual situation such as psychological 
counselling (Lawson et al. 2015), ethical counselling (Linkeviciute et al. 2015)(Boniolo 
and Sanchini 2016), other types of ethics support services (Gaucher, Lantos, and Payot 
2013)(Linkeviciute and Sanchini 2016) and various other groups of patient support. The 
latter might not necessarily take counselling as their primary mode of operation and put 
more focus on experience and idea sharing, practical advice and shared causes (e.g. charity 
work, fundraising for research, etc.). Hence, it should be recognised and also emphasised 
that some patients genuinely do not want to be active actors in medical decision-making 
process.   
 Meanwhile, assisting patients with informed decision making process and 
counselling needs would require physicians to be informed about latest evidence on cancer 
treatment during pregnancy, maternal and foetal outcomes, and remaining uncertainties, 
especially concerning the long term paediatric and maternal outcomes (Chapter 1). It 
would also be bound to close interdisciplinary collaboration not limited to 
multidisciplinary clinical team but expanding it with inclusion of psychologists, decisional, 
ethical and faith counsellors, social workers and patient navigators to name just a few. 
 6.2.2. Personalised patient care 
 
Caring for a patient involves an attempt to understand the reality this patient lives 
in, such as her way of seeing life, personal needs, expectations, commitments, desires and 
dreams (Feary 2003). This approach to caring corresponds closely with key features found 
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in ethics of care where patient’s wellbeing is promoted by providing good care in a broader 
sense. That means that care is not limited to a physical level but has to include 
psychological, relational, social, moral, and spiritual levels (Vanlaere and Gastmans 2011). 
To excel in this attention to the patient’s personal philosophy could be very useful 
(Boniolo and Sanchini 2016) as it helps getting to know not only the disease but also a 
person who is fighting it. 
Personalised patient care is argued to be an abandoned topic in currently popular 
personalised and also precision medicine69 debate where main focus is on tailoring medical 
treatment in accordance to genetic and epigenetic characteristics of the patient, including 
prevention, diagnosis, treatment and follow-up but missing out on noting the patient’s 
needs and preferences during all stages of her care (van Heijst 2011)(Cornetta and Brown 
2013)(Boniolo and Sanchini 2016). Overall, both in Europe and the USA personalised 
approaches to medical care are structured around the aim to provide the right treatment at 
the right dose, to the right patient at the right time70. 
Some argue that despite the importance, novelty and promise to improve health, 
personalised medicine is much more appreciated by the researchers and clinicians rather 
than patients, who are receivers of such care (Cornetta and Brown 2013). One possible 
explanation is that patients place more value on care which is perceived much broader than 
                                                 
69 The distinction between the two is till debated but while approaches in personalised medicine are centred 
around an individual patient, precision medicine seems to focus on patient groups who share some common 
characteristics.  
70European Science Foundation (ESF) Forward Look. Personalised Medicine for the European Citizen: 
towards more precise medicine for the diagnosis, treatment and prevention of disease. October 2012. 
http://www.esf.org/uploads/media/Personalised_Medicine.pdf [accessed 2016-60-30]; U.S. Food and Drug 
Administration (FDA). Paving the way for personalised medicine: FDA’s role in a new era of medicinal 
product development. October 2013. Report. 
http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421.pdf 
[accessed 2016-06-30] 
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treating a disease in a strictly technical sense (van Heijst 2011) and taking care of a patient 
as a whole human being with compassion (van Heijst and Leget 2011) and recognition of 
her personal philosophy (Boniolo and Sanchini 2016).  
 6.2.3. Protection of the vulnerable 
  
 Relational ethics approach assumes that general principles in bioethics are 
insufficient means for recognising the particularity of personal situations and personal 
narratives (Pollard 2015). Therefore, just a referral to four classical principles in 
biomedical ethics, which are respect for patient’s autonomy, nonmaleficence, beneficence 
and justice, cannot overcome the vulnerability posed to the patient by her individual 
circumstances. Such vulnerabilities can be potential as well as already materialised 
(Ferrarese 2011).  
 As I already mentioned, social connectedness and dependence could subject a 
pregnant cancer patient to various vulnerabilities. One of such vulnerabilities is known as 
co-creation, otherwise known as co-authoring, of narrative identity (McConnell 2016). 
Although everyone is potentially vulnerable and some propose to recognise this concept as 
respect for human vulnerability (Ten Have 2015), some persons and/or groups can be 
especially vulnerable due to diminished capacity to protect themselves and their interests, 
power imbalances and lack of control in given situation (Mackenzie, Rogers, and Dodds 
2014), which is also referred to as “poor bargaining position” (Kipnis 2003).  
 Potential vulnerability of ill pregnant women is rather widely recognised (Allesee 
and Gallagher 2011)(Sheppard 2015) but it is not to say that pregnant women should be 
secured in a bubble depriving them of cancer treatment interventions or of making their 
own choices. Recognition that pregnant woman facing potentially lethal disease could be 
vulnerable to numerous factors enables the creation of protection mechanisms (e.g. safety 
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net) to make sure that she is taking her treatment decisions in line with her wishes, 
exercising free will and has all relevant information to make an informed choice (Sheppard 
2015). 
  Some also talk about an obligation to promote resilience to vulnerability by 
helping to sustain autonomy (Lotz 2016). This, however, can be done in many different 
ways. If we follow the notion of respect for relational autonomy and creation of narrative 
identity in regard to our relationships then we have to acknowledge that all people are 
vulnerable to having their self-concepts shaped by others (McConnell 2016).  If we accept 
the possibility of narrative self-constitution, then we also have to accept that people depend 
on others to develop and maintain skills of self-narration which makes them vulnerable to 
having the content of their self-narratives co-authored by others (Matthews and Tobin 
2016).  
 On the other hand, however, co-authoring could be seen as an essential component 
for developing a self-narrative (DeGrazia 2005)(McConnell 2016). For example, if others 
do not treat a pregnant cancer patient as an autonomous agent, she might doubt her own 
capacity to tell her own story and become dependent on her co-authors to provide much of 
the material for her personal story and look out for reassurance on which narration is the 
best for her (McConnell 2016). Hence, another possible scenario is that pregnant cancer 
patient might not want to consider just her own interests and be willing to make sacrifices 
for the benefit of those who might be affected by her decision (Chapter 2). Self-narration 
also implies that one is responsible to others for her choices. Answerability (or self-
authorization) includes being responsive to requests for explanation and providing reasons 
for one’s beliefs, plans and choices (Westlund 2009). The agent must be willing to defend 
or revise her narrative in a light of critical questioning by others (DeGrazia 
2005)(McConnell 2016). Therefore, incorporating the element of reason giving into patient 
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counseling (Annoni 2016) could be a useful approach for identifying patient vulnerabilities 
and helping them to build resilience to it. 
6.3. Patient-focussed counselling approaches 
 
 As some philosophical counselling proponents suggest, counselling is not mere 
application of theory to practice but allows testing the theory against personal experience: 
“counselling sessions with women must involve an exploration of women’s life problems 
with the hope of broadening our concepts, expanding the reasons we give in support of our 
behaviour, illuminating the ways in which relationships have  been conceived, and 
enriching our theories” (Feary 2003). This is echoed by the voices of relational ethics 
advocating for the need to have a connection with a patient as a person in order to enable 
the nurses (and also physicians and other healthcare professionals) to understand what is 
important to the patient and what would serve best for her interests (van Heijst and Leget 
2011)(Pollard 2015).  
 Patient-focussed counselling could also help the patient to think in terms of self-
narrative or inner story, which is coloured by a sense of one’s own beliefs, desires, values, 
and character because continuing one’s own story could be a way of continuing to exist as 
a person (DeGrazia 2005). Therefore, recognising the importance of patient’s personal 
philosophy, involving her significant others in the counselling process and offering the 
opportunity to acquire all the information necessary for informed decision-making could 
help to provide state-of-the-art care tailored for each individual patient as well as this 
unique patient group who experience cancer in the course of their pregnancies.  
6.4. Remaining limitations and future directions 
 Discussion concerning ethics of cancer care during pregnancy remains highly 
theoretical while clinical approach mainly concerns physical care and technical 
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interventions giving just a brief concern for ethical issues which could arise in the clinical 
practice. Emerging data about cancer treatment and pregnancy compatibility seems to 
present the phenomenon as any other type of illness, which technically could be managed 
from a clinical point of view. Hence, the aspects concerning emotional, psychological, 
ethical, social and relational concerns experienced by those affected remain a highly 
unexplored territory.  
 The emerging evidence, that cancer treatment can be given to a pregnant woman 
without significant adverse effects on a developing foetus and a future child, seem to 
overshadow the importance of holistic approach to patient care. Hence guidelines review 
suggests that patient counselling is important and should be offered to the patients and their 
partners/family members.  
 However, voices of affected patients and their partners/family members are still 
missing from the mainstream debate as there are only very few studies exploring the 
experiences of cancer patients who are also parents (Elmberger, Bolund, and Lützén 2005) 
and pregnant patients who experience critical health conditions (Kenyon et al. 
2006)(Smyth, Jacoby, and Elbourne 2012). This knowledge gap is also recognised by 
Oncofertility scholars (Shen and Badr 2014). 
 There is only one study exploring the practices and clinicians’ attitudes towards 
cancer treatment in the course of pregnancy (Sileny N Han et al. 2013). More in depth 
understanding of experiences, attitudes and approaches held by different stakeholders to 
cancer care during pregnancy would help to form a comprehensive ethics guideline for 
healthcare professionals. Having such guideline would serve as an ethical reference tool 
for physicians, nurses, careers, counsellors and other professionals involved in pregnant 
cancer patients care.  
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 Current framework remains highly theoretical and would need to be developed 
further in line with advances in medicine and information collected by using social 
research methods. In order to proceed to the development of a guideline it would require 
better understanding of practices and views held by healthcare professionals as well as 
attitudes and experiences of patients and their families. Such work would require 
interdisciplinary collaboration between physicians, nurses and other healthcare 
professionals as well as social scientists, psychologists, ethicists and patient 
representatives.  
6.5. Summary 
 This chapter consolidates the knowledge and ideas gathered in preceding chapters 
of this work. I present a framework for ethical care of pregnant cancer patients based on 
recognition that relationships between pregnant cancer patient, her family and healthcare 
professionals play a very important role. I suggest that respect for patient’s autonomy 
should be re-specified as respect for relational autonomy in this context because doing so 
helps to understand patient’s personal philosophy better and take her personal views into 
account when assisting her with decisions concerning her cancer treatment and pregnancy 
care. I recognise that such approach might have some down-sides such as exposing the 
patient to influences by other parties (co-creation of her narrative identity). However, 
offering counselling services to pregnant cancer patients and their family members could 
help to identify their vulnerabilities and build resilience to them.  
 Furthermore, I expect that having this in-depth theoretical study of concepts found 
in ethics and informed by evidence-based research in medicine as well as social sciences, 
will serve as a solid background for reference when facing difficult choices in cancer care 
during pregnancy, as well as for working further in order to develop an ethics guideline to 
assist in addressing ethical uncertainties.  
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Conclusion 
 
 In this work I explored the ethical issues surrounding cancer care during pregnancy. 
In order to stay relevant to clinical practice and offer some reference for real life solutions I 
took every effort to research and understand the clinical background of the condition, use 
social science data on experiences and attitudes of affected stakeholders and systematically 
reviewed clinical practice guidelines for cancer care during pregnancy. 
 In regards to ethical issues, I examined the theoretical background looking to 
understand the background of maternal-foetal conflict and foetal interests in the light of 
prenatal harm. My approach to ethical problems arising in cancer care during pregnancy is 
that cancer diagnosis compromises the nurturing role a pregnant cancer patient has towards 
her foetus. This, however, is not to say that I support one particular choice of available care 
such as treating maternal cancer and continuing pregnancy, delaying treatment until the 
delivery or terminating the pregnancy.  
 I focus more on the process how such care could be delivered to the patient and, in 
some cases, her partner and/or family. Therefore, I suggest that relational context should be 
taken into account by recognising the patient as another human being with compassion and 
empathy, acknowledging her personal philosophy and offering personalised care while at 
the same time indentifying potential vulnerabilities the patient might have. 
 Clinical practice guidelines review revealed that these documents emphasize the 
importance of respect for pregnant patient’s autonomy but also take relational aspects into 
account. Moreover, they also recognise the importance of balancing maternal and foetal 
beneficence as well as protecting the vulnerable. In order to develop a framework for 
ethical care I build further on guidelines review by specifying what relational autonomy 
entails and identifying some safeguards to protect the individual patient to make well 
informed and considered choices  
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 I suggest that it is not only the relationships between the patient and her partner 
and/or family that are important but also relationships which arise between the patient and 
her healthcare team, which is known as relational ethics. Therefore, healthcare team also 
has a responsibility to establish a caring relationship with a patient. 
 Furthermore, I recognise the dangerous effects which relational approach to 
patient’s autonomy could have on an individual patient. Therefore, I suggest that the 
following concepts could serve as safeguards of individual autonomy when cancer care is 
delivered to pregnant patients. They are evidence-based information disclosure, 
personalised patient care and protection of the vulnerable. All of them could be 
incorporated in clinical care as well as other patient support services such as counselling. 
 I also support the idea that patients should be recognised as active participants and, 
in some cases, independent users of ethics support services. Hence, in this work I only 
explore the diversity of methods and approaches to such services without prioritising one 
method or approach over another. What I want to emphasis is that, should patients require 
ethics support, there should be some means available for delivering it. 
 Overall, I expect that my work will be a meaningful contribution to continuous 
development and delivery of ethical care for pregnant cancer patients. In a long-term 
perspective I hope that my work would serve as a foundational background for further 
research, point of reference for ethically minded solutions and further evolution of ethics 
guidance for healthcare professionals attending to pregnant patients with cancer. 
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Supplementary material  
 
Appendix A: Guidelines for fertility preservation in cancer patients   
Releasing body; 
year 
Scope Main statements regarding toxicity of cancer therapy, 
fertility preservation (FP) and future procreation 
 European expert 
panel consisting of 
physicians with 
expertise in the 
field of fertility 
preservation in 
cancer patients 
(Lambertini et al. 
2016) 
All cancer 
patients 
Pregnancy in cancer survivors should not be 
discouraged. 
All patients with potential interest in fertility 
preservation should be referred to fertility unit. 
National 
Comprehensive 
Cancer Network – 
NCCN, USA; 2014 
(Coccia et al. 2014) 
Adolescents 
and Young 
Adult (15-
39) 
Fertility preservation should be an integral part of 
cancer management.  
The use of contraception should be discussed with all 
women before initiation of treatment. 
Women diagnosed with cancer during pregnancy 
require individualised treatment by multidisciplinary 
team. 
All patients should have access to age-appropriate 
supportive care and medical subspecialty services. 
American Society 
for Reproductive 
Medicine – 
ASRM; 2013 
(American Society 
for Reproductive 
Medicine 2013) 
All cancer 
patients 
Clinicians should inform patients about FP options 
and future reproduction before gonadotoxic treatment 
begins.  
Concerns about welfare of resulting offspring are not 
sufficient reasons to deny assistance in reproduction. 
Parents may act to preserve fertility for minors 
(assent and likeliness to provide future benefit). 
PGD to avoid offspring inheriting high risk of cancer 
is acceptable. 
Patients should have access to mental health, genetic 
and financial counsellors.  
American Society 
of Clinical 
Oncology – 
ASCO; 2013 
(Loren et al. 2013) 
All cancer 
patients 
Discuss FP with all patients of reproductive age (with 
parents or guardians of children and adolescents). 
Refer interested (and ambivalent) patients to fertility 
specialist. 
Address FP before treatment starts. 
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Document FP discussion in medical records. 
Answer basic questions about FP and its impact on 
cancer treatment. 
Refer patients to psychosocial providers if patients 
experience distress. 
Encourage patients to participate in registries and 
clinical studies. 
European Society 
of Medical 
Oncology – ESMO 
(endorsed by 
Japanese Society of 
Medical Oncology 
– JSMO); 2013 
(Peccatori et al. 
2013) 
Cancer 
patients in 
reproductive 
age 
Male: sperm banking should be planned before 
treatment initiation. 
Female: Young women desiring future fertility 
should be counselled on available fertility 
preservation options before starting anti-cancer 
treatment. 
European Society 
of Breast Cancer 
Specialists – 
EUSOMA; 2012 
(Cardoso et al. 
2012) 
Young 
women 
(under 40) 
Fertility issues should always be discussed before the 
start of any breast cancer therapy. 
Discussion should allow time for reflection and 
involve partner, if present. 
Early referral to reproductive endocrinologist is 
warranted.  
International 
Society for 
Fertility 
Preservation – 
ISFP; 2012 (Jadoul 
and Kim 
2012)(Kim et al. 
2012)(Klemp and 
Kim 
2012)(Schmidt and 
Andersen 2012) 
Cancer 
patients of 
reproductive 
age 
All patients who desire to preserve fertility should be 
counselled and informed about available options. 
Recommendations should be individualised and not 
violate ethical principles. 
FP is strongly recommended if the chance of losing 
fertility is over 30%. 
Fertility 
preservation 
network 
FertiPROTEKT; 
2011 (von Wolff et 
al. 2011) 
Reproductive 
age women 
(14-40) 
All reproductive age women due to receive 
chemotherapy should be counselled on FP methods. 
All applicable methods should be mentioned. 
FP techniques must not affect the efficacy of 
oncological treatment. 
Expert consensus 
meeting in St 
Gallen; 2009 
(Goldhirsch et al. 
2009) 
Breast 
cancer 
patients 
Pregnancy after breast cancer has not been shown to 
negatively affect prognosis. 
Women should be counselled about the options for 
FP. 
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